{"title": "PDF", "author": "PDF", "url": "https://biomedizin.unibas.ch/fileadmin/user_upload/biomedizin/about_us/media/dbm_facts/DBM_Facts_09_2.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "2 0 9Periodisches Informationsblatt des Departementes Biomedizin\nUniversit\u00e4t Basel, Universit\u00e4tsspital Basel undUniversit\u00e4ts-Kinderspital beider Basel\nTranslating the biology of glioblastoma towards clinics | \nAdaptation: a key factor for living in New York City! | \nGedanken zu Advent und WeihnachtenRedaktion\nHeidi Hoyermann (Leitung)Verena J\u00e4ggin\n\u00dcbersetzungen\nPaula Cullen\nLayout \nMorf Bimo Print AG, Binningen\nPublikationen/Publications\nVerena J\u00e4ggin (Layout)\nMitarbeitende/Colleagues\nVerena J\u00e4ggin (Layout)\nAdministration\nManuela Bernasconi\nFotos\nArmin Bieri (privat)Verena J\u00e4ggin (43,44,45,46,50,52,54,58, 63) Lukas Landmann (privat)Anna Marsano (privat)Dieter Naeher (59, 60, 62)Gino Pancera (privat)\nTitelfoto\nClarita, Rom, Italien, Santa Maria Sopra Minerva\nDruck\nMorf Bimo Print AG, Binningen\nAnschrift\nRedaktion DBM FactsDepartement BiomedizinHebelstrasse 204031 Baseldbmfacts@unibas.ch\nDBM Facts 2|2009 Departement BiomedizinTranslating the biology of  \nglioblastoma towards clinics  \nfrom Adrian Merlo\nIMPRESSUMEditorial\n    1\nPublikationen /Publications  20\nArt\n40\nAuszeichnungen / Congratulations\n41\nMitarbeitende / Colleagues\n43\nIm Gespr\u00e4ch mit dem Personal-\ndienst der Universit\u00e4t Basel\n60\nDas DBM stellt sich vor\n63\nDiabetes mellitus: Why and how \ndoes the kidney fail?\nfrom Jonas Sieber and Andreas Jehle  10\nAdaptation: a key factor for living in New York City!\n \nfrom Anna Marsano16Eistauchen\nvon Armin Bieri  56\nGedanken zu Advent undWeihnachten\nvon J\u00fcrg Merz\n 58\n2\nDBM Facts 2|2009 Department of BiomedicineEDITORIAL\nRadek Skoda\nLeiter DBM\nDear readers,\n2009 is drawing to a close. It was a positive year for the DBM, which was able to develop further. On 1st September 2009 \nMichael Sinnreich took up his position as research group leader of the Neurobiology Lab. In addition, Matthias Liechti received a SCORE award from the Swiss National Science Foundation and since 1st October 2009 he has been leading the Psychopharmacology Research group. We wish them both a good start at the DBM and much success.\nThe Endocrinology Lab of Alex Eberle shut its doors on 30th November 2009, after 30 years in operation. Alex Eberle will \ncontinue to work on various projects for publication and takes on a responsible position for the University of Basel as vice-rector. The departure of Regine Landmann sees another founding member and manager of the former Department of Research. She is also taking on important duties and responsibilities as she takes up a position as vice-dean, and will still remain active in our faculty. We thank them both for their many contributions to the department and wish them much success and fulfilment in their new positions. \nIn the current issue Adrian Merlo and his team take us on a journey through the research activities of Neurooncology, and \nAndreas Jehle introduces us to the world of Molecular Nephrology. A selection of the latest publications can be found on page 20.\nWe experience advent at the USB from a very different perspective with hospital minister J\u00fcrg Merz (on page 58).\nI wish all of our readers an interesting read, Happy Christmas and a good 2010!\nRadek SkodaLiebe Leserinnen und Leser2009 neigt sich dem Ende zu. Ein positives Jahr f\u00fcr das DBM, das sich weiter entwickeln konnte. Am 1. September \n2009 hat Michael Sinnreich seine T\u00e4tigkeit als Forschungsgruppenleiter des Labors \u00abNeurobiology\u00bb aufgenommen. Zus\u00e4tzlich wurde Matthias Liechti ein SCORE Beitrag des Schweizerischen Nationalfonds zugesprochen, seit 1. Oktober 2009 leitet er die Forschungsgruppe \u00abPsychopharmacology Research\u00bb. Beiden einen guten Start am DBM und viel Erfolg!\nDas Labor \u00abEndocrinology\u00bb von Alex Eberle hat am 30. November 2009 seine Tore nach 30 Jahren geschlossen. \nAlex Eberle wird an der Ver\u00f6ffentlichung verschiedener Projekte noch weiterarbeiten und \u00fcbernimmt als Vizerektor Planung eine verantwortungsvolle Funktion f\u00fcr die Universit\u00e4t Basel. Mit Regine Landmann verl\u00e4sst uns ein weiteres Gr\u00fcndungsmitglied und Vorsteherin des ehemaligen Departements Forschung. Auch Regine Landmann \u00fcbernimmt als Vizedekanin Nachwuchs wichtige Aufgaben und bleibt in unserer Fakult\u00e4t t\u00e4tig. Beiden danke ich herzlich f\u00fcr ihre vielen Beitr\u00e4ge zum Departement und w\u00fcnsche viel Erfolg und Erf\u00fcllung in ihren neuen T\u00e4tigkeitsbereichen.\nIn der nun vorliegenden Ausgabe nehmen uns Adrian Merlo und sein Team mit auf die Reise in die \nForschungsaktivit\u00e4ten der \u00abNeurooncology\u00bb und Andreas Jehle f\u00fchrt uns in die Welt der \u00abMolecular Nephrology\u00bb ein. Eine Auswahl der neuesten Publikationen finden Sie ab Seite 20.\nEinmal aus ganz anderer Perspektive erleben wir die Adventszeit am USB mit Spitalpfarrer J\u00fcrg Merz (ab Seite 58). \nAllen Leserinnen und Lesern w\u00fcnsche ich eine interessante Lekt\u00fcre, Frohe Weihnachten und ein gutes 2010!\nRadek SkodaDBM Facts 2|2009 Departement Biomedizin2 WISSENSCHAFT | SCIENCE DEPARTEMENT BIOMEDIZIN USB\nTranslating the  \nbiology of glioblastoma \ntowards clinics\nFrom left to right (back row): Balasubramanian Sivasankaran, Brian Hemmings, Adrian Merlo, Serdar Korur, B\u00e9atrice Dolder Schlienger, \nMarie-Christine M\u00fcller, Jacqueline Rauch. From left to right (front row): Maria Maddalena Lino, Roland Huber, Elisabeth Taylor Iten\nDBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF BIOMED ICINE USB WISSENSCHAFT | SCIENCE 3\nGlioblastoma multiforme (GBM), the most common and \nmalignant primary tumor of the central nervous system (CNS) in adults [1], with an incidence of about 5/100\u2019000 represents an orphan disease [1]. GBM is characterized by exponential growth and diffuse invasiveness with a median survival of less than one year [2,3]. Although the diverse causative genotypes giving rise to a consi-stent pleomorphic phenotype are well defined, effec-tive therapy inducing tumor cell apoptosis has not been established so far. Following surgery, billions of invasive tumor cells remain to be targeted by systemic and local \ntherapies. Different physiological and physical factors \nrender GBM a daunting challenge [4] . The blood-brain barrier (BBB) restricts the passage of most chemical sub-stances into the neural tissue. In GBM, the BBB gets leaky because tumors can actively degrade tight junctions by \nsecreting soluble factors [5]. Nevertheless, drug uptake \nis very limited reaching about 1:1000\nth of systemically \ninjected compounds [6]. Drug uptake can be enhanced \nby designing lipophilic compounds or by directly injec-ting drugs into the interstitial space of the tumor.  In addition, progressive GBM cells stimulate the formation \nof new blood vessels by secreting vascular endothelial \ngrowth factor (VEGF). However, the resulting vessels are structurally abnormal and leaky, giving rise to edema, high interstitial fluid pressure and, consecutively, low oxygen tension. This hostile microenvironment  selects for a more malignant phenotype by clonal outgrowth of hypoxia-resistant tumor cells representing an additio-nal obstacle for GBM treatment [7].\nMolecular genetics of human gliomas\nOver the past twenty years, considerable progress has been made in the knowledge of genetic alterations in gliomas and subsequently, on mechanisms of gliomage-nesis. Unique combinations of major pathways control-ling growth and nutrition, cell cycle, apoptosis, genomic integrity and energy demand have been detected and confirmed in two recent studies by sequencing the enti-re genome of GBM [4]. The most frequent genetic altera-tions are amplification of the EGFR gene and subsequent \ndeletion that generates the constitutively active variant vIII; the homozygous deletion of the CDKN2A locus en-\ncoding both p14\nARF and p16INK4A tumor suppressors; mi-\ncrodeletions in the gene for NF1, a negative regulator of Ras signaling; allelic losses that uncover missense mu-tations of the PTEN and TP53 tumor suppressor genes \n[8]. More specific to oligodendroglioma (OG) \u2013 a less malignant glioma subtype - the combined allelic loss of chromosomes 1p and 19q, resulting from uneven translocation, is associated with better patient outcome \n[9,10]. The gene that is targeted by 1p/19q transloca-\ntion has not been identified so far. Recent genome-wide surveys of genetic alterations and mutations in glio-ma have further identified dominant mutations at the Krebs cycle gene IDH1 and low frequencies of missense \nmutations in the NF1 and RB1 gene [11,12]. 1p/19q loss \nassociated with IDH mutation is largely prevalent in OG \n(~80%) while TP53 mutation together with IDH mutation \nis dominant in astrocytic glioma (~80%) [13]. IDH status \nmay therefore become a biomarker for the distinction between GBM vs astrocytoma or OG [14].\nBrain tumor models in the mouse and in Drosophila  \nAmong the various glioma models, two murine models have been generated that give rise to glioblastomas with high penetrance [15]. In both models, co-operati-on of two distinct pathways is required: either activa-tion of both AKT and RAS, both operating downstream \nof growth factor and PTEN signaling, or simultaneous CNS-specific inactivation of TP53 and PTEN, leading to \nMyc activation. In the second model, the malignant gli-oma originated from a neural stem cell population with high self-renewal capacity [16,17]. Interestingly, a brain tumor model also exists in Drosophila that harbor a mu-\ntant brain tumor (brat) gene. The brat mutation prevents \nterminal differerentiation and promotes self-renewal of neural progenitor cells inducing brain tumors at larval stage [18]. Whether there is a brat-homologous pathway in human gliomas has not been clarified so far.\nIdentification of GPR26 and TRIM3 as candidate  \nglioma suppressor genes\nIn addition to PTEN on 10q23, somatic deletion map-\nping pointed to a second suppressor locus on 10q25-26 [19]. We found that the corresponding minimal area of loss contains the gene encoding the G protein-coupled receptor GPR26. Overexpression of GPR26 in HEK and \nin U87 glioma cells increased intracellular cAMP con-centration which is considered to induce astrocytic DBM Facts 2|2009 Departement Biomedizin4 WISSENSCHAFT | SCIENCE DEPARTEMENT BIOMEDIZIN USB\ndifferentiation. Interestingly, GPR26 is concomitantly \nsilenced with MGMT which also lies in the same region. \nGPR26 and MGMT could be epigenetically co-regulated \n[20]. The 10q25-26 region may therefore contain an important epigenetic pathway in brain tumorigenesis. Malignant gliomas harboring TP53 mutations are asso-\nciated with 11p15 allelic loss [21]. By performing soma-tic deletion mapping, we identified that a subgroup of patients with younger age had a 11p15 minimally lost region with putative homozygous deletions that target the TRIM3 gene. TRIM3 is the human orthologue of the \nDrosophila brain tumor suppressor gene brat [20]. This \npathway controlling the precursor cell pool may there-fore be conserved throughout evolution.\nInteraction between Notch and tenascin in gliomas\nThe developmental genes Notch1 and Notch2 are part of an emerging pathway in cancer including malignant gliomas [22]. We identified the Notch2 gene by tumor suppressor gene mapping on chromosome 1p11, com-paring glioblastomas with oligodendrogliomas [23]. This study was initiated by the counter-intuitive claim in the medical community that 1p loss may be predictive for chemoresponse. Our hypothesis was that 1p loss points to a prognostically better glioma pathway and that, therefore, chromosome 1p harbors a developmentally critical gene. Interestingly, the Notch2 status appears to correlate with the degree of malignancy: the Notch2 protein was not expressed in oligodendrogliomas that deleted the Notch2 gene locus. In contrast, Notch2 protein was highly expressed in most GBM which show retention at the Notch2 locus. The association of the \n1p/19q deletion with a more benign prognosis may the-\nrefore not be due to a more favorable response to medi-cal intervention, but may simply reflect the involvement of a glioma pathway linked with better outcome. This conception appears to be confirmed in a recent clinical study on anaplastic oligodendroglioma where there was no correlation between chemoresponse and genetic status [24]. Continuous expression of Notch2 may force tumor precursor cells into an undifferentiated state, while deleting this pathway appears to allow a higher degree of differentiation during gliomagenesis, e.g. the generation of oligodendroglioma .Tenascin-C (TNC) expression is known to correlate with malignancy in GBM [25]. It is one of the factors \u2013 be-side others [26] \u2013 that regulate tumor cell invasion and migration. In GBM cell lines, we found Notch2 and the related transcription co-factor RBPJk to be strongly co-expressed with TNC. The TNC gene was found to be \ntrans-activated by Notch2 in an RBPJk-dependent man-ner by an RBPJk binding element in the TNC promoter. \nTNC-stimulated glioma cell migration represents a me-chanism for the invasive properties of glioma cells con-trolled by Notch signaling and defines a novel glioma pathway that may be targeted for therapeutic interven-\ntion in GBM patients [27].\n \nAttacking biological resistance, the net effect of \nselection and mutationTo identify the genetic alterations in GBMs, 20,661 pro-tein coding genes were sequenced in a recent study to determine the presence of amplifications and dele-tions and to define gene expression profiles [11]. This comprehensive analysis confirmed the involvement of major cancer pathways as discussed above [28]. A vari-ety of genes that were not known to be altered in GBMs were discovered, however, at low frequency. The high mutational load in GBM was dramatically increased after radio- and chemotherapy using alkylating agents as pre-viously observed [29]. Intensive chemotherapy should therefore be cautiously indicated in low-grade gliomas.The epidermal growth factor receptor (EGFR) pathway triggers downstream phosphatidylinositol 3- kinase (PI3K)/RAS-mediated signaling cascades. However, complete blockade of EGFR activation does not result in apoptosis in human glioblastoma cells, suggesting addi-\ntional cross-talk between downstream pathways. Based \non these observations, we investigated combination therapies using protein kinase inhibitors against EGFR (AEE788), platelet-derived growth factor receptor (Glee-vec), and mammalian target of rapamycin (RAD001), assessing glioblastoma cell survival. Clinically relevant doses of AEE788, Gleevec (imatinib), and RAD001 (eve-rolimus) as single agent or in combination were not ca-pable to induce glioblastoma cell apoptosis. In contrast, simultaneous inactivation of the EGFR downstream targets mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase and PI3K triggered rapid tumor cell death (Figure 1). Blocking EGFR in combina-DBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF BIOMED ICINE USB WISSENSCHAFT | SCIENCE 5\ntion with sublethal concentrations of the microtubule \nstabilizer patupilone also induced apoptosis and redu-ced cell proliferation in glioblastoma cells, accompanied by downregulation of activity of AKT and ERK (Figure 1) [30]. These data underline the critical role of the PI3K/AKT/mTOR and the MAPKinase signaling cascades in the cell-intrinsic survival program of glioblastoma.\nTargeting the epigenome in GBM\nEpigenetic modulation of gene expression is essential for normal cellular development and is highly abnormal \nin cancers [31]. An epigenetic hallmark of cancer cells is \npromoter CpG island hypermethylation and transcripti-onal silencing of tumor suppressor genes and pro-dif-ferentiation factors. Repressive chromatin patterns me-diated by lysine methylation of histone 3 are typically associated with DNA hypermethylation in adult cancers and have also been detected in embryonic cancer cells [31]. This chromatin pattern in stem or progenitor cells may leave critical genes vulnerable to aberrant DNA hypermethylation and heritable gene silencing duri-ng tumor initiation and progression. Drugs that revert cancer-prone chromatin patterns may therefore be pro-mising to treat glioblastomas, e.g. histone deacetylase inhibitors (HDI). We have shown that the HDI trichosta-tin A, sodium butyrate, and low nanomolar doses of LAQ824 (Novartis) combined with the glycolysis inhi-bitor 2-deoxy-D-glucose strongly induced apoptosis in cancer cell lines of brain, breast, and cervix tumors in a p53-independent manner (Figure 2). HDIs upregulate p21 which was found to be blocked by concomitant ad-ministration of 2 deoxy-D-glucose [32]. A straightfor-ward explanation of these observations would be that the glioma cell\u2019s resistance to epigenetic remodeling is an energy-sensitive process.\nDifferentiation of glioblastoma stem cells by  \nblocking GSK3\u03b2  induces apoptosis\nThe cancer stem cell (CSC) hypothesis proposes that \ncancers are derived from a small fraction of cancer cells which constitute a self-sustaining cell reservoir. The stem cell phenotype may be acquired by a series of se-\nDBM Facts 2|2009 Departement Biomedizinreduced the expression of the stem cell markers Sox2 \nand Nestin, and, interestingly, also of glycogen synthase kinase 3-beta (GSK3\u03b2 ) which we found to be consistently \nexpressed in primary GBM. This suggested a functional link between Bmi1 and GSK3\u03b2 . Interference with GSK3\u03b2 \nactivity either with siRNA or with the specific inhibitor SB216763 or with Lithium chloride induced tumor cell differentiation and, in addition, enhanced tumor cell apoptosis, impaired formation of neurospheres in size and number, and reduced clonogenicity in a dose-de-pendent manner (Figure 3). GBM cell lines mostly con-\nsist of CD133-negative cells. Interestingly we found that \nex vivo cells from primary tumor biopsies allowed iden-tification of a CD133-negative subpopulation of cells that express stem cell markers and can be depleted by inactivation of GSK3\u03b2 . Drugs that inhibit GSK3\u03b2  inclu-\nding Lithium chloride - an established psychiatric drug - may deplete the GBM stem cell reservoir independently of the CD133-status [35].\nHow to treat GBM\nFor therapeutic exploitation, the challenge now is to detect crossroads within the aberrant and complex in-dividual signaling network that are common in most GBM. Given the extreme adaptability of GBM cells, a the-rapeutic intervention has to lead to tumor cell death to \nprevent sublethal hits of tumor cells with subsequent \noutgrowth of even more malignant clonal cell populati-ons. This critical requirement explains the inherent limi-tations of purely antiproliferative and anti-angiogenetic approaches as a main therapeutic pillar. Historically, treatment of GBM has relied on debulking surgery for the nodular component of the disease and unspecific cytotoxic stress for the invasive component of the di-sease. Usually, a combination of fractionated external beam radiotherapy and cytotoxic, mainly alkylating agents is being used leading mostly to a Pyrrhic victory.  Within 2 years following diagnosis, most patients will have died because of tumor progression or recurrence [36]. Interestingly, intense chemotherapy, e.g. using te-mozolomide, increased the mutational load within the cancer genome 17-fold in comparison to untreated GBM cells [11].Targeting non-overlapping pathways, rather than a single agent approach, is more likely to be effective. 6 WISSENSCHAFT | SCIENCE DEPARTEMENT BIOMEDIZIN USB\nlected mutations, or precursor cells acquire tumorigenic \nmutations. GBM cancer stem cells (GCSC) share gene ex-pression signatures with progenitor cells of the develo-ping forebrain [33]. A subpopulation of cells which carry the marker CD133 has been identified in many tumors including GBM. In another study on aggressive cancers, histologically poorly differentiated tumors showed pre-ferential overexpression of genes normally enriched in embryonic stem (ES) cells, combined with repression of Polycomb-regulated genes. The stem cell hypothe-sis may only represent one side of the coin, since it had \nbeen convincingly shown in a glioma animal model ex-\npressing EGFR in an ink4a/arf-deficient background that \nglioblastoma-like tumors can evolve both from precur-sor cells and from differentiated astrocytes [34]. Neu-ral stem cells and differentiated astrocytes have been equally permissive for tumorigenesis upon lowering the apoptotic treshold (arf: p53 pathway), deblocking cell cycle regulation (ink4a: Rb-pathway) and activation of EGFR (Ras-pathway). We found that Bmi1 is consistently and highly expressed in GBM. Down-regulation of Bmi1 by shRNAs induced a phenotype of differentiation and \nDBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF BIOMED ICINE USB WISSENSCHAFT | SCIENCE 7\nBlocking different pathways can inactivate the com-\npensatory crosstalk between them. Such a mechanism may be operative when two key cellular pathways are simultaneously targeted, e.g. PI3K from the PKB/mTOR-pathway and MEK from the MAPK pathway [30,37]. This approach is realized by reversing epigenetic modifica-tions using pharmacological inhibitors such as histone deacetylase inhibitors (HDI). HDI act selectively, altering the expression of only 2-10% of genes [38]. This new class of drugs targeting the epigenome was found to markedly synergize with 2-deoxyglucose [32], inducing \nhigh levels of apoptosis in most GBM cells. ATP depriva-\ntion may be the critical step in this combination, since energy supply is essential for the re-induction of mul-tifold gene-expression. Important regulatory genes in stem or progenitor cells may be vulnerable to aberrant DNA hypermethylation and heritable gene silencing and can potentially be re-induced by HDI [31]. Progress in systemic therapy introducing modern new drugs will be crucial to fundamentally improve long term prognosis of GBM patients in order to control the invasive compo-nent of the disease. Following successful local control by surgery, billions of invasive tumor cells are left be-hind within the perifocal edematous area that can also be detected in the contralateral brain hemisphere. The potential of local drug application has not been fully explored yet. Injecting targeted drugs directly into the enlarged extracellular space of a tumor or into the re-section cavity holds relevant promise of an additional therapeutic effects that does not rely on the passage through the BBB [6,39]. Indeed, small targeted radio-labeled peptidic vectors rapidly diffuse along axonal \npathways and perivascular clefts within a few minutes, \nfollowing the ususal routes of tumor cell infiltration. Be-ta-emitting radionuclides are useful to treat the nodular tumor  component. However, to target small infiltrating cell clusters, highly energetic short range alpha-emitters should be used, e.g. Bismuth-213 [40] or Astatine-211 that have been successfully tested in clinical pilot stu-dies [41]. Such protocols with low toxicity are especially promising for younger patients affected by low-grade gliomas given the limited toxicity due to tumor cell spe-cific targeting of the alpha-emitting radionuclides hoo-ked up to a carrier peptide. ConclusionsIt is unlikely that one day a single magic bullet will cure GBM. Two major genotypes lead to the very similar GBM phenotype which may require distinct drug approaches. The main goal of any drug approach has to be induction of apoptosis of tumor cells given the hypermutability of GBM as a reaction to a therapeutic challenge. Antiangi-ogenetic, antiproliferative and anti-invasive strategies represent adjuvant strategies. Systemically, novel drug combinations have to be developed that not only tar-get key molecules at the signaling crossroads, but also \nexploit energy demand and the epigenetic cancer pro-\ngram of GBM. Considering the many obstacles of drug distribution in the target area, advances in molecular di-sease imaging are needed to get direct answers on the therapeutic effect and the degree of drug penetration within the tumor. Besides systemic applications, local strategies also bear a great potential especially for at-tacking the invasive component of the disease, becau-se drug distribution follows the same avenues that are used by infiltrating tumor cells, perivascular clefts and axonal pathways.\nMaria Maddalena Lino, Jean-Louis Boulay, Serdar \nKorur, Roland Huber, Balasubramanian Sivasankaran, \nB\u00e9atrice Dolder, Elisabeth Taylor, Jacqueline Rauch, \nMarie-Christine M\u00fcller, Adrian Merlo.DBM Facts 2|2009 Departement Biomedizin8 WISSENSCHAFT | SCIENCE DEPARTEMENT BIOMEDIZIN USB\nReferences:\n1. Newton HB: Primary brain tumors: review of etiology, \ndiagnosis and treatment. Am Fam Physician  1994,  \n49:787-797\n2. Davis FG, McCarthy BJ: Current epidemiological trends \nand surveillance issues in brain tumors. Expert Rev Anti -\ncancer Ther 2001, 1:395-401\n3. Newton HB: Molecular neuro-oncology and develop- \nment of targeted therapeutic strategies for brain tumors. \nPart 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogene -\nsis. Expert Rev Anticancer Ther 2004, 4:105-128This is a com -\nplete review on the molecular aspects and development of targeted terapheutic strategies in brain tumor.\n4. Lino M, Merlo A: Translating biology into clinic: the case \nof glioblastoma.  Curr Opin Cell Biol 2009, 21:311-316\n5. Schneider SW, Ludwig T, Tatenhorst L, Braune S, Ober -\nleithner H, Senner V, Paulus W: Glioblastoma cells release \nfactors that disrupt blood-brain barrier features. Acta \nNeuropathol 2004, 107:272-276\n6. Merlo A, Hausmann O, Wasner M, Steiner P , Otte A,  \nJermann E, Freitag P , Reubi JC, Muller-Brand J, Gratzl O, et \nal.: Locoregional regulatory peptide receptor targeting \nwith the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study \nin human gliomas.  Clin Cancer Res 1999, 5:1025-1033\n7 . Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT: Angiogenesis in brain tumours.  Nat Rev  \nNeurosci   2007, 8:610-622\n8. Ohgaki H, Kleihues P: Population-based studies on \nincidence, survival rates, and genetic alterations in astro -\ncytic and oligodendroglial gliomas.  J Neuropathol Exp  \nNeurol  2005, 64:479-489\n9. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer \nB, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, \net al.: Phase III trial of chemotherapy plus radiotherapy \ncompared with radiotherapy alone for pure and mixed \nanaplastic oligodendroglioma: Intergroup Radiation \nTherapy Oncology Group Trial 9402. J Clin Oncol 2006, \n24:2707-2714\n10. Griffin CA, Burger P , Morsberger L, Yonescu R, Swierc -\nzynski S, Weingart JD, Murphy KM: Identification of \nder(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol \nExp Neurol 2006, 65:988-99411. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, \nAngenendt P , Mankoo P , Carter H, Siu IM, Gallia GL, et al.: \nAn Integrated Genomic Analysis of Human Glioblastoma \nMultiforme. Science  2008, \n12. Comprehensive genomic characterization defines \nhuman glioblastoma genes and core pathways.   \nNature  2008, 455:1061-1068\n13. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al.: \nIDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, \n360 :765-773\n14. Nobusawa S, Watanabe T, Kleihues P , Ohgaki H: IDH1 mutations as molecular signature and predictive factor \nof secondary glioblastomas. Clin Cancer Res 2009,  \n15:6002-6007\n15. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN: Combined activation of Ras and Akt in neural \nprogenitors induces glioblastoma formation in mice.  Nat \nGenet 2000, 25:55-57Shows that co-expression of activated \nRAS and AKT in neural progenitor cells in the mouse brain \ninduces glioblastoma.\n16. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen \nAJ, Perry SR, Tonon G, Chu GC, Ding Z, et al.: Pten and \np53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma.  Cold Spring Harb Symp Quant \nBiol 2008, 73:427-437\n17 . Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, et al.: p53 and Pten \ncontrol neural and glioma stem/progenitor cell renewal and differentiation.  Nature  2008, 455:1129 -1133\n18. Arama E, Dickman D, Kimchie Z, Shearn A, Lev Z: Muta -\ntions in the beta-propeller domain of the Drosophila \nbrain tumor (brat) protein induce neoplasm in the larval \nbrain.  Oncogene 2000, 19:3706-3716\n19. Maier D, Zhang Z, Taylor E, Hamou MF, Gratzl O, Van \nMeir EG, Scott RJ, Merlo A: Somatic deletion mapping on \nchromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in  \nlow-grade and high-grade gliomas.  Oncogene 1998, \n16:3331-3335\n20. Boulay JL, Ionescu MC, Sivasankaran B, Labuhn M, Dolder-Schlienger B, Taylor E, Morin P , Jr., Hemmings BA, \nLino MM, Jones G, et al.: The 10q25.3-26.1 G protein-cou -\npled receptor gene GPR26 is epigenetically silenced in human gliomas.  Int J Oncol 2009, 35:1123-1131DBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF BIOMED ICINE USB WISSENSCHAFT | SCIENCE 9\n21. Schiebe M, Ohneseit P , Hoffmann W, Meyermann R, \nRodemann HP , Bamberg M: Loss of heterozygosity at \n11p15 and p53 alterations in malignant gliomas.  \nJ Cancer Res Clin Oncol 2001, 127:325-328\n22. Radtke F, Raj K: The role of Notch in tumorigenesis: \noncogene or tumour suppressor? Nat Rev Cancer 2003, \n3:756-767\n23. Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana \nV, Ghaffari A, Luyken C, Sabel M, Zerrouqi A, Wasner M,  \net al.: Loss of NOTCH2 positively predicts survival in  \nsubgroups of human glial brain tumors.   \nPLoS ONE  20 07, 2:e576\n24. Mohile NA, Forsyth P , Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE: A \nphase II study of intensified chemotherapy alone as  \ninitial treatment for newly diagnosed anaplastic  \noligodendroglioma: an interim analysis.  \nJ Neurooncol 2008, 89:187-193\n25. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt \nHP , Kunze S, Steiner HH: Clinical impact and functional \naspects of tenascin-C expression during glioma pro -\ngression.  Int J Cancer 2002, 98:362-369\n26. Merlo A, Bettler B: Glioblastomas on the move.   \nSci STKE  2004, 2004 :pe18\n27 . Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MC, Zweifel C, Tolnay M, Wasner M, Mer -\ngenthaler S, et al.: Tenascin-C is a novel RBPJkappa-indu -\nced target gene for Notch signaling in gliomas.   \nCancer Res 2009,  69:458-465\n28. Knobbe CB, Merlo A, Reifenberger G: Pten signaling  \nin gliomas. Neuro-oncol 2002, 4:196-211\n29. Hunter C, Smith R, Cahill DP , Stephens P , Stevens C, \nTeague J, Greenman C, Edkins S, Bignell G, Davies H, et \nal.: A hypermutation phenotype and somatic MSH6 \nmutations in recurrent human malignant gliomas after \nalkylator chemotherapy.  Cancer Res 2006, 66:3987-3991\n30. Failly M, Korur S, Egler V, Boulay JL, Lino MM, Imber R, Merlo A: Combination of sublethal concentrations of \nepidermal growth factor receptor inhibitor and mic -\nrotubule stabilizer induces apoptosis of glioblastoma cells.  Mol Cancer Ther 20 07, 6:773-781\n31. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP , Chen W, Daniel VC, Yu W, et al.: A \nstem cell-like chromatin pattern may predispose tumor \nsuppressor genes to DNA hypermethylation and heri -\ntable silencing. Nat Genet 20 07, 39:237-24232. Egler V, Korur S, Failly M, Boulay JL, Imber R, Lino MM, \nMerlo A: Histone deacetylase inhibition and blockade of \nthe glycolytic pathway synergistically induce glioblas -\ntoma cell death.  Clin Cancer Res 2008, 14 :3132-3140\n33. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al.: Molecular subclasses of high-grade glioma predict \nprognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, \n9:157-173\n34. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, et al.: \nEpidermal growth factor receptor and Ink4a/Arf: conver -\ngent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte \naxis.  Cancer Cell 2002, 1:269-277\n35. Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P , Jr., Hemmings BA, Merlo A, Lino MM: GSK3beta regulates \ndifferentiation and growth arrest in glioblastoma. PLoS \nOne 2009, 4:e7443\n36. Walker MD, Green SB, Byar DP , Alexander E, Jr., Batzdorf \nU, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Jr., Mea -\nley J, Jr., et al.: Randomized comparisons of radiotherapy \nand nitrosoureas for the treatment of malignant glioma after surgery.  N Engl J Med 1980, 303:1323-1329\n37 . Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, \nVredenburgh JJ, Rich JN: Molecularly targeted therapy for \nmalignant glioma.  Cancer  20 07, 110:13-24\n38. Bolden JE, Peart MJ, Johnstone RW: Anticancer activi -\nties of histone deacetylase inhibitors. Nat Rev Drug Discov \n2006, 5:769-784\n39. Merlo A, Mueller-Brand J, Maecke HR: Comparing mono -\nclonal antibodies and small peptidic hormones for local \ntargeting of malignant gliomas. Acta Neurochir Suppl   \n2003, 88:83-91\n40. Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, \nHofer S, Kretzschmar M, Tolnay M, Apostolidis C, Waser B, \net al.: Local targeting of malignant gliomas by the diffus -\nible peptidic vector 1,4,7 ,10-tetraazacyclododecane-1-\nglutaric acid-4,7 ,10-triacetic acid-substance p. Clin Cancer \nRes 2006, 12:3843-3850\n41. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Fried -\nman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD: \nClinical experience with alpha-particle emitting 211At: \ntreatment of recurrent brain tumor patients with 211 At-labeled chimeric antitenascin monoclonal antibody \n81C6.  J Nucl Med 2008, 49:30-38DBM Facts 2|2009 Departement Biomedizin10 WISSENSCHAFT | SCIENCE DEPARTEMENT BIOMEDI ZIN USB\nDiabetes mellitus: \nWhy and how does \nthe kidney fail?\nA new research group started their work in the Laboratory for \u201cMolecular Nephrology\u201d of Prof. \nReto Krapf at the Department of Biomedicine in July 2008. The new team is investigating the \npathogenesis of diabetic kidney disease. One main focus of the research group lies in the iden-\ntification and molecular characterization of pro-apoptotic and anti-apoptotic factors determin-ing podocyte survival. Together with the group of PD Dr. Barbara Biedermann, the new team, \nled by Dr. Andreas Jehle, forms the second group in the Laboratory of \u201cMolecular Nephrology\u201d.\nFigure 1: Incidence and prevalence of end-stage renal disease in the U.S.\nIncidence and prevalence of end-stage renal disease in the U.S. according to underlying disease. Source: United States Renal Data System.DBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF  BIOMEDI CINE USB WISSENSCHAFT | SCIENCE 11\nWhy to do research on diabetic kidney disease?\nA combination of the following: The urgent need to \nmake progress in this research area, personal interest and \nexpertise, and the recent availability of novel cell culture models.\nDiabetes mellitus has become the most common \ncause of end-stage renal disease requiring renal replace -\nment therapy in the U.S. (Figure 1) and Europe. This is due \nto the fact that diabetes mellitus is increasing in prevalence \nand diabetes patients live longer. Only 20-40% of patients with diabetes ultimately develop nephropathy, and the \nnatural history of diabetic kidney disease is highly variable. \nProgression to end-stage renal disease is less likely in pa -\ntients with type 2, than with type 1, diabetes. Nonethe -\nless, the prevalence of type 2 diabetes is much greater, and most diabetic patients starting renal replacement therapy today have type 2 diabetes. It has become clear that hy -\nperglycemia alone is neither the only contributing factor, nor sufficient to cause diabetic kidney disease. An increas -\ning number of hemodynamic, metabolic, inflammatory, structural, and genetic factors have been identified  in the disease process [1]. However, further advances are urgently needed to give halt to the steep increase in its incidence and prevalence.Although new to the field of diabetic nephropathy, \nour group\u2019s expertise is based on a longstanding interest for the aging and failing kidney [2], which combined with a molecular background in renal physiology [3-5] as well as cell biology [6] should enable us to investigate diabetic kid-ney disease.\nFrom bench to bedside and back\nMost would agree that studying humans is ideal and \nrepresents \u201cthe gold standard\u201d for medical research. However, experimental models in animals and cell cul-ture models have proved to be important complimen-tary tools in many research fields where studies in hu-mans are limited. Specifically, cell culture models are indispensable to study and understand a disease pro-cess at the molecular level. This is particularly difficult for solid organs made up of terminally differentiated cells such as the kidney. Fortunately, different renal cells \nare available today, including the highly differentiated \npodocytes, which in conjunction with the glomerular endothelium and the glomerular basement membrane (GBM) constitute the filtration barrier (Figure 2).\nFigure 2: Structure of the glomerular filtration barrier\nThe human kidney contains about one million filtration units called glomeruli. A glomerulus consists of a bag-like Bowman\u2019s capsule  \ncontaining several capillary loops. The filtration barrier consists of the fenestrated endothelium of the capillary wall, the glomerular basement membrane (GBM), and the podocytes with their interdigitating foot processes. Picture: Karolinska Institute, Stockholm, Sweden.12 WISSENSCHAFT | SCIENCE INSTITUTE OF PHYSIOLOGY\nDBM Facts 2|2009 Departement Biomedizin12 WISSENSCHAFT | SCIENCE DEPARTEMENT BIOMEDI ZIN USB\nLoss and apoptosis of podocytes at the onset of \ndiabetic kidney disease\nUrinary loss of albumin and other proteins (= pro-\nteinuria) is an early characteristic of diabetic kidney di-sease.  Proteinuria is presumed to result from increased passage of proteins through the glomerular filtration barrier as a consequence of raised intraglomerular/transcapillary pressure as well as structural alterations of the glomerular filtration barrier. Importantly, studies in patients with type 1 and type 2 diabetes have shown an inverse relationship between urinary albumin excre-tion and the number and/or density of podocytes. Also, podocyte number predicted changes of urinary albu-min excretion over time in type 2 diabetic patients with albuminuria [7] (Figure 3).\n As podocytes have no, or only very limited, ability \nto replicate, apoptosis is likely a main mechanism for \npodocyte loss in diabetes. Of note, in a recent study in \nmice, apoptosis of podocytes occurred at the onset of diabetes, coincided with the onset of urinary albumin excretion, and preceded significant losses of podocytes as well as glomerular extracellular matrix accumulation [8]. Therefore, efforts to understand and potentially prevent mechanisms leading to damage, apoptosis and \nfinally loss of podocytes in patients with diabetic kidney \ndisease are needed.  \nA fine balance for life and death decisions\nThe \u201cright\u201d balance between pro-apoptotic and an-\nti-apoptotic (survival) factors will determine whether a \npodocyte will undergo apoptosis or not. In particular, owing to advances in the field of cancer research, the complexity of the apoptotic program which is characte-rized by considerable crosstalk between different apo-ptotic and survival pathways is already known in quite some detail. However, data about pro-apoptotic factors co-determining the faith of podocytes in diabetic kid-ney disease is limited and even less is known about anti-\nFigure 3: Podocyte number predicts change in urinary albumin excretion\nPodocyte number at basline in 16 Pima Indiens with type 2 diabetes mellitus and change in urinary albumine excretion ( \u2206 UAE) 4 years \nlater [7].INSTITUTE OF PHYSIOLOGY WISSENSCHAFT | SCIENCE 13\nDBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF  BIOMEDI CINE USB WISSENSCHAFT | SCIENCE 13\napoptotic signals counterbalancing apoptotic stimuli. \nImportant players in the life and death decisions of po-docytes with specific evidence to be involved in diabetic kidney disease are summarized in Figure 4.\nThe trick to grow and study podocytes \nFigure 4: The delicate balance between life and death\nThe balance between pro-apoptotic and anti-apoptotic (survival) factors will determine whether a podocyte will undergo apoptosis  \nor not. Apart from high glucose levels an increasing number of additional pro-apoptotic factors are known. Data about anti-apoptotic factors are still very limited. \nCell culture experiments allow direct study of me-\nchanistic events and control of the environment such \nthat a specific hypothesis can be tested. For podocytes, as for many other cell types, rapid dedifferentiation in vitro is a major problem. In the late 1990s Dr. Peter  \nMundel and co-workers achieved to culture differentia-ted podocytes outgrown from glomeruli [9]. However, in vitro studies with these primary podocytes were li-mited as differentiated podocytes do not proliferate. A major breakthrough was achieved by the generation of conditionally immortalized podocyte cell lines de-rived from the Immortomouse. In brief, this approach allows growing of highly proliferative podocytes in the presence of \u03b3-interferon at 33\u00baC which leads to the ex-\npression of a temperature sensitive SV40 large T anti-gen. After withdrawal of \u03b3-interferon and a temperature \nshift to 37\u00baC the cells stop proliferating, they turn to a quiescent state, and  express the vast majority of po-docyte-specific proteins described in vivo [10]. We are fortunate to be able to work with this cell culture model DBM Facts 2|2009 Departement Biomedizin14 WISSENSCHAFT | SCIENCE DEPARTEMENT BIOMEDI ZIN USB\nFigure 5: Palmitic acid induces apoptosis and necrosis of podocytes in a dose-dependent manner.\nPodocytes were incubate in medium containing fatty acid free BSA (control) or BSA complexed with variable concentrations of palmitic acid  \n(125 \u2013 500 M) for 38 h. Apoptosis of podocytes was determined by annexin V/PI staining followed by flow cytometry. Bar graph represents  \nthe mean percentages \u00b1 +/\u2013SD of annexin V-positive/PI-negative (early apoptotic) and annexin V-positive/PI-positive (late apoptotic/necrotic) \npodocytes (n = 3; * p < 0.05, ** p < 0.01). Unpublished data Sieber, and Jehle.\ndeveloped by Dr. Peter Mundel (currently in Miami) and \nin collaboration with him we have been able to generate our own conditionally immoratized podocyte cell lines from knockout mice. This should enable us to characte-rize the molecular pathways determining the fine balan-ce for life and death of podocytes in more detail. \nOngoing research\nThe important role of free fatty acids is well known \nfor the pathogenesis of diabetes mellitus.  Based on our \nown preliminary data free fatty acids seem also to be critically involved in the balancing act between life and death of podocytes (Figure 5). Currently we are explo-ring the molecular pathways involved herein and in col-laboration with Dr. Clemens Cohen from Zurich we are able to compare our in vitro findings with gene expressi-on analysis on glomerular and non-glomerular fractions of kidney biopsies from patients with diabetic kidney disease.  We hope to present and publish these data in detail in the near future. \nPhagocytosis of apoptotic cells is the final step of \nthe apoptotic program leading to an orderly disposal of damaged cells and preventing release of toxic, pro-inflammatory substances from the dying cell. Our pre-liminary data indicate that podocytes are able to pha-gocytose apoptotic podocytes themselves. Ongoing experiments aim at characterizing this in detail as well as the inflammatory or anti-inflammatory response eli-\ncited by this process. \n \nDBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF  BIOMEDI CINE USB WISSENSCHAFT | SCIENCE 15\nReferences:\n1. Dronavalli, S., I. Duka, and G.L. Bakris, The patho-\ngenesis of diabetic nephropathy.  Nat Clin Pract Endocrinol \nMetab, 2008. 4(8): p. 444-52.\n2. Jehle, A. and R. Krapf, [Kidney function and kidney \ndiseases in the elderly] . Schweiz Med Wochenschr, 2000. \n130(11): p. 398-408.\n3. Jehle, A.W., et al., Acid-induced stimulation of Na-Pi \ncotransport in OK cells: molecular characterization and \neffect of dexamethasone. Am J Physiol, 1997. 273(3 Pt 2):  \np. F396-403.\n4. Jehle, A.W., et al., IGF-I and vanadate stimulate  \nNa/Pi-cotransport in OK cells by increasing type II  \nNa/Pi-cotransporter protein stability.  Pflugers Arch, 1998. \n437(1): p. 149-54.\n5. Jehle, A.W., et al., Type II Na-Pi cotransport is regulated \ntranscriptionally by ambient bicarbonate/carbon dioxide \ntension in OK cells. Am J Physiol, 1999. 276(1 Pt 2):  \np. F46-53.\n6. Jehle, A.W., et al., ATP-binding cassette transporter A7 \nenhances phagocytosis of apoptotic cells and associated \nERK signaling in macrophages.  J Cell Biol, 2006. 174(4):  \np. 547-56.\n7. Meyer, T.W., P .H. Bennett, and R.G. Nelson, Podocyte \nnumber predicts long-term urinary albumin excretion in \nPima Indians with Type II diabetes and microalbuminuria. \nDiabetologia, 1999. 42(11): p. 1341-4.\n8. Susztak, K., et al., Glucose-induced reactive oxygen \nspecies cause apoptosis of podocytes and podocyte  \ndepletion at the onset of diabetic nephropathy.  Diabetes, \n2006. 55(1): p. 225-33.\n9. Mundel, P ., J. Reiser, and W. Kriz, Induction of  \ndifferentiation in cultured rat and human podocytes.  \nJ Am Soc Nephrol, 1997. 8(5): p. 697-705.\n10. Shankland, S.J., et al., Podocytes in culture: past,  \npresent, and future.  Kidney Int, 2007. 72(1): p. 26-36.Conclusion\nDiabetic kidney disease is the most common cause \nof end-stage renal disease in developed countries and \nachieving a better understanding of its pathogenesis is needed to avoid this serious condition. There is now ample evidence that damage, apoptosis and loss of po-docytes contributes to the pathogenesis of diabetic ne-phropathy. Results of in vitro experiments in conjunction with molecular analysis of kidney biopsies from patients with diabetic kidney disease harbor a great potential to identify new targets for the prevention and treatment \nof renal complication of diabetes mellitus. We hope that \nwe will be able to contribute to this progress with the ultimate aim to improve overall morbidity and mortality of affected patients. \nJonas Sieber and Andreas JehleDBM Facts 2|2009 Departement Biomedizin16 DBM INTERNATIONAL DEPARTEMENT BIOMEDI ZIN USB\nAdaptation: a key factor \nfor living in New York City!\nHow many books, movies and songs talk about living \nin New York City (NYC)?? So many\u2026 and you think that \nyou know it all and you are fully prepared for it, even if the NY life turns out to be like the one represented in the ironic comedies by Woody Allen. Well, I have to say that the life there did surprise me almost everyday, and not always in the most positive way. The change for me had actually been quite big - from the quiet, organized and neat Basel to NYC. After my PhD, I decided to work in the US since I was told that US research was really ad-vanced and conducted at a completely different \u2018pace\u2019 and level to that in Europe. So I joined the laboratory of Stem Cell and Tissue Engineering, directed by Professor Vunjak Novakovic at Columbia University. \nNeedless to say, there were many difficulties and \nthey occurred from the very beginning! I did not know anybody in the city and the fact that I had to move  \nthere, alone for the first time in my life, did not help. Despite the great prestige and fame of Columbia Univer-sity, they did not provide me with any accommodation \nFig 1. View of the diner which became famous in the Woody Allen movie.DBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF BIOMEDICINE USB DBM INTERNATIONAL 17\nor help, so at the beginning I had to find a bedroom in \nan apartment in the Dominican neighbourhood through internet. After two months of intense and problematic searching, I found a small studio of 18 square meters, with a kitchen at one wall and a tiny, tiny bathroom. The size of the studio was not what bothered me most, but the traffic lights just in front of my window, the great \nnoise coming from the street and the bus station, the \nassociated tradditional noise and pollution, and last BUT believe me not least, were my roommates! Yes, I soon \ndiscovered that I was not alone in the tiny studio\u2026 se-veral huge cockroaches were already living there. It see-med quite normal for a studio in Manhattan. But anyway.  I had learnt that they are the most evolved creatures in this world, and reportedly can survive a nuclear bomb, but the real talent of these creatures was not in these facts, but that they could make a human being so mise-rable! They were very comfortable walking around even \nwith the lights on, they can be very fast, and they can re-\nsist the most poisonous spray. Well, for the first months I didn\u2019t sleep much, because I was scared and city was noisy. I soon learned also that nobody would help me in case of danger, since the first evening I screamed quite loud for a long time as I fought against a big cockroach. Suddenly, in a moment of cold reality, I realized that I shouldn\u2019t scream so loud because my neighbours could also call the police. Well, nobody called anybody. Ob-viously it took me a while to adjust to my roommates, \nbut after few months my screaming was considerably lowered and I started to consider the cockroaches as the pets that I would have always liked to foster. Indeed when I came back home, I expected my \u2018pets\u2019 to run to welcome me\u2026 \nFortunately, after 8 months I found another studio \nwhich was very comfortable and big (50 square meters!) and I could rest much better and start to enjoy all the amusements that NYC offers! The greatest thing of NYC is that there is an opportunity for any pocket; even if you were without money you could enjoy free concerts, \nopera in the parks and concerts at the Lincoln Center \nand even of Broadway shows of very high quality at a very affordable price! \nMaking friends was also not easy, most of the time \nI felt really lonely even in such a big, crowded, cosmo-politan city, such as NYC. NYC has indeed always wel-comed people from the entire world, providing typical cooks and space for continuing their cultural habits. The multi-culture environment of NYC should be kept as an example for every city; there people from so different countries and cultures can live together in a respectful \nFig 2. View of Times Square, where the crowd of tourists is dazz -\nled by the countless bewitched advertisements 24 hours a day.\nFig 3. Picture of Manhattan from Long Island City during the \nManhattanhenge, which is a semi-annual occurrence in which \nthe setting sun aligns with the east-west streets of Manhattan's \nmain street grid. The term is derived from Stonehenge, at which the sun aligns with the stones on the solstices.18 WISSENSCHAFT | SCIENCE INSTITUTE OF PHYSIOLOGY\nDBM Facts 2|2009 Departement Biomedizinand peaceful way, willing to share their habits and in par-\nticular their typical food! However, the real New Yorkers seemed pretty doubtful if they met a friendly person, they possibly assign ulterior motives to friendliness. Consequently, it takes time for them to trust somebo-dy. It took me almost one year before I would have a few close friends. \nI really missed biking, hiking in nature and every  \nbreath I took made me think \u2018have I already compromised my health or am I still ok?\u2019 The noise of the city was unen-ding. I always tried to close my ears in the subway at the \npassage of the trains, at the continuous sirens of police \nor fireman trucks and ambulances. Most of the people, even though they are not in a hurry, kept running fast heedless that they were banging into others on the way.  \nCentral Park looked to me to be a bizarre refuge for \ngreen lovers, but with a still vivid memory of the beauti-ful Alps and green wide lawns, I felt so sad looking at all the people trying to enjoy the fake wild nature, walking, jogging, biking, doing Tai Chi among the trees, skating, even snowshoeing, cross-country and mountain skiing with either real or artificial snow!!! \nTwo very good friends told me their secret \u2018mantra\u2019 \nto survive NYC\u2019s stress and craziness: yoga and running. Well, I started to do both and I managed to increase my sleep and reduce the stress at work.\nThe first time I went to a Y oga studio, I was really \nlate, very stressed since I had to cross Manhattan to get there. When I finally got there, I had the impression that all the people who were getting out of class were so re-laxed and peaceful, and this cheerfulness somehow got on my nerves!! But as soon as I entered the little cosy studio, with warm colours and candles my mood chan-ged. The teacher\u2019s voice was amazingly sweet and gui-ded me into each step of the Asanas. I enjoyed the time \nin class, without realizing I focused so much on the de-\ntails of the instructions that my mind cleared, and at the end I was like one of those peaceful persons myself and I wondered if the class had worked its magic. Yoga chan-ged my life so drastically, that after two years of lear-ning, I was ready to undertake the \u2018teacher training\u2019 to get certified for sharing the benefits of practicing yoga with others. \n\u2018Going running\u2019 was something therapeutic for me \nand opened my relief valve to immediately release the pressure accumulated during a bad day. Soon I joined the NYC Road-Runner Club and started to participate in small races in the city. It was really beautiful and I beca-\nFig 4. The Jacqueline Kennedy Onassis Reservoir in Central Park, where I spent most of my time and where I ran away most of my sorrows. \nThis is the part of NYC that will remain in my heart forever. 18 DBM INTERNATIONAL DEPARTEMENT BIOMEDI ZIN USBINSTITUTE OF PHYSIOLOGY WISSENSCHAFT | SCIENCE 19\nDBM Facts 2|2009 Department of Biomedicine\nme a part of the crazy crowd that went running at 5 am, \nin sun, rain, ice or snow. At that point, amazingly, Central Park seemed to be the most beautiful place in the world, and the surrounding sky-scrapers were my Alps. Later  \nin spring 2008, along with some new friends I participa-ted in the annual lottery that allowed few people to par-ticipate in the NYC marathon. Much to my amazement, I happened to get the lucky number! Before I got time to digest this fact, I was already running late in terms of training myself. My friends convinced me not to miss this occasion, and soon I found myself gearing-up for \nthe longest run ever in my life! The 2nd of November is \ncurrently recorded in my diary as the first major joyous fitness event of my life and now when I look back I see only exhilaration, overwhelming emotion and pride. I had friends in all the 5 neighbourhoods waiting to cheer me on as I crossed one lap after another!\n It was suddenly so beautiful to see the entire city \nstopping for the runners and getting into the streets to cheer, give food, water, paper towels, a smile or a hug\u2026 Every neighbourhood was different: different people, different music bands, different rhythms. I enjoyed every second of this long, long journey when every unknown face smiled and encouraged me to run. Sud-denly, life takes a peculiar turn and you are running this race with 43,000 people, yet the spotlight senses only you and you feel as if you are carried over by a storm of humanity! To burst my bubble of cheerfulness, my knee started to hurt in the last 5 miles, so instead of running, I slowed down to a walk, yet the adrenalin failed to leave \nme, people were supporting me from everywhere, even \nmore than earlier, and finally I completed the 26.2 miles and I had tears streaming down my face.\nI don\u2019t know what this marathon did to me, but  \nsomehow I began to look on the brighter side of my stay there. Away from my closest family and friends, my ex-perience in NYC was beneficial as I had time to realise many things about myself. I probably would not have known the joy of yoga and the once-in-a-lifetime expe-rience of running a marathon, had I not crossed the oce-an and flown to NYC. Also at work, I had began to utilise every opportunity to learn and gradually I was able to handle the most critical and stressful situations. I felt myself growing more confident in my scientific abilities as I continued to work on cardiac tissue engineering. I was chiefly investigating the capability of mesenchymal stem cells to differentiate into cardiac lineage. In the end, we optimized conditions for generating in vitro functional cardiac patches by using neonatal rat cardi-omyocytes. I found myself patting myself on the back one evening, and somehow I felt, I had made it in NYC.\nOn one fine afternoon, at the metro station I hap-\npened to see some tourists who looked horrified at the cockroaches and rats proudly walking around; and then I saw them close their ears at the passage of the train. I found myself smiling at their predicament and thought that they too would get to know and love this city just as I had done\u2026. it would be just a matter of time. \u2018And if I can make it there, I\u2019m gonna make it anywhere, it\u2019s up to you, New Y ork New Y ork\u2019, croons Frank Sinatra and \nfrankly, I think it is quite true!\nAnna Marsano\nFig 5. NYC Marathon: the great joy after finishing the first half of \nthe 26.2 miles... later on the smile faded away!DEPARTMENT OF BIOMEDICINE USB DBM INTERNATIONAL 1920 PUBLICATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinSelected publications by DBM members\nBelow you can find the abstracts of recent articles published by members of the DBM. The abstracts are grouped \naccording to the impact factor of the journal where the work appeared. To be included, the papers must meet the following criteria: \n1. The first author, last author or corresponding author (at least one of them) is a member of the DBM. \n2. The DBM affiliation must be mentioned in the authors list as it appeared in the journal. 3. The final version of the article must be available (online pre-publications will be included when the correct volume,  \n     page numbers etc. becomes available). \nWe are primarily concentrating on original articles. Due to page constraints, abstracts of publications that appeared \nin lower ranked journals may not be able to be included. Review articles are generally not considered, unless they appeared in the very top journals (e.g. Cell, Science, Nature, NEJM, etc.). The final decision concerning inclusion of an abstract will be made by the chair of the Department of Biomedicine.\nIf you wish that your article will appear in the next issue of DBM Facts please submit a pdf file to the Departmental  \nAssistant, Manuela Bernasconi: manuela.bernasconi@unibas.chDeadline for the next issue is January 31, 2010.\nAbstract: \nFLT3-ITD\u2013mediated leukemogenesis is associated with increased expres-sion of oncogenic PIM serine/threonine kinases. To dissect their role in FLT3-ITD\u2013mediated transformation, we performed bone marrow recon-stitution assays. Unexpectedly, FLT3-ITD cells deficient for PIM1 failed to reconstitute lethally irradiated recipients, whereas lack of PIM2 induc-tion did not interfere with FLT3-ITD\u2013induced disease. PIM1-deficient bone marrow showed defects in homing and migration and displayed decreased surface CXCR4 expression and impaired CXCL12\u2013CXCR4 sig-naling. Through small interfering RNA\u2013mediated knockdown, chemical inhibition, expression of a dominant-negative mutant, and/or reexpres-sion in knockout cells, we found PIM1 activity to be essential for proper CXCR4 surface expression and migration of cells toward a CXCL12 gradi-ent. Purified PIM1 led to the phosphorylation of serine 339 in the CXCR4 intracellular domain in vitro, a site known to be essential for normal re-ceptor recycling. In primary leukemic blasts, high levels of surface CXCR4 were associated with increased PIM1 expression, and this could be sig-nificantly reduced by a small molecule PIM inhibitor in some patients. Our data suggest that PIM1 activity is important for homing and migration of hematopoietic cells through modification of CXCR4. Because CXCR4 also regulates homing and maintenance of cancer stem cells, PIM1 inhibitors may exert their antitumor effects in part by interfering with interactions with the microenvironment.\n1 Department of Internal Medicine III, Technical University, Munich 81739, Germany\n2 Department of Biomedicine, University Hospital, Basel 4031, Switzerland\n3 University of Oxford, Structural Genomics Consortium, Old Road Campus Research Centre, \nOxford OX3 7DQ, England, UK\n4 Centro M. Tettamanti-Clinica Pediatrica, Universita Milano-Bicocca, 20042 Monza, Italy\n5 Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg 79111, GermanyDissection of PIM serine/threonine kinases in FLT3-ITD\u2013induced leukemogenesis \nreveals PIM1 as regulator of CXCL12\u2013CXCR4-mediated homing and migration\nR. Grundler1, L. Brault2, C. Gasser2, A. N. Bullock3, T. Dechow1, S. Woetzel1, V. Pogacic2, A. Villa4, S. Ehret2, G. Berridge3, A. Spoo5,  \nC. Dierks5, A. Biondi4, S. Knapp3, J. Duyster1 and J. Schwaller2The Journal of Experimental Medicine 323, 1957\u20131970, 2009  IF15,4DEPARTMENT OF BIOMEDICINE PUBLICATIONS 21\nDBM Facts 2|2009 Department of BiomedicineAbstract: \n5-Fluorouracil (5-FU), a chemotherapeutic drug commonly used in cancer treatment, imbalances nucleotide pools, thereby favoring misincorpora-tion of uracil and 5-FU into genomic DNA. The processing of these bases by DNA repair activities was proposed to cause DNA-directed cytotoxicity, but the underlying mechanisms have not been resolved. In this study, we investigated a possible role of thymine DNA glycosylase (TDG), one of four mammalian uracil DNA glycosylases (UDGs), in the cellular response to 5-FU. Using genetic and biochemical tools, we found that inactivation of TDG significantly increases resistance of both mouse and human cancer cells towards 5-FU. We show that excision of DNA-incorporated 5-FU by TDG generates persistent DNA strand breaks, delays S-phase progression, and activates DNA damage signaling, and that the repair of 5-FU\u2013induced DNA strand breaks is more efficient in the absence of TDG. Hence, exci-sion of 5-FU by TDG, but not by other UDGs (UNG2 and SMUG1), prevents efficient downstream processing of the repair intermediate, thereby mediating DNA-directed cytotoxicity. The status of TDG expression in a cancer is therefore likely to determine its response to 5-FU\u2013based che-motherapy.Plos Biology 7, e10000093, 2009  IF14,1\nBase Excision by Thymine DNA Glycosylase Mediates DNA-Directed  \nCytotoxicity of 5-Fluorouracil\nC. Kunz1, F. Focke1, Y. Saito1, D. Schuermann1, T. Lettieri2, J. Selfridge3 and P. Sch\u00e4r1\nHepatology 50, 871\u2013879, 2009  IF11,3\nAbstract: \nIntrahepatic bile duct (IHBD) development begins with the differentia-tion of hepatoblasts into a single continuous biliary epithelial cell (BEC) layer, called the ductal plate. During ductal plate remodeling, tubular structures arise at distinct sites of the ductal plate, forming bile ducts that dilate into the biliary tree. Alagille syndrome patients, who suffer from bile duct paucity, carry Jagged1 and Notch2 mutations, indicating \nthat Notch2 signaling is important for IHBD development. To clarify the role of Notch2 in BEC differentiation, tubulogenesis, and BEC survival, we developed a mouse model for conditional expression of activated Notch2 in the liver. We show that expression of the intracellular domain of Notch2 (Notch2ICD) differentiates hepatoblasts into BECs, which form additional bile ducts in periportal regions and ectopic ducts in lobular regions. Ad-ditional ducts in periportal regions are maintained into adulthood and connect to the biliary tight junction network, resulting in an increased number of bile ducts per portal tract. Remarkably, Notch2ICD-expressing ductal plate remnants were not eliminated during postnatal develop-ment, implicating Notch2 signaling in BEC survival. Ectopic ducts in lobu-lar regions did not persist into adulthood, indicating that local signals in the portal environment are important for maintaining bile ducts.Conclusion: Notch2 signaling regulates BEC differentiation, the induc-tion of tubulogenesis during IHBD development, and BEC survivalNotch2 signaling promotes biliary epithelial cell fate specification and  \ntubulogenesis during bile duct development in mice\nJ. S. Tchorz1, J. Kinter2, M. M\u00fcller3, L. Tornillo4, M. H. Heim5 and B. Bettler1\n1 Department of Biomedicine, Institute of Physiology, University of Basel, Switzerland\n2 Department of Biomedicine, Division of Neurology, University of Basel, Switzerland\n3 Novartis Institute for Biomedical Research, Novartis Pharma AG, Basel, Switzerland\n4 Institute for Pathology, University Hospital Basel, Basel, Switzerland\n5 Department of Biomedicine, Division of Gastroenterology and Hepatology, University of Basel, \nSwitzerland1 Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, \nSwitzerland\n2 Institute of Cell Biology, ETH Z\u00fcrich, Z\u00fcrich, Switzerland\n3 Wellcome Trust Centre for Cell Biology, Institute of Cell and Molecular Biology, University of Edinburgh, Edinburgh, Scotland22 PUBLICATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinAbstract: \nTenascin-C (TNC) expression is known to correlate with malignancy in glioblastoma (GBM), a highly invasive and aggressive brain tumor that shows limited response to conventional therapies. In these malignant gliomas as well as in GBM cell lines, we found Notch2 protein to be strong-ly expressed. In a GBM tumor tissue microarray, RBPJk protein, a Notch2 cofactor for transcription, was found to be significantly coexpressed with TNC. We show that the TNC gene is transactivated by Notch2 in an RBPJk-\ndependent manner mediated by an RBPJk binding element in the TNC promoter. The transactivation is abrogated by a Notch2 mutation, which we detected in the glioma cell line Hs683 that does not express TNC. This L1711M  mutation resides in the RAM domain, the site of interaction be-\ntween Notch2 and RBPJk. In addition, transfection of constructs encod-ing activated Notch2 or Notch1 increased endogenous TNC expression identifying TNC as a novel Notch target gene. Overexpression of a domi-\nnant negative form of the transcriptional coactivator MAML1 or knocking down RBPJk in LN319 cells led to a dramatic decrease in TNC protein levels accompanied by a significant reduction of cell migration. Because addi-tion of purified TNC stimulated glioma cell migration, this represents a mechanism for the invasive properties of glioma cells controlled by Notch signaling and defines a novel oncogenic pathway in gliomagenesis that may be targeted for therapeutic intervention in GBM patients.\nCancer Research 69, 458\u2013465, 2009  IF7,6\n1 Laboratory of Molecular Neuro-Oncology, Department of Research, University Hospital,Basel, \nSwitzerland\n2 Neurosurgical Clinic, University Hospital,Basel, Switzerland\n3 Institute of Pathology, University Hospital,Basel, Switzerland\n4 Laboratory of Prenatal Medicine, Department of Research, University Hospital,Basel, Switzerland\n5Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, Basel, \nSwitzerland\n6 Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Centre Universitaire Romand de Neurochirurgie, and University of \n Lausanne, Lausanne, Switzerland\n7 National Center of Competence in Research, Molecular Oncology, Institut Suisse de Recherche Exp\u00e9rimentale sur le Cancer, SLS-EPFL, Epalinges, Switzerland\n8 Research Laboratories, diagene, Inc., Reinach, Switzerland\n9 Laboratory of Toxicology, Institute of Pharmacy, Free University, Brussels, BelgiumTenascin-C Is a Novel RBPJ\u03ba -Induced Target Gene for Notch Signaling in Gliomas\nB. Sivasankaran1, M. Degen5, A. Ghaffari1,2, M. E. Hegi6,7, M.F. Hamou6, M.C.S. Ionescu1, C. Zweifel1,2, M. Tolnay3, M. Wasner2,  \nS. Mergenthaler4, A. R. Miserez8, R. Kiss9, M. M. Lino1, A. Merlo1,2, R. Chiquet-Ehrismann5 and J. L. Boulay1\nAbstract: \nObjectives: To investigate whether human bone marrow-derived mes-enchymal stem cells (BM-MSCs) and articular chondrocytes (ACs) affect the in vitro proliferation of T lymphocytes and peripheral blood mono-nuclear cells (PBMCs) driven by the homeostatic interleukin (IL)2, IL7 and IL15 cytokines binding to the common cytokine receptor -chain (c) in the absence of T cell receptor (TCR) triggering.\nMethods: PBMCs, total T cells and T cell subsets (CD4+ and CD8+) were \nstimulated with IL2, IL7 or IL15 and exposed to cultured BM-MSCs and ACs at varying cell:cell ratio either in contact or in transwell conditions. Lymphocyte proliferation was measured by 3H-thymidine uptake or by flow cytometry of carboxyfluorescein succinimidyl ester (CFSE)-labelled lymphocytes.\nResults: MSCs and ACs enhanced and inhibited lymphocyte proliferation \ndepending on the extent of lymphocyte baseline proliferation and on the MSC/AC to lymphocyte ratio. Enhancement was significant on poorly pro-liferating lymphocytes and mostly at lower MSC/AC to lymphocyte ratio. Suppression occurred only on actively proliferating lymphocytes and at high MSC/AC to lymphocyte ratio. Neither enhancement nor inhibition required cell\u2013cell contact.\nConclusions: There is a dichotomous effect of MSCs/ACs on lymphocytes \nproliferating in response to the homeostatic IL2, IL7 and IL15 cytokines likely to be encountered in homeostatic and autoimmune inflammatory conditions. The effect is determined by baseline lymphocyte prolifera-tion, cell:cell ratio and is dependent on soluble factor(s). This should be taken into account when planning cellular therapy for autoimmune dis-ease (AD) using stromal-derived cells such as MSCs.Annals of the Rheumatic Diseases  68, 1352\u20131359, 2009  IF7,2\nHuman bone marrow mesenchymal stem cells and chondrocytes promote \nand/or suppress the in vitro proliferation of lymphocytes stimulated by  \ninterleukins 2, 7 and 15\nC. Bocelli-Tyndall1,2, L. Bracci1,3, S. Schaeren1, C. Feder-Mengus1, A. Barbero1, A. Tyndall2 and G. C. Spagnoli1\n1 Institute of Surgical Research and Hospital Management and Department of Biomedicine, \nUniversity Hospital Basel, Basel, Switzerland \n2 Department of Rheumatology, University of Basel, Basel, Switzerland \n3 Department of Cell Biology and Neurosciences, Istituto Superiore di Sanit\u00e0, Rome, Italy\nDEPARTMENT OF BIOMEDICINE PUBLICATIONS 23\nDBM Facts 2|2009 Department of BiomedicineOncogene 28, 2969\u20132978, 2009  IF 7,2\nAbstract: \nAlterations of DNA methylation patterns have been suggested as bio-markers for diagnostics and therapy of cancers. Every novel discovery in the epigenetic landscape and every development of an improved ap-proach for accurate analysis of the events may offer new opportunity for the management of patients. Using a novel high-throughput mass spec-trometry on matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) silico-chips, we determined semiquantitative methylation changes of 22 candidate genes in breast cancer tissues. For the first time we analysed the methylation status of a total of 42 528 CpG dinucleotides on 22 genes in 96 different paraffin-embedded tissues (48 breast cancer-ous tissues and 48 paired normal tissues). A two-way hierarchical cluster analysis was used to classify methylation profiles. In this study, 10 hyper-methylated genes (APC, BIN1, BMP6, BRCA1, CST6, ESRb, GSTP1, P16, P21 \nand TIMP3) were identified to distinguish between cancerous and normal \ntissues according to the extent of methylation. Individual assessment of the methylation status for each CpG dinucleotide indicated that cytosine hypermethylation in the cancerous tissue samples was mostly located near the consensus sequences of the transcription factor binding sites. These hypermethylated genes may serve as biomarkers for clinical mo-lecular diagnosis and targeted treatments of patients with breast cancer.Methylation profiles of 22 candidate genes in breast cancer using  \nhigh-throughput MALDI-TOF mass array\nR. Radpour1, C. Kohler1, M. M. Haghighi2, A. X. C. Fan1, W. Holzgreve3 and X. Y. Zhong1\n1 Laboratory for Prenatal Medicine and Gynecologic Oncology, Women\u2019s Hospital/Department of \nBiomedicine, University of Basel, Basel, Switzerland\n2 Department of Biology, Faculty of Science, IAU, East of Tehran Branch, Tehran, Iran\n3 University Medical Center Freiburg, Freiburg, Germany\nAbstract: \nSilencing of gene expression by aberrant cytosine methylation is a promi-nent feature of human tumors, including colorectal cancers. Epigenetic changes of this type play undisputed roles in cell transformation when they involve genes that safeguard genome stability, and they can also be detected in precancerous lesions and seemingly normal peritumoral tis-sues. We explored physiological conditions associated with aberrant pro-moter methylation involving two DNA-repair genes in normal colorectal mucosa. Samples of cecal, transverse colon, sigmoid and rectal mucosa collected from 100 healthy individuals undergoing screening colonos-copy were analysed for hMLH1 and MGMT promoter methylation with a \nquantitative PCR assay. Positivity in at least one colon segment was com-mon in both sexes, with methylation involving 0.1\u201318.8% of the alleles (median=0.49%). Samples from males showed no consistent patterns for either promoter, but there were striking age- and colon segment-specific differences in the female subgroup. Here, the prevalence of hMLH1 and \nMGMT methylation increased significantly with age, particularly in the right colon, where there was also an age-related increase in the percent-age of alleles showing hMLH1 methylation. Concomitant methylation of both promoters was also significantly more common in the right colon of women. These findings paralleled immunohistochemical patterns of hMLH1 and MGMT protein loss in an independent series of 231 colorectal \ncancers and were consistent with current epigenetic profiles of colorectal cancer subsets. They suggest the intriguing possibility that the epigenetic signatures of cancers may have early-stage, normal-tissue counterparts that reflect potentially important aspects of the initial carcinogenetic pro-cess.Normal colorectal mucosa exhibits sex- and segment-specific susceptibility to \nDNA methylation at the hMLH1 and MGMT promoters\nM. Menigatti1,6, K. Truninger2,6, J. O. Gebbers3, U. Marbet4, G. Marra5 and P. Sch\u00e4r1\n1 Department of Biomedicine, University of Basel, Basel, Switzerland\n2 SRO Hospital Langenthal, Langenthal, Switzerland\n3 Department of Pathology, Cantonal Hospital Lucerne, Lucerne, Switzerland\n4 Clinic of Internal Medicine, Cantonal Hospital Altdorf, Altdorf, Switzerland\n5 Institute of Molecular Cancer Research, University of Zurich, Zurich, SwitzerlandOncogene 28, 899\u2013909, 2009  IF 7,2\n24 PUBLICATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinThe Journal of Immunology 183, 2217\u20132221, 2009  IF 6,0\nAbstract: \nDuring fetal life, CD4+CD3\u2013 lymphoid tissue inducer (LTi) cells are re-\nquired for lymph node and Peyer\u2019s patch development in mice. In adult animals, CD4\n+CD3\u2013 cells are found in low numbers in lymphoid organs. \nWhether adult CD4+CD3\u2013 cells are LTi cells and are generated and main-\ntained through cytokine signals has not been directly addressed. In this study we show that adult CD4\n+CD3\u2013 cells adoptively transferred into neo-\nnatal CXCR5\u2013/\u2013 mice induced the formation of intestinal lymphoid tissues, demonstrating for the first time their bona fide LTi function. Increasing IL-7 availability in wild-type mice either by IL-7 transgene expression or treatment with IL-7/anti-IL-7 complexes increased adult LTi cell numbers through de novo generation from bone marrow cells and increased the survival and proliferation of LTi cells. Our observations demonstrate that adult CD4\n+lineage\u2013 cells are LTi cells and that the availability of IL-7 deter-\nmines the size of the adult LTi cell pool.Cutting Edge: IL-7 Regulates the Peripheral Pool of Adult ROR\u03b3+ Lymphoid  \nTissue Inducer Cells\nS. Schmutz1, N. Bosco2, S. Chappaz1, O. Boyman3, H. Acha-Orbea4, R. Ceredig5, A. G. Rolink2 and D. Finke1\n1 Division of Developmental Immunology, Department of Biomedicine, University of Basel, Basel, \nSwitzerland\n2 Division of Developmental and Molecular Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland\n3 Division of Immunology and Allergy, University Hospital of Lausanne (Central University Hospital of Vaud), Lausanne, Switzerland\n4 Department of Biochemistry, University of Lausanne, Epalinges, Switzerland; and \n5 Regenerative Medicine Institute, National Centre for Biomedical Engineering Science,  \nDepartment of Physiology, National University of Ireland, Galway, IrelandThe Faseb Journal 23, 4011\u20134021, 2009  IF7,0\nAbstract: \nT-cadherin (T-cad) promotes survival, proliferation, and migration of en-dothelial cells and induces angiogenesis. We aimed to identify domains of T-cad functionally relevant to its effects on endothelial cell behavior. To specifically target the functional properties of the 5 cadherin repeat domains (EC1\u2013EC5) of T-cad, endothelial cells were transduced with len-tivectors containing specific T-cad-domain-deletion mutant constructs (I, II, III, IV, V). Empty (E) lentivector-transduced cells served as control. Similarly to overexpression of native T-cad, cells expressing II, III, or IV dis-played elevated levels of p-Akt and p-GSK3\u03b2  and increased proliferation \nrates (for II, III) vs. E. I- and V-transduced cells exhibited reduced levels of p-Akt and p-GSK3\u03b2  and retarded growth rates vs. E. Stimulatory effects \nof native T-cad overexpression on Akt and GSK3\u03b2  phosphorylation were \ndose dependently inhibited by coexpression of I or V. Subsequent func-tional analyses compared only I-, II-, and V-mutant constructs with E as a negative control. Unlike II cells, I and V cells failed to exhibit homophilic ligation and deadhesion responses on a substratum of T-cad protein. In the wound assay, migration was increased for II cells but impaired for I and V cells. In endothelial cell-spheroid assay, angiogenic sprouting was augmented for II cells but inhibited for I and V cells. We conclude that EC1 and EC5 domains of T-cad are essential for its proangiogenic effects. I and V constructs may serve as dominant-negative mutants and as potential tools targeting excessive angiogenesis.\u2014Joshi, M. B., Kyriakakis, E., Pfaff, D., Rupp, K., Philippova, M., Erne, P., Resink, T. J. Extracellular cadherin repeat domains EC1 and EC5 of T-cadherin are essential for its ability to stimulate angiogenic behavior of endothelial cells. Extracellular cadherin repeat domains EC1 and EC5 of T-cadherin are essential \nfor its ability to stimulate angiogenic behavior of endothelial cells\nM. B. Joshi1, E. Kyriakakis1, D. Pfaff1, K. Rupp1, M. Philippova1, P. Erne2, and T. J. Resink1\n1 Department of Biomedicine, Laboratory for Signal Transduction, Basel University Hospital, Basel, \nSwitzerland\n2 Division of Cardiology, Kantonsspital Luzern, Luzern, SwitzerlandDEPARTMENT OF BIOMEDICINE PUBLICATIONS 25\nDBM Facts 2|2009 Department of BiomedicineAbstract: \nLipoproteins (Lpp) are ligands of TLR2 and signal by the adaptor MyD88. As part of the bacterial cell envelope, Lpp are mainly involved in nutrient acquisition for Staphylococcus aureus. The impact of Lpp on TLR2-MyD88 \nactivation for S. aureus in systemic infection is unknown. S. aureus strain \nSA113 deficient in the enzyme encoded by the prolipoprotein diacylglyc-eryl transferase gene (\u2206 lgt), which attaches the lipid anchor to pro-Lpp, \nwas used to study benefits and costs of Lpp maturation. Lpp in S. aureus  \ninduced early and strong cytokines by TLR2-MyD88 signaling in murine peritoneal macrophages. Lpp contributed via TLR2 to pathogenesis of sepsis in C57BL/6 mice with IL-1\u03b2 , chemokine-mediated inflammation, and high bacterial numbers. In the absence of MyD88-mediated inflam-mation, Lpp allowed bacterial clearing from liver devoid of infiltrating cells, but still conferred a strong growth advantage in mice, which was shown to rely on iron uptake and storage in vitro and in vivo. With iron-restricted bacteria, the Lpp-related growth advantage was evident in in-fection of MyD88\n\u2013/\u2013, but not of C57BL/6, mice. On the other hand, iron \noverload of the host restored the growth deficit of \u2206lgt in MyD88\u2013/\u2013, but \nnot in immunocompetent C57BL/6 mice. These results indicate that iron acquisition is improved by Lpp of S. aureus but is counteracted by inflam-\nmation. Thus, lipid anchoring is an evolutionary advantage for S. aureus to \nretain essential proteins for better survival in infection.Lipoproteins in Staphylococcus aureus Mediate Inflammation by TLR2 and \nIron-Dependent Growth In Vivo\nM. Schmaler1, N. J. Jann1, F. Ferracin1, L. Z. Landolt1, L. Biswas2, F. G\u00f6tz2 and R. Landmann1\n1 Department of Biomedicine, Division Infection Biology, University Hospital Basel, Basel,  \nSwitzerland\n2 Microbial Genetics, University T\u00fcbingen, GermanyThe Journal of Immunology 182, 7110\u20137118, 2009  IF 6,0\nMolecular and Cellular Biology 29, 4841\u20134851  IF 5,9\nAbstract: \nRecombinant alpha interferon (IFN-\u03b1 ) is used for the treatment of viral \nhepatitis and some forms of cancer. During these therapies IFN-\u03b1  is in-\njected once daily or every second day for several months. Recently, the long-acting pegylated IFN-\u03b1 (pegIFN-\u03b1 ) has replaced standard IFN-\u03b1  in \ntherapies of chronic hepatitis C because it is more effective, supposedly by inducing a long-lasting activation of IFN signaling pathways. IFN sig-naling in cultured cells, however, becomes refractory within hours, and little is known about the pharmacodynamic effects of continuously high IFN-\u03b1  serum concentrations. To investigate the behavior of the IFN sys-tem in vivo, we repeatedly injected mice with IFN-\u03b1  and analyzed its ef-\nfects in the liver. Within hours after the first injection, IFN-\u03b1  signaling be-\ncame refractory to further stimulation. The negative regulator SOCS1 was rapidly upregulated and likely responsible for early termination of IFN-\u03b1 signaling. For long-lasting refractoriness, neither SOCS1 nor SOCS3 were instrumental. Instead, we identified the inhibitor USP18/UBP43 as the key mediator. Our results indicate that the current therapeutic practice us-ing long-lasting pegIFN-\u03b1  is not well adapted to the intrinsic properties of \nthe IFN system. Targeting USP18 expression may allow to exploit the full therapeutic potential of recombinant IFN-\u03b1 .Alpha Interferon Induces Long-Lasting Refractoriness of JAK-STAT Signaling in \nthe Mouse Liver through Induction of USP18/UBP43\nM. Sarasin-Filipowicz1,2, X. Wang1, M. Yan3, F. H. T. Duong1, V. Poli4, D. J. Hilton5, D. E. Zhang3 and M. H. Heim1\n1 Department of Biomedicine, University Hospital Basel, CH-4031 Basel, Switzerland\n2 Division of Gastroenterology and Hepatology, University Hospital Basel, CH-4031 Basel,  \nSwitzerland\n3 Moores UCSD Cancer Center, Department of Pathology and Division of Biological Sciences, \nUniversity of California San Diego, La Jolla, California 92093\n4 Department of Genetics, Biology and Biochemistry, University of Turin, 10126 Turin, Italy\n5 Division of Molecular Medicine, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3050, Australia26 PUBLICATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinAbstract: \nFetal bovine serum (FBS) and fibroblast growth factor (FGF)-2 are key supplements for the culture of stromal vascular fraction (SVF) cells from adipose tissue, both for typical monolayer (2D) expansion and for streamlined generation of osteogenic\u2013vasculogenic grafts in 3D perfu-sion culture. The present study investigates whether factors present in human platelet lysate (PL) could substitute for FBS and FGF-2 in 2D and 3D culture models of SVF cells from human lipoaspirates. SVF cells were grown in medium supplemented with 10% FBS+FGF-2 or with 5% PL. In 2D cultures, PL initially supported SVF cell proliferation, but resulted in growth arrest shortly after the first passage. Freshly isolated SVF cells cul-Tissue Engineering 15, 869\u2013875, 2009  IF 5,4\nPlatelet Lysate as a Serum Substitute for 2D Static and 3D Perfusion Culture of \nStromal Vascular Fraction Cells from Human Adipose Tissue\nA. M. M\u00fcller1, M. Davenport1, S. Verrier2, R. Droeser1, M. Alini2, C. Bocelli-Tyndall1,3, D. J. Schaefer4, I. Martin1 and A. Scherberich1\n1 Tissue Engineering Group, Laboratory 405, Department of Biomedicine, Institute for Surgical \nResearch and Hospital Management, University Hospital Basel, Basel, Switzerland.\n2 Biomaterials & Tissue Engineering, AO Research Institute, Davos, Switzerland.\n3 University Department of Rheumatology, Felix Platter Spital, Basel, Switzerland.\n4 Clinic of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery,  \nUniversity Hospital Basel, Basel, Switzerland.tured with both media under perfusion for 5 days within 3D ceramic scaf-\nfolds induced bone formation after subcutaneous implantation in nude mice. However, blood vessels of donor origin were generated only using FBS+FGF-2\u2013cultured cells. This was unexpected, because the proportion of CD34\n+/CD31+ endothelial lineage cells was significantly higher with PL \nthan that of FBS+FGF-2 (33% vs. 3%, respectively). These results support the use of PL as a substitute of FBS+FGF-2 for short-term culture of hu-man SVF cells, and indicate that more specific serum-free formulations are required to maintain a functionally vasculogenic fraction of SVF cells expanded under 3D perfusion.Abstract: \nA stereotactic biopsy of a 17-year-old woman revealed an active inflam-matory demyelinating lesion compatible with pattern III multiple sclerosis (MS) according to Lucchinetti et al. The biopsy included a white matter region distant from the active inflammatory demyelinating lesion with abnormal MRI signal, lacking histopathological signs of demyelination and/or oligodendrocyte apoptosis. Expression analysis of this area re-vealed a strong up-regulation of neuronal nitric oxide synthase (nNOS). Furthermore, detection of nitrotyrosine provided evidence for reactive Brain Pathology 19, 459\u2013466, 2009  IF 5,5\nMolecular Changes in White Matter Adjacent to an Active Demyelinating Lesion \nin Early Multiple Sclerosis\nT. Zeis1, A. Probst2, A. J. Steck1, C. Stadelmann3, W. Br\u00fcck3, N. Schaeren-Wiemers1\n1 Neurobiology, Department of Biomedicine and Neurology, University Hospital Basel,  \nPharmacenter, Basel, Switzerland.\n2 Institute of Neuropathology, University Hospital Basel, Basel, Switzerland.\n3 Institute of Neuropathology, Georg-August-University G\u00f6ttingen, G\u00f6ttingen, Germany.nitrogen species (RNS)-mediated damage to oligodendrocytes. Concomi-\ntantly, genes involved in neuroprotection against oxidative stress such as heme oxygenase 1 were up-regulated. Even though a single case report, this study shows earliest molecular changes in white matter surround-ing an actively demyelinating lesion during the first manifestation of MS, pointing toward a more widespread pathological process. Therapeutic targeting of the identified mechanisms of tissue injury might be crucial to prevent further lesion formation or secondary tissue damage.DEPARTMENT OF BIOMEDICINE PUBLICATIONS 27\nDBM Facts 2|2009 Department of BiomedicineAbstract:\nGlycosaminoglycans (GAG) are essential extracellular matrix molecules which regulate tissue flexibility, a parameter that is reduced in airways of patients with asthma and chronic obstructive pulmonary disease (COPD). We investigated the expression of GAG and their metabolising enzymes in primary human airway smooth muscle cells (ASMC) obtained from healthy donors (controls) and patients with asthma or COPD.Total GAG synthesis was assessed by [3H]-glucosamine incorporation. GAG were isolated, purified, fractionated by electrophoresis and charac-terised using specific GAG-degrading enzymes. Secretion of hyaluronic acid (HA) by ASMC from patients with asthma or COPD was significantly European  Respiratory Journal 34, 616\u2013628, 2009  IF5,3\nDecreased hyaluronan in airway smooth muscle cells from patients with \nasthma and COPD\nI. Klagas1, S. Goulet2, G. Karakiulakis1, J. Zhong2, M. Baraket3, J. L. Black3,4, E. Papakonstantinou1 and M. Roth2,3,4\n1 Dept Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, \nGreece. \n2 Pulmonary Cell Research, Dept Research, University Hospital Basel, Basel, Switzerland. 3 Dept Pharmacology, University of Sydney, and 4 The Woolcock Institute for Medical Research, Sydney, \nAustraliadecreased compared with controls. RT-PCR analysis and western blotting \nrevealed that this decrease was associated with a significant reduction in the expression of HA synthase-1 and -2 and a significant increase of hy-aluronidase-1. Furthermore, the expression of the HA receptor CD44 was significantly decreased, whereas the receptor for HA-mediated motility was not expressed in asthma or COPD.Our results indicate that there is a decreased expression of HA in asthma and COPD associated with a synergistic regulation of HA metabolising enzymes that may regulate the pathological airway remodelling in these lung diseases.\nAbstract: Materials and Methods:The genomic effects of tumor-endothelial interactions in cancer are not yet well characterized. To study this interaction in breast cancer, we set up an ex vivo coculture model with human benign and malignant breast epithelial cells with endothelial cells to determine the associated gene ex-pression changes using DNA microarrays.Results:The most prominent response to coculture was the induction of the M-phase cell cycle genes in a subset of breast cancer cocultures that were absent in cocultures with normal breast epithelial cells. In monoculture, tumor cells that contained the stem cell-like CD44\n+/CD24- signature had \na lower expression of the M-phase cell cycle genes than the CD44-/CD24+ \ncells, and in the CD44+/CD24- cocultures, these genes were induced. Pre-\ntreatment gene expression profiles of early-stage breast cancers allowed evaluating in vitro effects in vivo. The expression of the gene set derived from the coculture provided a basis for the segregation of the tumors into two groups. In a univariate analysis, early-stage tumors with high  \nexpression levels (n = 137) of the M-phase cell cycle genes had a signifi-cantly lower metastasis-free survival rate (P = 1.8e - 5, 50% at 10 years) and overall survival rate (P = 5e - 9, 52% at 10 years) than tumors with low expression (n = 158; metastasis-free survival, 73%; overall survival, 84%).Conclusions:Our results suggest that the interaction of endothelial cells with tumor cells that express the CD44\n+/CD24- signature, which indicates a low pro-\nliferative potential, might explain the unexpected and paradoxical associ-ation of the CD44\n+/CD24- signature with highly proliferative tumors that \nhave an unfavorable prognosis.Neoplasia 11, 987\u20131002, 2009  IF5,2\nTumor-Endothelial Interaction Links the CD44+/CD24- Phenotype with Poor \nPrognosis in Early-Stage Breast Cancer\nM. Buess1,2, M. Rajski2, B. M. L Vogel-Durrer2, R. Herrmann2,3 and C. Rochlitz2,3\n1 Medical Oncology, St. Claraspital, Basel, Switzerland\n2 Department of Biomedicine, University of Basel, Basel, Switzerland\n3 Department of Medicine, Division of Oncology, University of Basel, Basel, Switzerland28 PUBLICATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinAbstract:\nCommon receptor \u03b3 chain (c-\u03b3 ) cytokines (CKs) support proliferation of \nCD8+ T cells in presence or absence of antigen triggering and help main-\ntaining the immunologic memory. We addressed the effects of low (<=5 \nng/mL)-dose interleukin (IL)-2, IL-7, or IL-15 on human naive and memory antigen-specific CD8\n+ T cells. Peripheral blood CD8+ lymphocytes prolifer-\nated with decreasing efficiency in response to IL-15, IL-7, and IL-2. Of note, IL-15 preferentially promoted expansion of CD45RA-/CD8\n+ T-cell memory \nsubset. Accordingly, cytotoxic T lymphocytes specific for cytomegalovirus-derived antigens from seropositive donors proliferated in response to IL-15 and, to lesser extent to IL-7, but poorly to IL-2. CD8\n+ T cells were then \npretreated with CK before antigen stimulation using, as read out, specific cytotoxic activity. After the pretreatment with IL-15, but not IL-2, previ-Journal of Immunotherapy 32, 252\u2013261, 2009  IF 4,8\nDifferential Responsiveness to IL-2, IL-7, and IL-15 Common Receptor \u03b3\nChain Cytokines by Antigen-specific Peripheral Blood Naive or Memory Cytotoxic \nCD8+ T Cells From Healthy Donors and Melanoma Patients\nR. Rosenthal1, C. Groeper1, L. Bracci1, M. Adamina1, C. Feder-Mengus1, P. Zajac1, G. Iezzi1, M. Bolli1, W. P. Weber1, D. M. Frey1,  \nU. von Holzen2, D. Oertli1, M. Heberer1 and G. C. Spagnoli1\n1 Institute of Surgical Research and Hospital Management, Department of Biomedicine, University \nHospital of Basel\n2 Department of Surgery, Kantonsspital Olten, Olten, Switzerlandously experienced viral antigens induced vigorous cytotoxic responses. \nMinor effects of IL-7 were also detectable. In contrast, IL-2 best supported the cytotoxic T lymphocyte generation from prevailingly naive CD8\n+ T cells \nfrom HLA-A*0201+ healthy donors, specific for L27Melan-A/MART-126-35 \nmelanoma-associated antigen. Cells from melanoma patients were tested before and after Melan-A/MART-1\u2013targeted antigen-specific immunothera-py. Untreated patients showed heterogeneous patterns of responsiveness to c-\u03b3  CK. However, when naive patients whose CD8\n+ T cells best responded \nto IL-2 were vaccinated, a modified responsiveness pattern was detectable. After immunization, cells displayed a significantly higher response to IL-15 than to IL-2 pretreatment. Thus, responsiveness to c-\u03b3  CK is critically influ-\nenced by naive or memory status of peripheral blood CD8\n+ T cells.\nAbstract: \nBrominated furanones from marine algae inhibit multicellular behaviors of gram-negative bacteria such as biofilm formation and quorum sens-ing (QS) without affecting their growth. The interaction of furanone with QS in gram-positive bacteria is unknown. Staphylococci have two QS sys-tems, agr and luxS, which lower biofilm formation by two different path-ways, RNAIII upregulation and bacterial detachment, and polysaccharide intercellular adhesin (PIA) reduction, respectively. We synthesized natu-ral furanone compound 2 [(5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone] from Delisea pulchra and three analogues to investigate \ntheir effect on biofilm formation in gram-positive bacteria. Compound 2, but not the analogues, enhanced the biofilms of Staphylococcus epider-\nmidis 1457 and 047 and of S. aureus Newman at concentrations between \n1.25 and 20 \u00b5M. We show the growth inhibition of S. epidermidis and S. \naureus by free furanone and demonstrate bactericidal activity. An induc-tion of biofilm occurred at concentrations of 10 to 20% of the MIC and cor-related with an increase in PIA. The biofilm effect was agr independent. It was due to interference with luxS, as shown by reduced luxS expression \nin the presence of compound 2 and independence of the strong biofilm formation in a luxS mutant upon furanone addition. Poly(L-lysine)-graft-\ned/poly(ethylene glycol)-grafted furanone was ineffective on biofilm and not bactericidal, indicating the necessity for free furanone. Free furanone was similarly toxic for murine fibroblasts as for staphylococci, excluding a therapeutic application of this compound. In summary, we observed a biofilm enhancement by furanone in staphylococci at subinhibitory con-centrations, which was manifested by an increase in PIA and dependent on luxS.Antimicrobial Agents and Chemotherapy 180, 4159\u20134166, 2009  IF 4,7\nFuranone at Subinhibitory Concentrations Enhances Staphylococcal Biofilm \nFormation by luxS Repression\nR. Kuehl1, S. Al-Bataineh2, O. Gordon1, R. Luginbuehl3, M. Otto4, M. Textor2 and R. Landmann1\n1 Division of Infection Biology, Department of Biomedicine, University Hospital Basel, Basel, \nSwitzerland\n2 BioInterfaceGroup, Laboratory for Surface Science and Technology, Department of Materials, ETH Zurich, Switzerland\n3 RMS Foundation, Bettlach, Switzerland\n4 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 33, 1W10, 9000 Rockville Pike, Bethesda, Maryland 208924DEPARTMENT OF BIOMEDICINE PUBLICATIONS 29\nDBM Facts 2|2009 Department of BiomedicineAbstract: \nLimited treatment options are available for implant-associated infections caused by methicillin (meticillin)-resistant Staphylococcus aureus (MRSA). \nWe compared the activity of daptomycin (alone and with rifampin [rifam-picin]) with the activities of other antimicrobial regimens against MRSA ATCC 43300 in the guinea pig foreign-body infection model. The dapto-mycin MIC and the minimum bactericidal concentration in logarithmic phase and stationary growth phase of MRSA were 0.625, 0.625, and 20  \n\u00b5g/ml, respectively. In time-kill studies, daptomycin showed rapid and \nconcentration-dependent killing of MRSA in stationary growth phase. At concentrations above 20 \u00b5g/ml, daptomycin reduced the counts by >3 \nlog10 CFU/ml in 2 to 4 h. In sterile cage fluid, daptomycin peak concen-trations of 23.1, 46.3, and 53.7 \u00b5g/ml were reached 4 to 6 h after the \nadministration of single intraperitoneal doses of 20, 30, and 40 mg/kg of body weight, respectively. In treatment studies, daptomycin alone re-duced the planktonic MRSA counts by 0.3 log10 CFU/ml, whereas in com-bination with rifampin, a reduction in the counts of >6 log10 CFU/ml was observed. Vancomycin and daptomycin (at both doses) were unable to cure any cage-associated infection when they were given as monother-apy, whereas rifampin alone cured the infections in 33% of the cages. In combination with rifampin, daptomycin showed cure rates of 25% (at 20 mg/kg) and 67% (at 30 mg/kg), vancomycin showed a cure rate of 8%, linezolid showed a cure rate of 0%, and levofloxacin showed a cure rate of 58%. In addition, daptomycin at a high dose (30 mg/kg) completely pre-vented the emergence of rifampin resistance in planktonic and adherent MRSA cells. Daptomycin at a high dose, corresponding to 6 mg/kg in hu-mans, in combination with rifampin showed the highest activity against planktonic and adherent MRSA. Daptomycin plus rifampin is a promising treatment option for implant-associated MRSA infections.\nEfficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-\nResistant Staphylococcus aureus: Importance of Combination with Rifampin\nA. K. John1, D. Baldoni1, M. Haschke2, K. Rentsch3, P. Schaerli4, W. Zimmerli5 and A. Trampuz1,6\n1 Infectious Diseases, Department of Biomedicine, University Hospital Basel, Basel, Switzerland\n2 Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland\n3 Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland\n4 Infectious Diseases, Transplantation and Immunology, Novartis Pharma Schweiz AG, Bern, \nSwitzerland\n5 Basel University Medical Clinic, Kantonsspital, Liestal, Switzerland\n6 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland\nAbstract: \nOver the last decade, the rapidly expanding interest in the involvement of DNA methylation in developmental mechanisms, human diseases, and malignancies has highlighted the need for an accurate, quantitative, and high-throughput assay. Existing methods are limited and are often too laborious for high-throughput analysis or inadequate for quantitative analysis of methylation. Recently, a MassCLEAVE assay has been devel-oped using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to analyze base-specific methylation patterns after bisulfite conversion. To find an efficient and more cost-effective high-throughput method for analyzing the methylation profile in breast can-cer, we developed a method that allows for the simultaneous detection of multiple target CpG residues by using thymidine-specific cleavage mass array on matrix-assisted laser desorption/ionization time-of-flight silicon chips. We used this novel quantitative approach for the analysis of DNA methylation patterns of four tumor suppressor genes in 96 breast tissue samples from 48 patients with breast cancer. Each individual contributed a breast cancer specimen and corresponding adjacent normal tissue. We evaluated the accuracy of the approach and implemented critical im-provements in experimental design. Molecular Cancer Research 6, 1702\u20131709, 2008  IF 4,5\nHigh-Throughput Hacking of the Methylation Patterns in Breast Cancer by In \nvitro Transcription and Thymidine-Specific Cleavage Mass Array on MALDI-TOF Silico-Chip\nR. Radpour1, M. M. Haghighi2, A. Xiu-Cheng Fan1, P. M. Torbati3, S. Hahn1, W. Holzgreve1 and X. Y. Zhong1\n1 Laboratory for Prenatal Medicine and Gynecologic Oncology, Women\u2019s Hospital/Department of \nBiomedicine, University of Basel, Basel, Switzerland\n2 Department of Genetics, Azad University, East Tehran Branch, Iran\n3 Department of Pathology, Shaheed Beheshti Medical University, Tehran, IranAntimicrobial Agents and Chemotherapy 53, 2179\u20132724, 2009  IF 4,730 PUBLICATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinAbstract: \nGPhosphoinositide 3-kinase (PI3K)/protein kinase B/Akt and Ras/mito-gen-activated protein kinase pathways are often constitutively activated in melanoma and have thus been considered as promising drug targets. Exposure of melanoma cells to NVP-BAG956, NVP-BBD130, and NVP-BEZ235, a series of novel, potent, and stable dual PI3K/mammalian target of rapamycin (mTOR) inhibitors, resulted in complete G1 growth arrest, reduction of cyclin D1, and increased levels of p27KIP1, but negligible apoptosis. In contrast, treatment of melanoma with the pan-class I PI3K inhibitor ZSTK474 or the mTORC1 inhibitor rapamycin resulted only in mi-nor reduction of cell proliferation. In a syngeneic B16 mouse melanoma tumor model, orally administered NVP-BBD130 and NVP-BEZ235 effi-ciently attenuated tumor growth at primary and lymph node metastatic sites with no obvious toxicity. Metastatic melanoma in inhibitor-treated mice displayed reduced numbers of proliferating and significantly small-er tumor cells. In addition, neovascularization was blocked and tumoral necrosis increased when compared with vehicle-treated mice. In conclu-sion, compounds targeting PI3K and mTOR simultaneously were advan-tageous to attenuate melanoma growth and they develop their potential by targeting tumor growth directly, and indirectly via their interference with angiogenesis. Based on the above results, NVP-BEZ235, which has entered phase I/II clinical trials in patients with advanced solid tumors, has a potential in metastatic melanoma therapy. Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target \nof Rapamycin Inhibitors\nR. Marone1, D. Erhart1, A. C. Mertz1, T. Bohnacker1, C. Schnell3, V. Cmiljanovic2, F. Stauffer3, C. Garcia-Echeverria3, B. Giese2,  \nS. M. Maira3 and M. P. Wymann1\n1Institute of Biochemistry and Genetics, Department of Biomedicine and \n2Department of Chemistry, University of Basel, and 3Oncology Disease Area, Novartis Institutes \nfor Biomedical Research, Basel, Switzerland\nAbstract: \nD\u03b1-Melanocyte-stimulating hormone (\u03b1 -MSH) is known to bind to the \nmelanocortin receptor 1 (MC1R) which is overexpressed on melanotic and amelanotic melanoma cells. \u03b1-MSH analogues are potential candi-\ndates for specific targeting of melanoma metastases. Several linear and cyclic radiolabeled MSH peptides have been designed and tested in the past, showing both high affinity for the MC1R in vitro and good incorpora-tion in tumor xenografts in vivo. However, considerable kidney reabsorp-tion of the radiopeptides could not be avoided. With the aim to increase the tumor-to-kidney ratio, we synthesized six glycosylated derivatives of NAPamide, an \u03b1-MSH octapeptide analogue with high tumor selectivity \nand coupled them to the chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). The peptides were evaluated in vitro for MC1R Bioconjugate Chemistry 20, 984\u2013993, 2008 IF4,3\nGlycosylated DOTA\u2212\u03b1-Melanocyte-Stimulating Hormone Analogues for  \nMelanoma Targeting: Influence of the Site of Glycosylation on in Vivo  \nBiodistribution\nJ. P. Bapst, M. Calame, H. Tanner and A. N. Eberle\nLaboratory of Endocrinology, Department of Biomedicine, University Hospital and University\nChildren\u2019s Hospital, Basel, Switzerlandbinding and bioactivity and, after labeling with 111In, for in vitro cellular \nuptake and in vivo tissue distribution in mice carrying B16F1 melanoma tumors. The glycopeptides showed excellent binding affinities in the low nanomolar to subnanomolar range using both murine and human mela-noma cell lines. However, five glycopeptides displayed lower selectivity in vivo than the parent DOTA\u2212NAPamide, because of either a lower tumor uptake or a higher kidney uptake. In particular C-terminal extension of the amide group by a galactosyl moiety increased the kidney retention dramatically. By contrast, an N-terminally positioned galactose residue in DOTA\u2212Gal-NAPamide improved the tumor-to-kidney ratio (4\u221248 h AUC of 1.34) by a factor of about 1.2 as compared to the parent DOTA\u2212NAPamide (4\u221248 h AUC of 1.11), thus serving as new lead compound for MC1R-tar-geting molecules.Molecular Cancer Research 7, 601\u2013613, 2009  IF 4,5DEPARTMENT OF BIOMEDICINE PUBLICATIONS 31\nDBM Facts 2|2009 Department of BiomedicineAbstract: \nRyanodine receptors plays a crucial role in skeletal muscle excitation\u2013contraction coupling by releasing calcium ions required for muscle con-traction from the sarcoplasmic reticulum. At least three phenotypes associated with more than 100 RYR1 mutations have been identified; in order to elucidate possible pathophysiological mechanisms of RYR1 mu-\ntations linked to neuromuscular disorders, it is essential to define the mu-tation class by studying the functional properties of channels harbour-ing clinically relevant amino acid substitutions. In the present report we investigated the functional effects of the c.7304G > T RYR1 substitution \n(p.Arg2435Leu) found in a patient affected by central core disease. Both parents were heterozygous for the substitution while the proband was homozygous. We characterized Ca2\n+ homeostasis in myoD transduced \nmyotubes from controls, the heterozygous parents and the homozygous proband expressing the endogenous mutation. We also expressed the re-combinant mutant channels in heterologous cells and characterized their [\n3H]ryanodine binding and single channel properties. Our results show \nthat the p.Arg2435Leu substitution affects neither the resting [Ca2+], nor Cell Calcium 45, 192\u2013197, 2009 IF4,3\nA recessive ryanodine receptor 1 mutation in a CCD patient increases channel \nactivity\nF. Ghassemi1,2, M. Vukcevic3,4, L. Xu1,2, H. Zhou5, G. Meissner1,2, F. Muntoni5, H. Jungbluth6, F. Zorzato7 and S. Treves3,4\nthe sensitivity of the ryanodine receptor to pharmacological activators, \nbut rather reduces the release of Ca2+ from intracellular stores induced \nby pharmacological activators as well as by KCl via the voltage sensing dihydropyridine receptor.Abstract: We investigated the activity of linezolid, alone and in combination with ri-fampin (rifampicin), against a methicillin-resistant Staphylococcus aureus  \n(MRSA) strain in vitro and in a guinea pig model of foreign-body infec-tion. The MIC, minimal bactericidal concentration (MBC) in logarithmic phase, and MBC in stationary growth phase were 2.5, >20, and >20 \u00b5g/\nml, respectively, for linezolid; 0.01, 0.08, and 2.5 \u00b5g/ml, respectively, \nfor rifampin; and 0.16, 0.63, >20 \u00b5g/ml, respectively, for levofloxacin. In \ntime-kill studies, bacterial regrowth and the development of rifampin re-sistance were observed after 24 h with rifampin alone at 1x or 4x the MIC and were prevented by the addition of linezolid. After the administration of single intraperitoneal doses of 25, 50, and 75 mg/kg of body weight, linezolid peak concentrations of 6.8, 12.7, and 18.1 \u00b5g/ml, respectively, \nwere achieved in sterile cage fluid at 3 h. The linezolid concentration re-mained above the MIC of the test organism for 12 h with all doses. Anti-microbial treatments of animals with cage implant infections were given twice daily for 4 days. Linezolid alone at 25, 50, and 75 mg/kg reduced the planktonic bacteria in cage fluid during treatment by 1.2 to 1.7 log10 CFU/ml; only linezolid at 75 mg/kg prevented bacterial regrowth 5 days after the end of treatment. Linezolid used in combination with rifampin (12.5 mg/kg) was more effective than linezolid used as monotherapy, reducing the planktonic bacteria by 3 log10 CFU (P < 0.05). Efficacy in the eradica-tion of cage-associated infection was achieved only when linezolid was combined with rifampin, with cure rates being between 50% and 60%, whereas the levofloxacin-rifampin combination demonstrated the high-est cure rate (91%) against the strain tested. The linezolid-rifampin com-bination is a treatment option for implant-associated infections caused by quinolone-resistant MRSA.Antimicrobial Agents and Chemotherapy 53, 1142\u20131148, 2009  IF 4,3\nLinezolid Alone or Combined with Rifampin against Methicillin-Resistant \nStaphylococcus aureus in Experimental Foreign-Body Infection\nD. Baldoni1, M. Haschke2, Z. Rajacic1, W. Zimmerli3 and A. Trampuz1,4\n1 Infectious Diseases Research Laboratory, Department of Biomedicine, University Hospital Basel, \nBasel, Switzerland\n2 Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland\n3 Basel University Medical Clinic, Kantonsspital, Liestal, Switzerland\n4 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland\n1 Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill,  \nNC 27599-7260, USA\n2 Department of Molecular and Cellular Physiology, University of North Carolina, Chapel Hill,  \nNC 27599-7260, USA\n3 Department of Anaesthesia, Basel University Hospital, Hebelstrasse 20, 4031 Basel, Switzerland\n4 Department of Biomedicine, Basel University Hospital, Hebelstrasse 20, 4031 Basel, Switzerland\n5 The Dubowitz Neuromuscular Centre, UCL Institute of Child Health, London WC1N 1EH, UK\n6 Department of Paediatric Neurology, Neuromuscular Service, Evelina Children\u2019s Hospital,  \nSt. Thomas\u2019 Hospital, Lambeth Palace Road, London SE1 7EH, UK\n7 Dipartimento di Medicina Sperimentale e Diagnostica, Universita\u2019 di Ferrara, 44100 Ferrara, Italy32 PUBLICATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinBiochemical Journal 416, 271-280, 2008  IF4,3\nAbstract: \nT-cad (T-cadherin), a glycosylphosphatidylinositol-anchored cadherin su-perfamily member, is expressed widely in the brain and cardiovascular system, and absent, decreased, or even increased, in cancers. Mecha-nisms controlling T-cad expression are poorly understood. The present study investigated transcriptional regulation of T-cad in ECs (endothelial cells). Conditions of oxidative stress (serum-deprivation or presence of H2O2) elevate T-cad mRNA and protein levels in ECs. Reporter gene analy-sis, using serially deleted T-cad promoter stretches ranging from \u221299 to \u22122304 bp, located the minimal promoter region of T-cad within \u2212285 bp from the translation start site. Reporter activity in ECs transfected with the \u2212285 bp construct increased under conditions of oxidative stress, and this was normalized by antioxidant N-acetylcysteine. An electrophoretic-mobility-shift assay revealed a specific nucleoprotein complex unique to \u2212156 to \u2212203 bp, which increased when nuclear extracts from oxidatively stressed ECs were used, suggesting the presence of redox-sensitive bind-ing element(s). MS analysis of the nucleoprotein complex unique to \u2212156 to \u2212203 bp after streptavidin\u2013agarose pull-down detected the presence of the redox-active protein thioredoxin. The presence of thioredoxin-1 in a nuclear extract from oxidatively stressed ECs was demonstrated af-ter immunoprecipitation and immunoblotting. Transfection of ECs with thioredoxin-1 small interfering RNA abrogated oxidative-stress-induced up-regulation of T-cad transcripts and protein. We conclude that thiore-doxin-1 is an important determinant of redox-sensitive transcriptional up-regulation of T-cad in ECs.A requirement for thioredoxin in redox-sensitive modulation of T-cadherin \nexpression in endothelial cells\nM. B. Joshi1, D. Ivanov1, M. Philippova1, E. Kyriakakis1, P. Erne2 and T. J. Resink1\n1 Department of Research, Cardiovascular Laboratories, Basel University Hospital, Hebelstrasse \n20, CH 4031 Basel, Switzerland\n2 Division of Cardiology, Lucerne Cantonal Hospital, CH 6000 Lucerne, Switzerland\nAbstract: \nIn this study, we first aimed at determining whether human articular chon-\ndrocytes (HAC) proliferate in aggregates in the presence of strong chondro-\ncyte mitogens. We then investigated if the aggregated cells have an enhanced chondrogenic capacity as compared to cells cultured in monolayer. HAC from \nfour donors were cultured in tissue culture dishes either untreated or coated \nwith 1% agarose in the presence of TGFb-1, FGF-2 and PDGF-BB. Proliferation and stage of differentiation were assessed by measuring respectively DNA \ncontents and type II collagen mRNA. Expanded cells were induced to differ-\nentiate in pellets or in Hyaff\u00ae-11 meshes and the formed tissues were analy-sed biochemically for glycosaminoglycans (GAG) and DNA, and histologically \nby Safranin O staining. The amount of DNA in aggregate cultures increased significantly from day 2 to day 6 (by 3.2-fold), but did not further increase \nwith additional culture time. Expression of type II collagen mRNA was about \ntwo orders of magnitude higher in aggregated HAC as compared to monolayer \nexpanded cells. Pellets generated by aggregated HAC were generally more in-tensely stained for GAG than those generated by monolayer-expanded cells. \nScaffolds seeded with aggregates accumulated more GAG (1.3-fold) than scaf-\nfolds seeded with monolayer expanded HAC. In conclusion, this study showed that HAC culture in aggregates does not support a relevant degree of expan-\nsion. However, aggregation of expanded HAC prior to loading into a porous \nscaffold enhances the quality of the resulting tissues and could thus be in-troduced as an intermediate culture phase in the manufacture of engineered \ncartilage grafts. European Cells and Materials 16, 92\u201399, 2008 IF4,3\nCartilage tissue engineering using pre-aggregated human articular  \nchondrocytes\nF. Wolf, C. Candrian, D. Wendt, J. Farhadi, M. Heberer, I. Martin, A. Barbero\nDepartments of Surgery and of Biomedicine, University Hospital, Basel, SwitzerlandDEPARTMENT OF BIOMEDICINE PUBLICATIONS 33\nDBM Facts 2|2009 Department of BiomedicineAbstract: \nThe antipsoriatic dimethylfumarate (DMF) has been anecdotically report-ed to reduce asthma symptoms and to improve quality of life of asthma patients. DMF decreases the expression of proinflammatory mediators by inhibiting the transcription factor NF-B and might therefore be of interest for the therapy of inflammatory lung diseases. In this study, we deter-mined the effect of DMF on platelet-derived growth factor (PDGF)-BB- and TNF-induced asthma-relevant cytokines and NF-\u03ba B activation by primary \nhuman asthmatic and nonasthmatic airway smooth muscle cells (ASMC). Confluent nonasthmatic and asthmatic ASMC were incubated with DMF (0.1\u2013100 \u00b5M) and/or dexamethasone (0.0001\u20130.1 \u00b5M), NF-\u03ba B p65 siRNA \n(100 nM), the NF-B inhibitor helenalin (1 \u00b5M) before stimulation with \nPDGF-BB or TNF (10 ng/ml). Cytokine release was measured by ELISA. NF-B, mitogen and stress-activated kinase (MSK-1), and CREB activation was determined by immunoblotting and EMSA. TNF-induced eotaxin, RANT -\nES, and IL-6 as well as PDGF-BB-induced IL-6 expression was inhibited by DMF and by dexamethasone from asthmatic and nonasthmatic ASMC, but the combination of both drugs showed no glucocorticoid sparing effect in either of the two groups. NF-B p65 siRNA and/or the NF-\u03ba B inhibitor AJP - Lung Cellular and Molecular Physiology 297, 326\u2013339, 2009  IF 3,9\nDimethylfumarate inhibits NF-\u03baB function at multiple levels to limit airway \nsmooth muscle cell cytokine secretion\nP. S eidel1,2,3, I. Merfort2, J. M. Hughes3, B. G. G. Oliver4, M. Tamm1 and M. Roth1\n1 Pulmonary Cell Research, Department of Research and Pneumology, Department of Internal \nMedicine, University Hospital Basel, Basel, Switzerland\n2 Institute of Pharmaceutical Sciences, Department of Pharmaceutical Biology and Biotechnology, University of Freiburg, Freiburg, Germany\n3 Respiratory Research Group, Faculty of Pharmacy, University of Sydney, Sydney, Australia \n4 Discipline of Pharmacology, University of Sydney, Sydney, Australiahelenalin reduced PDGF-BB- and TNF-induced cytokine expression, sug-\ngesting the involvement of NF-\u03ba B signaling. DMF inhibited TNF-induced \nNF-\u03baB p65 phosphorylation, NF-\u03ba B nuclear entry, and NF-B-DNA complex \nformation, whereas PDGF-BB appeared not to activate NF-\u03ba B within 60 \nmin. Both stimuli induced the phosphorylation of MSK-1, NF-\u03ba B p65 at \nSer276, and CREB, and all were inhibited by DMF. These data suggest that DMF downregulates cytokine secretion not only by inhibiting NF-\u03ba B but \na wider range of NF-\u03ba B-linked signaling proteins, which may explain its \npotential beneficial effect in asthma.\nAbstract:Objective: As compared to knee chondrocytes (KC), talar chondrocytes (TC) have superior synthetic activity and increased resistance to catabolic stimuli. We investigated whether these properties are maintained after TC are isolated and expanded in vitro.\nMethods: Human TC and KC from 10 cadavers were expanded in mono-\nlayer and then cultured in pellets for 3 and 14 days or in hyaluronan meshes (Hyaff\u00ae-11) for 14 and 28 days. Resulting tissues were assessed biochemically, histologically, biomechanically and by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The proteoglycan and collagen synthesis rates in the pellets were also measured following ex-posure to Interleukin-1 beta (IL-1\u03b2 ).\nResults: After 14 days of pellet culture, TC and KC expressed similar lev-els of type I collagen (CI) and type II collagen (CII) mRNA and the result-ing tissues contained comparable amounts of glycosaminoglycans (GAG) and displayed similar staining intensities for CII. Also proteoglycan and collagen synthesis were similar in TC and KC pellets, and dropped to a Intra-individual comparison of human ankle and knee chondrocytes in vitro: relevance  \nfor talar cartilage repair\nC. Candrian1,2, E. Bonacina1,3,4, J. A. Frueh1, D. Vonwil1, S. Dickinson5, D. Wirz6, M. Heberer1, M. Jakob1, I. Martin1 and A. Barbero1\n1 Departments of Surgery and Biomedicine, University Hospital, Basel, Switzerland\n2 Departments of Orthopaedic Surgery and Traumatology, Bruderholzspital, Basel, Switzerland\n3 I.R.C.C.S. Istituti Ortopedici Galeazzi, Milano, Italy\n4 LaBS, Bioingeneering Department, Politecnico di Milano, Milano, Italy\n5 Department of Cellular & Molecular Medicine, University Walk, Bristol, UK\n6 Laboratory for Orthopaedic Biomechanics, Clinical Morphology & Biomedical Engineering, \nUniversity of Basel, SwitzerlandOsteoarthritis and Cartilage 17, 489\u2013496, 2009 IF3,7\ncomparable extent in response to IL-1\u03b2 . Following 14 days of culture in \nHyaff\u00ae-11, TC and KC generated tissues with similar amounts of GAG and \nCI and CII. After 28 days, KC deposited significantly larger fractions of GAG and CII than TC, although the trend was not reflected in the measured biomechanical properties.\nConclusion: After isolation from their original matrices and culture \nexpansion, TC and KC displayed similar biosynthetic activities, even in the presence of catabolic stimuli. These in vitro data suggest a possible equivalence of TC and KC as autologous cell sources for the repair of talar cartilage lesions.34 PUBLICATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinAbstract: \nIt is generally accepted that the presence of a second language (L2) has  \nan impact on the neuronal substrates build up and used for language processing; the influence of the age of L2 exposure, however, is not es-tablished. We tested the hypothesis that the age of L2 acquisition has an effect on the cortical representation of a multilingual repertoire in 44 multilinguals with different age of exposure to a L2 (simultaneous or co-vert simultaneous exposure to L1 and L2, sequential acquisition of L1 and L2 between 1 and 5 years, late learning of L2 after 9 years of age) and all fluent in a late learned L3. Regional activation in a language produc-tion task showed a high in-between-subject variability, which was higher than within-subject variability between L1, L2, and L3. We, therefore, per-formed a single subject analysis and calculated the within-subject vari-ance in the numbers of activated voxels in Broca\u2019s and Wernicke\u2019s area. Subjects with early exposure to L2 showed low variability in brain acti-vation in all three languages, in the two early as well as the late learned language. In contrast, late multilinguals exhibited higher variability. Thus, cerebral representation of languages is linked to the age of L2 acquisi-tion: early exposure to more than one language gives rise to a language Neuropsychologia 47, 625\u2013633, 2009  IF 3,6\nThe age of second language acquisition determines the variability in activation \nelicited by narration in three languages in Broca\u2019s and Wernicke\u2019s area\nC. Bloch1, A. Kaiser1, E. Kuenzli1, D. Zappatore2, S. Haller3, R. Franceschini4, G. Luedi2, E. W. Radue3 and C. Nitsch1\n1 Section of Functional Neuroanatomy, Department of Biomedicine, University of Basel, Pesta-\nlozzistrasse 20, CH-4056 Basel, Switzerland\n2 Institute of Romance Languages, University of Basel, Maiengasse 51, CH-4056 Basel, Switzerland\n3 Section of Neuroradiology, University Hospital of Basel, Hebelstrasse 32, CH-4031 Basel,  \nSwitzerland\n4 Centre for Language Studies, Free University of Bozen, Via Dante 9, I-39100 Bozen, Italyprocessing network that is activated homogeneously by early and late \nlearned languages, while the inhomogeneous activation in late multilin-guals indicates more independent access to the multilingual repertoire. Early passive exposure to L2 results in the same low variance as active bilingual upbringing. Variability in local brain activity increases progres-sively from the simultaneous to late L2 exposure, indicating a gradual transition from the mode of early bilingual language representation to that of late ones.Abstract: We describe a calorimetric assay for the detection of methicillin-resistant Staphylococcus aureus (MRSA) within 5 h. Microbial heat was calculated in culture with and without cefoxitin. Among 30 genetically distinct clinical isolates, 19/20 MRSA (95%) and 10/10 methicillin-susceptible Staphylo-\ncoccus aureus (100%) were correctly identified. Microcalorimetry may be useful for rapid MRSA screening.Performance of Microcalorimetry for Early Detection of Methicillin Resistance \nin Clinical Isolates of Staphylococcus aureus\nD. Baldoni1, H. Hermann1, R. Frei2, A. Trampuz1,3 and A. Steinhuber1\n1 Infectious Diseases Research Laboratory, Department of Biomedicine, University Hospital, Basel, \nSwitzerland\n2 Microbiology Laboratory, Laboratory Medicine, University Hospital, Basel, Switzerland\n3 Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel,  \nSwitzerlandJournal of Clinical Microbiology 47, 774\u2013776, 2009  IF 3,7Journal of\nClinical MicrobiologyAMERICAN\nSOCIETY FOR\nMICROBIOLOGYDEPARTMENT OF BIOMEDICINE PUBLICATIONS 35\nDBM Facts 2|2009 Department of BiomedicineAbstract: \nSIR, Cadherins play important roles in controlling keratinocyte growth, differentiation and survival.1 Inappropriate expression or function of cad-herins underlies many diseases of the epidermis. 2 Inverse associations between expression of atypical glycosylphosphatidylinositol-anchored T-cadherin (T-cad) and benign and malignant skin diseases [psoriasis vulgaris,3 invasive squamous cell carcinoma4 and basal cell carcinoma (BCC)5] have been reported but not yet confirmed. We examined T-cad protein expression in normal skin specimens and skin biopsies from 40 patients with BCC using goat antirecombinant human T-cad (aa 23\u2013692) antibodies (R&D Systems, Abingdon, U.K.) and a universal immunoper-oxidase polymer detection system (N-Histofine_ Simple Stain MAX PO; Nichirei Biosciences, Tokyo, Japan). BCCs were subclassified as superficial (n = 12), nodular (n = 18) or infiltrative (n = 10) in terms of their histologi-cal morphology.6We found T-cad expression in all BCC specimens, irrespective of their his-tological classification (Fig. 1). Generally T-cad staining was stronger in BCC than in the basal cell layer of the epidermis and was very prominent at intercellular borders at tumour expansile edges, which appear to be theBritish Journal Dermatology 161, 199\u2013202, 2009  IF 3,4\nHigh T-cadherin expression is a feature of basal cell carcinoma\nS. A. Buechner1, M. Philippova2, P. Erne3, T. Mathis1 and T. J. Resink2\n1 Blumenrain 20, CH 4051 Basel, Switzerland\n2 Department of Biomedicine, Laboratory for Signal Transduction, Basel University Hospital,  \nCH 4031 Basel, Switzerland\n3 Division of Cardiology, Kantonsspital Luzern, CH 6000 Luzern, Switzerlandleading, invasive fronts of the tumours. In superficial BCC (Fig. 1a \u2044a+,b \n\u2044b+) and nodular BCC (Fig. 1c \u2044c+,d \u2044d+) there was a strong preferential membranous expression of T-cad on the palisading peripheral BCC cells and within the peripheral cleft at the junction between lesion and stroma (see Fig. 1a \u2044a+,b \u2044b+). The stromal cells within the nodules were also positive for T-cad, although the expression intensity of the palisading pe-ripheral cells was stronger. In addition, staining patterns on the central stromal cells of some tumours were irregular and scattered, with vary-ing intensity of expression. No differences in T-cad expression between the peritumoral epidermis and the epidermis in nontumoral skin biopsies were detectable. \nAbstract: The myelin and lymphocyte protein (MAL) is a raft-associated membrane protein predominantly expressed by oligodendrocytes and Schwann cells. Here we show that MAL regulates myelination in the peripheral ner-vous system. In mice overexpressing MAL, myelination was retarded and fibers were hypomyelinated, whereas myelination in MAL knockout mice was accelerated. This was not due to impaired Schwann cell proliferation, differentiation or axonal sorting. We found that the expression level of  p75 neurotrophin receptor mRNA and protein was strongly reduced in developing sciatic nerves in MAL-overexpressing mice. This reduction is well correlated with the observed alterations in myelination initiation, speed of myelination and alterations in Remak bundle development. Our results suggest a functional role for MAL in peripheral myelination by in-fluencing the expression of membrane components that mediate axon-glia interaction during ensheathment and myelin wrapping.\nEuropean Journal of Neuroscience 29, 2276\u20132290, 2009 IF3,3\nThe myelin protein MAL affects peripheral nerve myelination: a new player \ninfluencing p75 neurotrophin receptor expression\nA. M. Buser, D. Schmid, F. Kern, B. Erne, T. Lazzati and N. Schaeren-Wiemers\nNeurobiology, Department of Biomedicine and Neurology, University Hospital Basel, \nPharmacenter 7007, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland36 PUBLICATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinReproductive BioMedicine Online 18, 407\u2013411, 2008  IF3,0\nAbstract: \nIt has recently been reported that high concentrations of circulating cell-free (ccf) nucleic acids in plasma and serum could be used as biomarkers for non-invasive monitoring a wide variety of malignant and benign pro-liferations and inflammatory conditions. Endometriosis is one of the most common benign gynaecological proliferations with inflammatory activa-tion in premenopausal women. Real-time multiplex polymerase chain reaction was used for synchronized quantification of the glyceraldehyde-3-phosphate dehydrogenase gene sequence in nuclear DNA (nDNA) and the ATP synthase-8 gene sequence in mitochondrial DNA (mtDNA). DNA was extracted from 500 microl serum and plasma of 19 cases with en-dometriosis to measure the total amount of ccf nDNA and ccf mtDNA. The concentration of ccf nDNA in plasma was significantly higher in the endometriosis group than in the control group (P = 0.046). The cut-off value selected by a receiver operating characteristic curve could provide a sensitivity of 70% and a specificity of 87% to discriminate between the minimal or mild cases and normal controls. The finding of significantly increased concentrations of ccf nDNA in plasma of patients with endome-triosis suggests that ccf nDNA might be a potential biomarker for devel-oping non-invasive diagnostic test in endometriosis.Circulating cell-free DNA as a potential biomarker for minimal and mild endo-\nmetriosis\nR. Zachariah, S. Schmid, R. Radpour, N. Buerki, A.X. Fan, S. Hahn, W. Holzgreve and X.Y. Zhong\nLaboratory for Prenatal Medicine and Gynecologic Oncology, Women\u2019s Hospital, Department of\nBiomedicine, University of Basel, Switzerland.\nChemico-Biological Interactions 180, 472\u2013477, 2009  IF3,0\nAbstract: \nPatients ingesting pivalic acid containing prodrugs develop hypocarni-tinemia. Pivalic acid is cleaved from such drugs and excreted renally as pivaloylcarnitine. Plasma concentrations (reflecting the concentration in the glomerular filtrate entering the proxinmal tubule) in patients treated with cefditoren pivoxil are approximately 5 \u00b5M for pivaloylcarnitine and \n10 \u00b5M for carnitine. Kinetic studies were performed using L6 cells over-\nexpressing the human kidney carnitine transporter (hOCTN2) to assess the mechanisms leading to hypocarnitinemia in such patients. l-carnitine transport showed saturation kinetics (Km 6.3 \u00b5M) and could be inhibited \ncompetitively by pivaloylcarnitine (Ki 70 \u00b5M). Pivaloylcarnitine was also \ntransported by OCTN2 (Km 212 \u00b5M) and its transport could be inhibited competitively by l-carnitine (Ki 7.8 \u00b5M). Haldane and Eadie-Hofstee plots \nwere linear for both carnitine and pivaloylcarnitine. Our data indicate that both carnitine and pivaloylcarnitine bind to OCTN2 at a single, identical site. Considering the low plasma and tubular pivaloylcarnitine concentra-tion, the high Km of pivaloylcarnitine regarding OCTN2 and the inhibition of pivaloylcarnitine transport by carnitine, pivaloylcarnitine is unlikely to be reabsorbed under these conditions. On the other hand, our data indi-cate that the renal reabsorption of carnitine is not impaired in patients treated with pivalic acid containing prodrugs. Hypocarnitinemia in such patients therefore develops due to massive renal losses of pivaloylcar-nitine and not due to inhibition of carnitine reabsorption by pivaloylcar-nitine.Interaction between pivaloylcarnitine and l-carnitine transport into L6 cells \noverexpressing hOCTN2\nL. Todesco1, M. Bodmer1, K. Vonwil1, D. H\u00e4ussinger2 and S. Kr\u00e4henb\u00fchl1\n1 Division of Clinical Pharmacology & Toxicology and Department of Research,  \nUniversity Hospital, CH-4031 Basel, Switzerland\n2 Department of Chemistry, University of Basel, Basel, SwitzerlandDEPARTMENT OF BIOMEDICINE PUBLICATIONS 37\nDBM Facts 2|2009 Department of BiomedicineAbstract:\nBackground and purpose: Amyotrophic lateral sclerosis (ALS) is clas-\nsically assumed to be a neurodegenerative disorder. Inflammation has been observed in CNS tissue in ALS patients. We investigated the expres-sion and prognostic relevance of proinflammatory chemokines in ALS.\nMethods: We analyzed nine chemokines, eotaxin, eotaxin-3, IL-8, IP-10, \nMCP-1, MCP-4, macrophage derived chemokine (MDC), macrophage in-flammatory protein-1\u03b2  (MIP-1\u03b2 ), and serum thymus and activation- regu-\nlated chemokine (TARC) in serum and cerebrospinal fluid (CSF) of 20 ALS- and 20 non-inflammatory neurological disease (NIND)-patients.\nResults: MCP-1 and IL-8 levels in CSF in ALS were significantly higher than \nin NIND (1304 pg/ml vs. 1055 pg/ml, P = 0.013 and 22.7 pg/ml vs. 18.6 pg/ml, P = 0.035). The expression of MCP-1 and IL-8 were higher in CSF than in serum (P < 0.001). There was a trend towards higher MCP-1 CSF levels in ALS patients with shorter time between first symptoms and diag-nosis (r = \u22120.407; P = 0.075).European Journal of Neurology 16, 771\u2013774, 2009  IF 2,5\nIncreased levels of inflammatory chemokines in amyotrophic lateral sclerosis\nJ. Kuhle1,2, R. L. P. Lindberg2, A. Regeniter3, M. Mehling1,2, A. J. Steck1,2, L. Kappos1,2 and A. Czaplinski1\n1 Neurobiology, Department of Biomedicine and Neurology, University Hospital Basel,  \nPharmacenter, Klingelbergstrasse 50-70, 4056 Basel, Switzerland\n2 Therapeutic Area Neurodegeneration, Serono Laboratories, 9 Chemin de Mines, 1202 Geneva, \nSwitzerlandConclusions: We confirmed previous findings of increased MCP-1 levels \nin CSF of ALS patients. Furthermore, increased levels of IL-8 in CSF sug-gest a stimulation of a proinflammatory cytokine cascade after microglia \nactivation. We found a tendency for higher MCP-1 values in patients with \na shorter diagnostic delay, who are known to have also a shorter survival. This may suggest an association of higher MCP-1 levels with rapidly pro-gressing disease.\nAbstract:Introduction: We develop a multiplex quantitative real-time PCR for synchronized analysis of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) to investigate relative mtDNA abundance in paired normal and cancerous breast tissues.\nMaterials and methods: The amounts of nDNA and mtDNA in 102 tissue \nsamples were quantified for both glyceraldehype-3-phosphodehydroge-nase (GAPDH) gene and mtDNA encoded ATPase (MTATP) 8 gene. The av-erage threshold cycle (Ct) number values of the nDNA and mtDNA were used to calculate relative mtDNA content in breast tissues.Journal of Cancer Research and Clinical Oncology 135, 983\u2013989, 2009  IF 2,3\n1 Laboratory for Prenatal Medicine and Gynecologic Oncology, Department of Biomedicine, \nWomen\u2019s Hospital, University of Basel, Hebelstrasse 20, Room Nr. 416, 4031 Basel, Switzerland\n2 Azad University, East of Tehran Branch, Tehran, Iran\n3 University Medical Center, University of Freiburg, Hugstetter Str. 49, 79106 Freiburg, GermanyResults: The median delta Ct (\u2206 Ct) and the median mtDNA content for \nnormal and cancerous breast tissues were 6.73 and 2.54, as well as 106.50 \nand 5.80 (P = 0.000, respectively). The mtDNA content was decreased in 82% of cancerous breast tissues compared with the normal ones. The changes were associated with hormone receptor status.Conclusion  Our finding suggests that decreased mtDNA content in breast cancer may have diagnostic and prognostic value for the disease.Mitochondrial DNA content in paired normal and cancerous breast tissue  \nsamples from patients with breast cancer\nA. Xiu-Cheng Fan1, R. Radpour1, M. Montazer Haghighi2, C. Kohler1, P. Xia1, S. Hahn1, W. Holzgreve1,3 and X. Y. Zhong138 PUBLICATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinAbstract: \nAxonal regeneration after lesions is usually not possible in the adult cen-tral nervous system but can occur in the embryonic and young postnatal nervous system. In this study we used the model system of mouse ento-rhino-hippocampal slice cultures to assess the potential of pharmacologi-cal treatments with compounds targeting signal transduction pathways to promote growth of entorhinal fibers after mechanical lesions across the lesion site to their target region in the dentate gyrus. Compounds act-ing on the cyclic AMP-system, protein kinase C and G-proteins have been shown before to be able to promote regeneration. In this study we have European Journal of Pharmacology 612, 35\u201340, 2009 IF2,3\nModulators of signal transduction pathways can promote axonal regeneration \nin entorhino-hippocampal slice cultures\nB. Bonnici and J. P. Kapfhammer\nAnatomical Institute, Department of Biomedicine Basel, University of Basel, 4056 Basel, \nSwitzerlandconfirmed the potential of drugs affecting these systems to promote axo-\nnal regeneration in the central nervous system. In addition we have found that inhibition of the phosphoinositide 3-kinase pathway and of the inosi-\ntol triphosphate receptor also promoted axonal growth across the lesion \nsite and are thus potential novel drug targets for promoting axonal regen-eration after central nervous system lesions. Our findings demonstrate that slice culture models can be used to evaluate compounds for their potential to promote axonal regeneration and that the pharmacological modulation of signal transduction pathways is a promising approach for promoting axonal repair.\nInternational Journal of Oncology 34, 1135\u20131138, 2009  IF2,2\nAbstract: \nBok is a proapoptotic member in the Bcl-2 family and the expression of Bok is regu-\nlated by cellular stresses. In the present study, we have isolated and characterized a natural antisense transcript of Bok, BOKAS. The BOKAS gene consists of 2 exons, that expresses as a non-protein coding transcript. Both BOKAS and Bok are transcribed \nfrom the same locus but in opposite orientations. The mRNA expression of BOKAS \nwas only detected in testis and certain cancer tissues but not in other normal adult tissues examined. Overexpression of BOKAS alone exhibited no significant anti- or pro-apoptotic activity but it was able to inhibit Bok-induced apoptosis in HeLa cells. Our results suggest that BOKAS may function specifically in the human testis, where \nit serves as an antisense molecule to regulate Bok-induced apoptosis. In addition, \nnatural antisense transcripts were identified for BAD and BCL2L12.A natural antisense transcript, BOKAS, regulates the pro-apoptotic activity of \nhuman Bok\nH. Zhang, S. Gao and C. De Geyter\nUniversity Women\u2019s Hospital Basel and Research Department of University Hospital, \nCH-4031 Basel, Switzerland.DEPARTMENT OF BIOMEDICINE PUBLICATIONS 39\nDBM Facts 2|2009 Department of BiomedicineAbstract: \nPhosphoinositide 3-kinase gamma (PI3Kgamma) plays a major role in chronic inflammation and allergy. It is a heterodimer of a catalytic p110gamma subunit and an adaptor protein, either p101 or the p101  \nhomolog p84 (p87(PIKAP)). It is unclear whether both PI3Kgamma  \ncomplexes specifically modulate responses such as chemotaxis and degranulation. In mast cells, the p84:p110gamma complex synergizes with immunoglobulin E (IgE)- and antigen-clustered FcepsilonRI recep-tor signaling and is required to achieve maximal degranulation. During this process, PI3Kgamma is activated by ligands of heterotrimeric gua-nine nucleotide-binding protein (G protein)-coupled receptors (GPCRs), in particular adenosine receptors, through autocrine and paracrine pathways. Here, we show that p110gamma needs p84 to relay signals from GPCRs to formation of phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P(3)], phosphorylation of Akt, migration of cells, and synergistic adenosine-enforced degranulation. Furthermore, the ab-sence of adaptor subunits could not be compensated for by increased p110gamma abundance. Differentiated, p110gamma null cells also lost adaptor proteins. Complementation of p110gamma null mast cells with p101 and p110gamma restored the activation of Akt and cell migration, but failed to support degranulation. Lack of degranulation was attributed to a change in the spatiotemporal localization of PI3Kgamma-derived Pt-dIns(3,4,5)P(3); although both p84:p110gamma and p101:p110gamma complexes initially deposited PtdIns(3,4,5)P(3) at the plasma membrane, p101:p110gamma-derived PtdIns(3,4,5)P(3) was rapidly endocytosed to motile, microtubule-associated vesicles. In addition, p84:p110gamma, but not p101:p110gamma signaling was sensitive to disruption of lipid rafts. Our results demonstrate a nonredundant function for the p101 and p84 PI3Kgamma adaptor proteins and show that distinct pools of Pt-dIns(3,4,5)P(3) at the plasma membrane can elicit specific cell responses.\nSciences Signaling 2, 74\u2013, 2009  IF N.A\nPI3Kgamma adaptor subunits define coupling to degranulation and cell  \nmotility by distinct PtdIns(3,4,5)P3 pools in mast cells\nT. Bohnacker, R. Marone, E. Collmann, R. Calvez, E. Hirsch and M. P. Wymann\nInstitute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, \nMattenstrasse 28, Basel, Switzerland.\nAbstract: \nRationale: Inflammation, increased fibroblast proliferation, and in-creased deposition of extracellular matrix (ECM) are hallmarks of early lung fibrosis and asthma. Transforming growth factor-\u03b2  (TGF-\u03b2 ) has been \nsuggested as a key regulator of lung tissue homeostasis with several and often opposite effects on fibroblast proliferation and ECM production. In human and animal model systems, it has been shown that TGF-\u03b2  induced \nseveral signaling cascades including Smads, p38 mitogen-activated pro-tein (MAP) kinases, and extracellular signal-regulated kinases 1/2 (ERK). Information on how TGF-\u03b2  regulates and controls normal primary lung \nfibroproliferation and ECM production is not present.Objectives: We sought to dissect the effects of TGF-\u03b2  on fibroprolifera-\ntion and ECM production of primary adult human lung fibroblasts and elucidate the involved signaling pathways.Results: Depending on the presence of fetal bovine serum (FBS; 10%), TGF- \u03b2 exerted opposite effects on fibroproliferation. In the absence of \nFBS, low TGF-\u03b2  concentrations (0.01 and 0.001 ng/ml) significantly in-\nduced fibroproliferation. In the presence of FBS, TGF-\u03b2  (1 ng/ml, 10 ng/\nml) significantly reduced fibroproliferation. TGF-\u03b2  dose-dependently in-creased ECM deposition, which was independent of the presence of FBS. The anti-proliferative effect of TGF-\u03b2  was associated with increased pros-\ntaglandin E2 (PGE2) production, that was induced via p38\u03b4  and ERK 1/2 \nMAP kinases. Indomethacin (2.5 \u00b5M) and a small interfering RNA specific \nfor p38 MAP kinase completely reversed the TGF-\u03b2 -dependent inhibition \nof fibroblast proliferation.Conclusions: Both pro- and anti-proliferative cascades can be activated by TGF-\u03b2 . In a mitogenic or inflammatory environment TGF-\u03b2  induces \nPGE2 synthesis via activation of p38\u03b4  MAP kinase, which then exerts a \nstrong antiproliferative effect. This dualistic nature of TGF-\u03b2  may exist in \norder to maintain lung tissue integrity.Dissecting the Dualistic Effects of Transforming Growth Factor (TGF)-\u03b2 on \nFibroproliferation and Extracellular Matrix Production in Primary Human Lung \nFibroblasts \u2013 The Role of p38\u03b4 MAP Kinase\nK. E. Hostettler1,2,3, S. Goulet1, M. Roth1,3, J. Zhong2,3, J. K. Burgess2,3, J. L. Black2,3, M. Tamm1, P. Borger1,3 \n1 Pulmonary Cell Research, Department of Biomedicine, University Hospital Basel, 4031 Basel, \nSwitzerland\n2 Respiratory Research Group, Department of Pharmacology, University of Sydney, Sydney, 2006 New South Wales, Australia\n3 Woolcock Institute of Medical Research, University of Sydney, Sydney, 2006 New South Wales, AustraliaThe Open Critical Care Medicine Journal 2, 28\u201337, 2009  IF N.A40 BABYS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement Biomedizin40 ART DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinAndreas Heusler-Strasse / vor dem Geb\u00e4ude der Wirtschaftsmittelschule \nIn der Wirtschaftskrise der dreissiger Jahre wurde der Arbeitsrappen eingef\u00fchrt. \nVon jedem Franken Lohn wurde ein Rappen abgezweigt, um die Wirtschaft - vor-nehmlich bauliche Objekte - wieder anzukurbeln. Innerhalb von zehn Jahren kamen mehr als 40 Millionen Franken zusammen. In den 1950er Jahren wurden mit dem \u00fcbriggebliebenen Kapital des Arbeitsrappens Altwohnungen renoviert. Die Figur aus Bronze (Fischm\u00e4nnlein) steht in der Mitte der Bronzeschale und zeigt in der offenen rechten Hand ein Geldst\u00fcck (eben den Arbeitsrappen). Die heutige Wirtschaftsmittelschule wurde 1943 mit Hilfe des Arbeitsrappens gebaut. Der Brunnen wurde deshalb als Erinnerung an diese Massnahme vor dieser Schule \nerstellt.Arbeitsrappen-Brunnen\nDEPARTMENT OF BIOMEDICINE  AUSZEICHNUNGEN | CONGRATULATIONS 41\nDBM Facts 2|2009 Department of BiomedicineDissertationen\nSeit dem 31. M\u00e4rz 2009 darf sich Naja Jann von der \nForschungsgruppe Infection Biology (Departement Bio-\nmedizin USB) Frau Dr. nennen. Sie befasste sich in ihrer Dissertation mit dem Thema: \u201eNeutrophil antimicrobial defense against Staphylococcus aureus \u2013 Contribution of Cathelicidin and the NADPH oxidase\u201c.\nIm August 2009 stellte sich Nicole Guetg von der For-\nschungsgruppe Synaptic Plasticity (Institut f\u00fcr Physio -\nlogy) erfolgreich den Fragen des Dissertationskomitees. \nSie besch\u00e4ftigte sich in ihrer Doktorarbeit mit dem \nThema \u201eGABAB Receptor Localization and Regulation\u201c.\nAm 4. September 2009 hat Xiucheng Fan von der For-\nschungsgruppe Prenatal Medicine and Gyn. Oncology \n(Departement Biomedizin USB) seine Dissertation erfolg-reich abgeschlossen. Der Titel seiner Doktorarbeit hiess: \u201eInvestigation of Quantitative and Qualitative MtDNA Al-teration in Breast Cancer\u201c.\nMit der Doktorpr\u00fcfung am 9. Oktober 2009 schloss  \nNicola Miglino von der Forschungsgruppe Pneumology \n(Departement Biomedizin USB) erfolgreich seine Disser-tationszeit ab. Das Thema seiner Doktorarbeit lautete: \u201eNovel molecular pathologies in asthma and COPD\u201c.Am 27. Oktober 2009 war es f\u00fcr Daniela Baldoni von \nder Forschungsgruppe Infectious Diseases (Departe-ment Biomedizin USB) soweit, sie beendete erfolgreich ihre Doktorandenzeit, in der sie sich mit \u201eInnovative Me-thods for the Diagnosis and Treatment of Implant-asso-ciated Infections\u201c auseinandergesetzt hatte.\nAm 29. Oktober 2009 stellte sich Serdar Korur von der \nForschungsgruppe Neurooncology (Departement Bio-\nmedizin USB) dem Dissertationskomitee. Der Titel sei-ner Doktorarbeit lautete: \u201eThe role of the Bmi1-GSK3\u03b2 \npathway in glioblastoma\u201c.\nMathias Schmaler von der Forschungsgruppe Infection \nBiology (Departement Biomedizin USB) ging dem Thema \u201eStaphylococcus aureus lipoproteins \u2013 TLR2-mediated activation of innate and adaptive immunity\u201c nach und darf seit dem 16. November 2009 den Doktortitel tragen.\nHerzlichen Gl\u00fcckwunsch an alle!DBM Facts 2|2009 Departement Biomedizin42 AUSZEICHNUNGEN | CONGRATULATIONS DEPARTEMENT BIOMEDIZIN\nAuszeichnungen\nProf. Markus Heim von der Forschungsgruppe Hepatology \n(Departement Biomedizin USB) ist zum 1. Oktober 2009 \nPreise\nJunior Hepatology Prize an Jan Tchorz\nJan Tchorz von der Forschungsgruppe Synaptic Plastici-\nty (Institut f\u00fcr Physiologie) hat f\u00fcr seine Arbeit \u201eNotch2 signaling promotes biliary epithelial cell fate specifica-tion and tubulogenesis during bile duct development in mice\u201c (Hepatology 2009 Sep;50(3):871-3) den Junior Hepatology Prize erhalten.\nBioValley Poster Awards vergebenAm BioValley Science Day am 23. Oktober 2009 durften \nJason Gill von der Forschungsgruppe Pediatric Immu-\nnology (Departement Biomedizin Mattenstrasse 28) und Romy Walser von der Forschungsgruppe Cancer- and Immunobiology (Departement Biomedizin Mattenstrasse 28) den Preis in der Kategorie Gold im Wert von 2\u2018000.- CHF entgegennehmen. In der Kategorie Silber, die mit 1\u2018500.- CHF dotiert ist, erhielten Katrin Benakovitsch \nvon der Forschungsgruppe Cell Migration and Neurito-genesis (Departement Biomedizin Mattenstrasse 28) und Neha Pandey von der Forschungsgruppe Tumor-\nbiology (Departement Biomedizin Mattenstrasse 28) den Preis. In der Kategorie Bronze (500.- CHF) geh\u00f6rte Alexandre Goncalves von der Forschungsgruppe Developmental Genetics (Departement Biomedizin Mattenstrasse 28) zu den gl\u00fccklichen Preistr\u00e4gern.\nHerzliche Gratulation !zum neuen Mitglied des Nationalen Forschungsrats, Ab-teilung III (Biologie und Medizin), berufen worden.42 AUSZEICHNUNGEN | CONGRATULATIONS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement BiomedizinDEPARTMENT OF BIOMEDICINE EINTRITTE | NEW COLLEAGUES 43\nDBM Facts 2|2009 Department of Biomedicine DBM Facts 1|2009 Department of Biomedicine\nLuigi Costa\nPneumologyPetra Bernegger\nTissue EngineeringCorinna Baumgartner\nCardiovasc. Mol. Imaging\nGino Lee\nMolecular NephrologyLaura Keglowich\nPneumologySimone Keck\nTransplantation ImmunologySimon Hostettler\nExp. Immunology\nFabienne Harrisberger\nNeurobiologyChiara Giovenzana\nTissue EngineeringAnne Christin Gerspach\nGastroenterologyHatice Genc\nAdm. ICFS\nSarah Thommen\nChildhood Leukemia\nMelissa Manser\nExp. ImmunologyZuzanna Makowska\nHepatologyDEPARTEMENT \nBioMED iziN \nUSB\nBenjamin Pippenger\nTissue EngineeringDEPARTMENT OF BIOMEDICINE EINTRITTE | NEW COLLEAGUES 4344 EINTRITTE | NEW COLLEAGUES DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement Biomedizin\nAnja Nusser\nDevelop. & Mol. Immunology\nBin Fan\nOcul. Pharmac. & PhysiologyStefano Vavassori\nExp. ImmunologySabina Tresch\nExp. Hematology\nNicole von Burg\nDevelop. & Mol. ImmunologyGregor Hutter\nBrain Tumor Biology\nMatthias Liechti\nPsychopharmacology Res.Friederike Kesten\nImmunobiologyJunyi Han\nOncology Surgery\nElisabeth Hohmann\nMolecular DiagnosticsSuzanne Edwards\nMolecular ResearchEmanuele Trella\nOncology Surgery\nAlexandra Gerber\nBrain Tumor Biology\nYves Hartmann\nTechnical Support\niNST iTUT\nF\u00dcR  \nMED iziNiSCHE  \nMikRo Biologi EiNST iTUT F\u00dcR  \nBioCHEM iE UND  \ngENET ik\nDEPARTMENT OF BIOMEDICINE EINTRITTE | NEW COLLEAGUES 45\nDBM Facts 2|2009 Department of Biomedicine\nVal\u00e9rie Jacquier\nSynaptic PlasticityPascal Scheidegger\nMolecular ResearchiNST iTUT\nF\u00dcR  \nPHYS iologi E\nDEPARTEMENT  \nBIOMEDIZIN USB\nBilal Azakir, Neurobiology \nMichael Sinnreich, NeurobiologyDonatina Kunz,  Cardiothoratic Surgical ResearchFelicitas M\u00fcller, DermatologyTeo Soon Siong, Exp. HematologyKawa Yousef, Oncology SurgerysMatthias Mehling, ImmunobiologyINSTITUT F\u00dcR BIOCHEMIE \nUND GENETIK\nMatthias Kreuzaler, Developmental \nand Molecular ImmunologyNadine Gehre, Developmental and Molecular Immunology\nINSTITUT F\u00dcR PHYSIOLOGIE\nJosef Bischofberger, \n Cellular NeurophysiologyINSTITUT F\u00dcR  \nMEDIZINISCHE MIKRO-  \nBIOLOGIE\nJuan Caceres Morales,  \nTechnical SupportMelanie Hug, Molecular DiagnosticsNesrin Saridas, Technical SupportAusserdem haben angefangen:\nDEPARTEMENT  \nBIOMEDIZIN USB\nDietlinde John,  \nCardiothoratic Surgical ResearchHeidi Bodmer, PneumologyInterne Wechsel:\nDEPARTEMENT  \nBIOMEDIZIN USB\nIsabelle De Bie, Prenatal Medicine\nXiucheng Fan, Prenatal MedicineAndrea Steinhuber,  Infectious DiseasesLinda Kenins, Exp. HematologyIsabelle Plaisance, Cardiobiology Marianne Messerli, Prenatal Medicine Karin Probst, Infectious Diseases Micha\u00ebl Facompr\u00e9, Exp. Immunology Michel Mallaun,  Transplantation Immunology Dragana Jankovic, \nChildhood Leukemia\nINSTITUT F\u00dcR PHYSIOLOGIE\nMohammed Akaaboune,   Synapse Formation\nINSTITUT F\u00dcR  \nMEDIZINISCHE MIKRO-  \nBIOLOGIE\nMaria Clemente, Technical SupportAustritte:46 BABYS DEPARTEMENT BIOMEDIZIN\nDBM Facts 2|2009 Departement Biomedizin\nYves Hartmann,\nneuer Betriebsassistent am Departement  \nBiomedizin USB\nSeit dem 1. Oktober 2009 hat Yves Hartmann seine T\u00e4tigkeit am Departe-\nment Biomedizin USB aufgenommen. Gemeinsam mit Armin Bieri sorgt er daf\u00fcr, dass an unserem Institut die Betriebsabl\u00e4ufe m\u00f6glichst reibungslos vonstatten gehen. Yves ist Jahrgang 1971, gelernter Biologielaborant Rich-tung Pharma, hat seine Ausbildung von 1987 bis 1990 bei Sandoz-Wander in Bern absolviert. Nach 22 Jahren bei Sandoz/Novartis, wo er zum Schluss als Teamleiter f\u00fcr Labor und Office Support amtete, kam er nun zu uns ans Unispital, um die Nachfolge von Monika Hermle anzutreten und alles bei Novartis Gelernte nun auch bei uns in die Tat umzusetzen. So werden es einige schon gemerkt haben, die Anwendung von Gesundheits- und Sicher-heitsvorschriften ist Yves gewohnt und auch Ver- und Entsorgungsfragen bereiten ihm kein Kopfzerbrechen. Wer Fragen hat oder Hilfe braucht, kann sich jederzeit an ihn wenden. Denn auch hier hat er durchaus die gleiche \nAuffassung wie Monika. Yves ist in Allschwil aufgewachsen, verheiratet und Hundepapa von zwei Cairn Terriern, er mag gerne englischen Humor und den 300m Schiessverein, dessen Pr\u00e4sident er seit 15 Jahren ist. \nYves, wir heissen Dich herzlich willkommen!\nHeidi Hoyermann\n46 EINTRITTE | NEW COLLEAGUES DEPARTEMENT BIOMEDIZIN\nDie Redaktion von DBM Facts w\u00fcnscht\nallen Leserinnen und Lesern sch\u00f6ne Weihnachten \nund ein gutes neues Jahr!\nThe Editorial team of DBM Facts wishes\nall its readers a Merry Christmas and a\nHappy New Year!DEPARTMENT OF BIOMEDICINE BABYS 47\nDBM Facts 2|2009 Department of BiomedicineCongratulations\nDas DBM gratuliert ganz herzlich!\nManuel Philipp Lindinger\nGeboren am 24.4.2009\nGiulia Banfi (Di Maggio)\nGeboren am 21.7 .2009\nKlaara G\u00f6ritz (Pelttari)\nGeboren am 19.9 2009\nOliver Finley Hess\nGeboren am 14.7 .200948 PENSIONIERUNGEN/R ETIREMENTS INSTITUTE OF PHYSIOLOGY\nDBM Facts 2|2009 Departement BiomedizinFig. 1. Structure of endocytic compartments in rat livers infused \nwith peroxidase for 10 min as shown by reconstruction of serial \nEM sections. (A) Two hepatocytes partially imaged between the \nbasolateral cell pole (indicated by endothelium, end) and the apical canaliculus (can). Endocytic compartments are present in all regions. Note the multitude of tubules, only part of which \nis shown in this low power reconstruction, linking different com -\npartments and extending over long distances (arrows). (B) Early \nendosomes (EE) in the basolateral cytoplasm are connected by \nmostly branched (arrows) tubules. Only part of the many small \n(60 nm) vesicles is shown (arrowheads). (C) Endocytic vesicles in the perinuclear region are interconnected by a closely knit tubu -\nlar network. All large vesicles are MVB except for one lysosome (Lys). (D) Endocytic vesicles in the apical cytoplasm include apical endosomes (aE), lysosomes (Lys), and MVB (not labeled) and are \nlinked by tubules. Mesh width = section thickness = 80-120 nm. \nVolume (E) and surface (F) densities of endocytic compartments after continuous peroxidase infusion (n = 3). Micr Res Techn 69 \n(2006): 693-707\nZur Emeritierung  \nvon Lukas Landmann\nEnde Juni 2008 ist \nLukas Landmann, Extraordinarius  f\u00fcr Anatomie und Embyologie, in den Ruhestand getreten. Lukas Landmann begann seine wis -\nsenschaftliche Lauf -\nbahn als Zoologe in Basel in der ausklin -\ngenden Aera Adolf Portmann. Den damaligen Ans\u00e4tzen des Zoologischen Instituts folgend, basierte seine For -\nschung auf der pr\u00e4zisen Beobachtung von Form und Gestalt im Tierreich, welche zur Aufkl\u00e4rung heute noch g\u00fcltiger, entwicklungsgeschichtlicher Zusammenh\u00e4nge  \nin den verschiedenen Tierst\u00e4mmen  f\u00fchrte. Die Beobach -\ntungen wurden damals, d.h. vor dem digitalen Zeitalter, als Zeichnungen und Photographien dokumentiert. Heute w\u00fcrde man in Neu-Deutsch auch eine Zeichnung oder eine Photographie von damals als \u2018Image\u2019 bezeich -\nnen, bedeutet doch Image nichts anderes als ein wie auch immer erzeugtes Abbild eines physischen Objek -\nt e s .   F \u00fc r  L u k a s  L a n d m a n n  i s t  I m a g i n g  e i n e  l e b e n s l a n g e  Leidenschaft geblieben. Sie  begann im Jahre 1970 mit einer fr\u00fchen Publikation (zusammen mit A. Portmann) \u00fcber \u2018Schneckenh\u00e4user\u2019, erschienen in der Zeitschrift \u2018Du\u2019. Imaging hat seit damals eine st\u00fcrmische Entwick -\nlung erfahren, welche durch verbesserte F\u00e4rbemethoden, \nneue mikroskopische Verfahren und durch den Einsatz \nvon Rechnern die Dynamik und die Beziehung subzellul\u00e4 -\nrer Strukturen zueinander auch mit lichtmikroskopischen Methoden sichtbar zu machen erlaubte. Imaging ist damit in der zell- und molekularbiologischen Forschung unver -\nzichtbar geworden, und seine Bedeutung ist 2008 mit der Verleihung des Chemie-Nobelpreises f\u00fcr die Entwicklung von gezielter Fluoreszenzmarkierung von einzelnen Pro -\nteinen in lebenden Zellen unterstrichen worden. Lukas Landmann war mit seinem methodischen Ansatz in der ehemaligen Vorklinik unserer Fakult\u00e4t ein einsamer Pionier, und die Bedeutung seines Engagements und sei -\nner ausserordentlichen Kompetenz wurde nicht immer von allen verstanden. Er hat die neuen Entwicklungen des Imaging und dessen Anwendungspotential fr\u00fch erkannt und trotz bescheidener Unterst\u00fctzung z\u00e4h und weit -\ngehend auf sich allein gestellt verfolgt und eingesetzt. Dabei suchte er stets seine morphologischen Resultate mit physiologischen oder molekularbiologischen Ergeb -\n48 PENSIONIERUNGEN/R ETIREMENTS DEPARTEMENT BIOMEDIZIN    INSTITUTE OF PHYSIOLOGY PENSIONIERUNGEN/R ETIREMENTS 49\nDBM Facts 2|2009 Department of Biomedicine\nFig. 2. Fig. 3. Surface renderings (upper left) and singular opti -\ncal sections (lower right) show the subcellular distribution of \nthe bulk phase endocytosis marker dextran (A, B), and of the \npathway-specific marker proteins asialoglycoprotein (C, D) and pIgA (E, F) after 2.5 (A, C, E) and 30 min (B, D, F). Dextran applied \nin a 5 min pulse labeled a tubulovesicular compartment con -\nsisting of interconnected 200-nm tubules and 300-nm vesicles \nand extending in all cellular regions. The line in (A) traces a \ncontinuous series of vesicles and tubules connecting the baso -\nlateral and the apical cell pole. Initially (A), extran labels the \nnetwork homogenously with a concentration in the basolateral \ncytoplasm. Later (B), dextran is concentrated in apical vesicles. \nAsialoglycoprotein concentrates in vesicles right after start of uptake (C) their number and size increasing by 30 min (D). In \ncontrast, pIgA signal forms finer elements including tubules (E). \nPositive vesicles are distributed in all regions and concentrate in the apical cytoplasm after longer time intervals (F). Contrast has \nbeen adjusted in singular sections to show low intensity tubules \nand high intensity vesicles simultaneously. Bar = 5 \n\u00b5m. Volume \nof endocytic markers applied in a 5 min pulse (G) increases \nrapidly, peaks at 2.5 (dextran, n = 3) and 5 (ligands, n = 4) min and \ndecreases thereafter. Colocalization of ligands displays similar, but less pronounced kinetics. Correlation coefficient and percen -\ntage of ligand present in colocalizing volume (H), which peak at 1 min, indicate rapid sorting of asialoglycoprotein and pIgA.nissen zu kombinieren. Dies zeigt exemplarisch eine Stu -\ndie \u00fcber die canalicul\u00e4ren Tight Junctions von Leberzellen \nbei mehreren Cholestasemodellen (1). Die Flexibilit\u00e4t und Aussagekraft quantitativer mikroskopischer Methoden nutzte er geschickt zum Nachweis und der Charakterisie -\nrung eines apikalen Endozytosewegs in Leberzellen  (2). Stets bewusst war er sich der Gefahr der Ueberinterpreta -\ntion von digital verarbeiteten Bildern. Er besch\u00e4ftigte sich daher l\u00e4ngere Zeit mit dem Problem der 3D Kolokalisation und mit dem Vermeiden von falsch positiven Resultaten, was ihn zu einem Verfechter des Image Processing durch \nDekonvolution machte (3,4).Lukas war aber nicht nur weitsichtiger Pionier, sondern \nauch ein \u2018good citizen\u2019 des DBM. In den Prozess der Studi -\nenreform hat er sich aktiv eingebracht. Noch heute schim -\nmert im Curriculum der ersten beiden Studienjahre das Konzept durch, das er mit zwei Kollegen spontan erarbei -\ntet hat. In kritischer Zeit hat er mit der interimistischen Uebernahme der Leitung des Anatomischen Instituts die damalige Departementsleitung des DKBW unterst\u00fctzt. \nZahlreiche Kollegen in Basel und ausw\u00e4rts hat er an seiner \nhevorragenden technischen Expertise teilhaben lassen und damit auch vielen Arbeiten, die prim\u00e4r nicht in sei -\nnem Labor entstanden sind, zum Durchbruch verholfen. Um so bedauerlicher ist es, dass sein Bem\u00fchen, f\u00fcr das DBM eine technische Plattform f\u00fcr modernste lichtmikro -\nskopische Verfahren aufzubauen und seinen Mitgiedern mit Rat und Tat zur Seite zu stehen, von der Universi -\nt\u00e4t nicht honoriert worden ist.  Dass dies nicht geschah, hat ihn tief getroffen. Denn als Team Player erwartete er, dass Versprechungen eingehalten oder bei ver\u00e4nderten Umst\u00e4nden neu ausgehandelt werden sollten. Deshalb hat er das DBM entt\u00e4uscht und im Unfrieden verlassen. \nAuch nach seiner Pen -\nsionierung ist Lukas Landmann dem Ima -\nging treu geblieben. Er hat soeben einen Bild -\nband \u00fcber die zahlrei -\nchen Facetten unserer Stadt Basel kreiert, der in diesen Wochen in \neinem bekannten Basler Verlag erschienen ist. Unsere besten W\u00fcnsche begleiten ihn in seinen neuen Lebens -\nabschnitt, der leider durch den k\u00fcrzlichen Tod seiner Frau \u00fcberschattet wird.\nHans-Rudolf Brenner\n1) C. Rahner, B. Stieger, and L. Landmann, Structure-function correlation of \ntight junctional impairment after intrahepatic and extrahepatic cholestasis \nin rat liver. Gastroenterology, 1996. 110: p. 1564-1578 (s. auch Kommentar dazu von: Anderson, J.M. Leaky junctions and cholestasis, Gastroenetero -\nlogy 110 (1996):1662-1665).\n2) Marbet, P., et al., Quantitative Microscopy Reveals 3D Organization and \nKinetics of Endocytosis in Rat Hepatocytes Micr. Res. Techn., 2006. 69:  \np. 693-707.3)  Landmann, L., Deconvolution improves colocalization analysis of multiple \nfluorochromes in 3D confocal data sets more than filtering techniques.  \nJ. Micr., 2002. 208(2): p. 134-147.\n4.) Landmann, L. and P. Marbet, Colocalization analysis yields superior \nresults after image restoration. Micr. Res. Techn., 2004. 64: p. 103-112.DEPARTMENT OF BIOMEDICINE PENSIONIERUNGEN/R ETIREMENTS 4950 PENSIONIERUNGEN/R ETIREMENTS INSTITUTE OF PHYSIOLOGY\nDBM Facts 2|2009 Departement BiomedizinRegine Landmann-Suter hat selbstredend unz\u00e4hlige  \nFacetten. Im Versuch sie zu charakterisieren mag einem \ndie Symbolik des Leuchtturms in den Sinn kommen;  \ndiszipliniert, ruhig und ohne einem zu nahe zu treten,  \nvermittelt und vermittelte Regine immer Halt und  \nOrientierung. Nur ist ein Leuchtturm nat\u00fcrlich viel zu  \nstatisch um die Dynamik und den unerm\u00fcdlichen Ein-satz von Regine Landmann in vielen ganz unterschied-\nlichen Gebieten zu fassen. Auch passend zum Leucht-\nturm hat Regine aber viele Wellen anbrausen und St\u00fcrme kommen und gehen gesehen, kennt sie doch das Haus \nRegine \nLandmann-Suter\nseit 1977 als sie im Labor von Professor Fritz B\u00fchler  \nbegonnen hatte. Und an Ausstrahlung und Leuchtkraft \nhat sie in den mehr als 30 Jahren nie auch nur ein Lux verloren.\nIhre berufliche T\u00e4tigkeit hatte sie nach dem Medizin-  \nstudium 1972 in Genf aufgenommen, wo sie auch  \neinen Teil ihres Studiums absolvierte. Regine war eine \nder ersten Frauen, die in der Inneren Medizin bei Pro-fessor Alex M\u00fcller gearbeitet hat. Nach 4 Jahren kli-nischer Arbeit in Genf und Utrecht kam sie nach Basel \nzur\u00fcck. Sie nahm bei der Ciba-Geigy ihre Forschung auf \nund wechselte dann ans Departement Forschung. \u00dcber die Jahre entwickelte sich ihre Forschung zun\u00e4chst in Richtung Onkologie (Prof. J. P. Obrecht und F. Gudat), bevor es in Richtung Immunologie/Infektiologie (Prof. Werner Zimmerli) mit Aufenthalten in London (1984) und La Jolla (1995) weiterging. Seitdem leitete sie ihre unabh\u00e4ngige Forschungsgruppe am Departement For-schung (jetzt im Departement Biomedizin integriert). \nIhre 4 T\u00f6chter sind zwischen 1973 und 1984 auf die Welt \ngekommen. Sie haben Regine Landmanns T\u00e4tigkeit als Forscherin im Sinne von \u00abtake your time\u00bb beeinflusst; interessante Forschung ist nicht immer mit sofortigen Resultaten verbunden. Regine zeigte mit ihrem un-brechbaren Optimismus, wie auch ein komplexes Le-ben gut gestaltet werden kann: Familie UND die For-schung waren und sind wichtig und m\u00f6glich, wenn die n\u00f6tige Ausgewogenheit zwischen den beiden Lebens-50 PENSIONIERUNGEN/R ETIREMENTS DEPARTEMENT BIOMEDIZIN    INSTITUTE OF PHYSIOLOGY PENSIONIERUNGEN/R ETIREMENTS 51\nDBM Facts 2|2009 Department of Biomedicinebereichen gew\u00e4hrleistet ist. Regine kann heute stolz auf \nihre T\u00f6chter UND auf ihre Forschung zur\u00fcckblicken. Ge-rade deshalb ist sie ein Vorbild und exzellentes Beispiel f\u00fcr alle jungen Frauen, die Familie UND akademische Entwicklung in Einklang bringen m\u00f6chten. \nIn der Tat hat Regine ihre wohl besten akademischen \nJahre in den letzten 15 Jahren erlebt \u2013 Exzellenz in  \nder Forschung mit besten wissenschaftlichen Publika-tionen \u2013 inklusive 2008 und 2009 \u2013 Verantwortungen in der Aus- und Weiterbildung junger Dissertanden der \nMedizinischen und Naturwissenschaftlichen Fakult\u00e4ten, \nVerantwortung f\u00fcr das DF \u2013 welches sie interimistisch 2000-2001 geleitet hat \u2013 und f\u00fcr die Universit\u00e4t als  \nPr\u00e4sidentin der Gleichstellungskommission. Regine hat das \u00abmentoring\u00bb f\u00fcr junge Akademikerinnen erfolgreich eingef\u00fchrt. Das Programm l\u00e4uft bestens und sollte auch weiter in Anspruch genommen werden. \nDabei ist Regine eine echte Baslerin: Bescheidenheit \nverkn\u00fcpft mit herausragender Expertise, selbstloser Unterst\u00fctzung der Forschung und ein gro\u00dfes Interesse allgemein an Wissenschaft und Kunst. Im DF ist sie im-mer bereit mitzuhelfen, zu erkl\u00e4ren und an Zusammen-arbeiten mitzuwirken (aber nur bei guten Projekten!).\nMan sieht ihrem Gesicht sofort an, ob es ihr gut geht \noder nicht. Es ist so sch\u00f6n, ihr zu begegnen, wenn sie einem mit ihrem strahlenden L\u00e4cheln entgegen kommt! Manchmal bedr\u00fccken sie aber auch Probleme, und dann ist ihr Ausdruck entsprechend; aber Probleme sind da, um gel\u00f6st zu werden, wie sie sagt. Die typische Basler \nMundart ist ihr eigen, und sie wird euch daher erkl\u00e4-\nren k\u00f6nnen, wie man sprachlich Burkart von Burckardt (ckdt!) unterscheidet. Und dazu spricht sie nat\u00fcrlich perfektes Franz\u00f6sisch, die Sprache der Diplomaten \u2026\nWarum gehen die Jahre so schnell vorbei? Man m\u00f6ch-\nte zum Augenblicke sagen \u00abverweile doch, du bist so sch\u00f6n\u00bb. Zum Gl\u00fcck wird Regine weiter aktiv sein. Sie hat Pl\u00e4ne bez\u00fcglich der Entwicklung eines Bakteriologie-Labors in Vietnam \u2013 wo sie zum Teil auch weilen wird \u2013 und sie hat zudem f\u00fcr die n\u00e4chsten Jahre eine wichtige Arbeit unserer Fakult\u00e4t \u00fcbernommen, die Nachwuchs-f\u00f6rderung. Schon wenige Wochen nach Aufnahme ihrer neuen fakult\u00e4ren Funktion hat sie Vorschl\u00e4ge unterbrei-tet. Unser Nachwuchs kann sich freuen, denn er wird unterst\u00fctzt \u2013 nicht nur als Gruppe, sondern auch auf individueller Ebene. Bitte, Regine, mach weiter so. Den Ruhestand kann es f\u00fcr Dich ja ohnehin nicht geben, wird doch die \u00abNachwuchsf\u00f6rderung\u00bb im allerdirektesten Sinn \u2013 Deiner 4 T\u00f6chter also \u2013 Dir wohl viele stolze und freudige Momente, aber wenig Ruhe bescheren.\nLiebe Regine, von Deiner Lebenserfahrung und Experti-\nse m\u00f6chten noch viele junge Menschen profitieren!\nJ\u00fcrg Schifferli\nDEPARTMENT OF BIOMEDICINE PENSIONIERUNGEN/R ETIREMENTS 51\nVerantwortlich ist man nicht nur f\u00fcr das, was man \n tut, sondern auch f\u00fcr das, was man nicht tut. \nLaotse52 WISSENSCHAFT | SCIENCE INSTITUTE OF PHYSIOLOGY\nDBM Facts 2|2009 Departement BiomedizinDEPARTMENT OF BIOMEDICINE Moroni 52 52 PENSIONIERUNGEN/R ETIREMENTS DEPARTEMENT BIOMEDIZIN    \nFarewell to  \nOla Filipowicz\nAt the end of the year, Prof. Aleksandra Wodnar-Filipo-\nwicz, or Ola, as she is called by her friends and collabo-rators, retires from her position as research group lea-der and deputy head of the Laboratory for Hematology in the Department of Biomedicine, and as professor in  \nExperimental Hematology at the medical faculty. The track of an outstanding scientific career will not come to an end but will just shift gears and change focus slightly.\nAleksandra Wodnar-Filipowicz was born in Warsaw where she graduated in biochemistry. A rapid and fas-cinating scientific career developed: A PhD programme at the Institute for Molecular Biology in Nutley, research adjunct at the Institute of Biochemistry and Biophysics in Warsaw, back as postdoc to Nutley and, in 1985 as a research fellow to the Friedrich Miescher Institute in Basel, together with her husband, Witold.\nIn 1990, she was asked by Prof. Catherine Nissen and \nProf. Bruno Speck to join the hematology team and to \nlead the research programme on aplastic anemia. She \nrapidly pushed the field forward and her seminal pa-pers on the role of FLT-3 ligand and stem cell factor in aplastic anemia remain  reference works. They formed the basis for her habilitation on the topic \u201cControl of blood cell development and function by hematopoietic growth factors\u201d.\nThis work on the control and regulation of normal he-\nmatopoietic was extended during the last decade to the control of leukemic stem cells by their niche-environ-INSTITUTE OF PHYSIOLOGY WISSENSCHAFT | SCIENCE 53\nDBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF BIOMEDICINE PENSIONIERUNGEN/R ETIREMENTS 53\nment and by natural killer cells. Results from this re-\nsearch form the basis for the clinical translational stem cell transplantation programme on the use of these NK cells in the context of haploidentical donor trans-plants, one of the key leading experimental transplant programmes of the University Hospital Basel. The excel-lence of her research is probably best reflected in her award from the medical faculty for the highest ranking in publications last year.\nOla\u2019s life goes beyond pure science, it is devoted to  \nscience and family. Her attention to family life is not only \nreflected in her two children but also in the care she gi-ves the collaborators in her team and her students. Few research group leaders at the department have such a track record of so many students winning the best me-dical thesis and other awards.\nHer lectures are rated amongst the best and for many \nyears she has been continuously invited as a teacher by the European School of Hematology. I myself have had the privilege to collaborate with Ola for many years on several local, national, and international projects related to scientific, educational, and administrative projects. I was always impressed by her rare gift of being able to concentrate on the essentials while also seeking con-sensus amongst partners.\nFor all those who know Prof. Aleksandra Wodnar-Fili-\npowicz, it is no surprise that she will not \u201cretire\u201d. Her devotion to science and education will continue within new fields, some of them already ongoing. She is, and \nwill continue as, coordinator of the recently established \nCompetence Centre of the University of Basel, the Basel Stem Cell Network BSCN. She holds a temporary man-date as advisor on stem cells by WHO. She will maintain an advisory function on many editorial and scientific boards and, last but not least, as mentor in the \u201cFrauen-f\u00f6rderung\u201d program of the university. We will look for-ward to her achievements in the future.\nThank you, Ola, for all of your work and all the best.\nAlois Gratwohl\nEin Winterabend\nWenn der Schnee ans Fenster f\u00e4llt, \nlang die Abendglocke l\u00e4utet, vielen ist der Tisch bereitet und das Haus ist wohlbestellt. \nMancher auf der Wanderschaft \nkommt ans Tor auf dunklen Pfaden. \nGolden bl\u00fcht der Baum der Gnaden aus der Erde k\u00fchlem Saft. \nWanderer, tritt still herein; \nSchmerz versteinerte die Schwelle. Da ergl\u00e4nzt in reiner Helle auf dem Tische Brot und Wein.\nGeorg Trakl, (1887 - 1914), \u00f6sterreichischer  \n   fr\u00fchexpressionistischer Dichter und Lyriker54 WISSENSCHAFT | SCIENCE INSTITUTE OF PHYSIOLOGY\nDBM Facts 2|2009 Departement Biomedizin54 PENSIONIERUNGEN/R ETIREMENTS DEPARTEMENT BIOMEDIZIN    \nMonika kann man nicht beschreiben, Monika muss man \nerleben. Oder vielleicht doch? Machen wir den Versuch einer Ann\u00e4herung. An Monika zu denken, gleicht f\u00fcr viele erst einmal dem Gef\u00fchl, beschwingt auf der Stras-se zu fahren und einen Streifenwagen im R\u00fcckspiegel zu sehen. Der erste Gedanke: K\u00f6nnte ich etwas falsch gemacht haben? Zweiter Gedanke: Wie ist die Laune des Polizeibeamten? Dritter Gedanke: Ja nichts Falsches sa-gen. Wer einmal mit kurzen Hosen im B2 Labor erwischt Monika Hermle\nwurde oder Rettungst\u00fcren mit Utensilien verstellt hat, weiss, wovon ich rede. Aber: Monika ist auch die erste, die selbst Hand anlegt, um die T\u00fcr frei zu r\u00e4umen und mit einem freundschaftlichen Klaps auf die Schulter dem Hosens\u00fcnder signalisiert, dass alles wieder gut ist.  \nWer es noch nicht ahnt, Monika ist unsere Betriebsor-\nganisatorin und Sicherheitsbeauftragte. Durch sie habe ich gelernt, wie man einen Feuerl\u00f6scher bedient, dass man nicht von jedem geliebt werden kann (und darf) und sich nicht unter kriegen zu lassen. Sie ist eine Frau \nmit Zivilcourage! Und nicht nur das: Sie ist eine sehr ver-\nsierte Laborantin mit viel Erfahrung und grossem Hin-tergrundwissen. \nDas wusste auch Gilbert Thiel, der damalige Leiter des \nNephrologie- und Typisierungslabors, als er sie im Fr\u00fch-jahr 1980 von M\u00fcnchen ans damalige Departement Bi-omedizin nach Basel holte, da sie eine Spezialtechnik beherrschte, die es an unserem Institut damals noch nicht gab, die \u00abMikropunktion an Rattennieren\u00bb. Drei Jahre sp\u00e4ter wurde Monika Cheflaborantin. Ihr Spezial-gebiet blieben Mikrooperationen technischer Art und an Tieren. \nEnde der Neunziger Jahre wurde Monika von den tech-\nnischen Mitarbeitenden als ihre Vertreterin in die Be-reichsleitung gew\u00e4hlt, in der sie die Interessen der La-borantinnen und Laboranten vertrat. Sie organisierte Ausbildungen in diesem Bereich und war Ansprechpart-INSTITUTE OF PHYSIOLOGY WISSENSCHAFT | SCIENCE 55\nDBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF BIOMEDICINE PENSIONIERUNGEN/R ETIREMENTS 55\nnerin f\u00fcr so manches Problem. In dieser Zeit wechsel-\nte sie auch zu 50% in den Stab des Departements und behielt 50% ihrer T\u00e4tigkeit im Labor bei, weiterhin der Nephrologie verpflichtet, die jetzt von J\u00fcrg Steiger ge-leitet wurde. \nDer Aufgabenbereich im Stab legte eine Erh\u00f6hung auf \n100% nahe, was dann im Jahr 2002 auch geschah. Moni-ka \u00fcbernahm aufgrund ihrer grossen tierexperimentel-len Kenntnisse unter anderen auch weitere Aufgaben in der Tierversuchsstation.\nIm Laufe der Jahre hat sie in ihrem T\u00e4tigkeitsfeld das \nDBM, oder sagen wir in alter Tradition, das DF, auf Vor-derfrau gebracht. Vieles hat sie inzwischen wohl ge-ordnet an ihren Nachfolger Yves Hartmann \u00fcbergeben, manches wird noch folgen. \nMit Monika geht eine \u00c4ra zu Ende. Viele werden ihren \nrauhen, aber herzlichen Ton genauso vermissen, wie ihre Kompetenz und die interessanten, vielf\u00e4ltigen Ge-spr\u00e4che mit ihr.\nMonika, m\u00f6ge Dir die T\u00e4tigkeit als Pr\u00e4sidentin des Quar-\ntiervereins in Deiner Heimatgemeinde Riehen genauso viel Erf\u00fcllung bereiten wie Deine k\u00fcnstlerischen Heraus-\nforderungen und lass\u2019 uns zwischendurch einmal anru-\nfen d\u00fcrfen, wenn wir nicht mehr weiter wissen.\nHeidi Hoyermann56 WISSENSCHAFT | SCIENCE INSTITUTE OF PHYSIOLOGY\nDBM Facts 2|2009 Departement BiomedizinWenn man das Gef\u00fchl hat, dass Tauchen eine aufw\u00e4n-\ndige und spezielle Sportart ist (meine Ausr\u00fcstung wiegt im Normalfall ca. 60 Kilo), so ist das Eistauchen die Qua-dratur davon. Zur Tauchausr\u00fcstung hinzu kommt noch viel Sicherungsmaterial (Leinen, Leitern) und Werkzeug zum Aufbrechen der Eisschicht (Bohrer, Axt, Motor-s\u00e4ge). Des Weiteren muss man je nachdem amtliche Bewilligungen und Erlaubnis der privaten Grundbesit-zer einholen. So ein Unternehmen muss also gut vor-bereitet und organisiert sein. Und da ein zugefrorenes Gew\u00e4sser nicht gerade vor der Haust\u00fcre liegt, ergeben \nsich lange Anfahrtswege.\nTauchgang im Silvaplanersee\nNach zwei Wochen Vorbereitung und einer halben Tages-\nreise ist es endlich soweit, wir stehen am Ufer des Silva-planersees und besprechen, wo und wie das Eisloch ge-macht werden soll. Zum Gl\u00fcck  haben wir zwei erfahrene Eistaucher dabei. Die etwa 50 m vom Ufer eine geeignete Stelle aussuchen und mit einem Eisbohrer beginnen, ein erstes Loch zu bohren. Danach gilt es zuerst einmal, ein entsprechend gro\u00dfes Loch zu s\u00e4gen. Es kann niemand sagen, dass es einem beim Eistauchen nicht auch warm werden kann! Das Eis hat immerhin eine St\u00e4rke von gut 10 cm! Nach einer weiteren halben Stunde sind wir als erstes Tauchpaar fertig ausger\u00fcstet.\nDie Sicherungsleinen werden angeschlossen, wir sind \nbereit zum Abtauchen. Mit viel Adrenalin im Blut und t\u00fcchtigem Herzklopfen steigen wir ins eiskalte Wasser und lassen uns auf 3 Meter sinken.\nNach dem gegenseitigen Durchche-cken der Tauchausr\u00fcstung (funkti-oniert alles, ist alles dicht?) schaue ich mich ein erstes Mal richtig um. Im Schein der Taucherlampe ist alles in einem bl\u00e4ulichen weissen Licht. Fas-zinierend und mystisch!\nWir gleiten in fast vollkommener \nSchwerelosigkeit langsam auf den \nGrund in 15 Metern Tiefe zu. In die-ser Tiefe ist fast schon kein Tageslicht mehr vorhanden, es ist jetzt blau-schwarz und absolut still. Ich h\u00f6re nur mein eigenes Herz schlagen, 56 FREIZEIT | FREETIME DEPARTEMENT BIOMEDIZIN\nEistauchen\nFertig zum EinstiegNach dem Einstieg\nINSTITUTE OF PHYSIOLOGY WISSENSCHAFT | SCIENCE 57\nDBM Facts 2|2009 Department of Biomedicinemein Atmen und das Rauschen der ausgeatmeten Luft.  \nMit Handzeichen verst\u00e4ndigen wir uns, dass wir wieder auftauchen bis unter die Eisschicht. Wir beobachten fas-\nziniert das Blasenspiel unserer ausgeatmeten Luft unter \ndem Eis.\nIch probiere, kopf\u00fcber unter dem Eis zu gehen. Nach \nmehreren Anl\u00e4ufen gelingt es mir, ein eigenartiges Ge-\nf\u00fchl. Nach ein paar Schritten verliere ich den Orientie-\nrungssinn und das Gleichgewicht, es wird mir flau im Magen. Ich probiere wieder, meine normale Tauchposi-tion einzunehmen (den Kopf oben und die Beine unten), aber das geht nicht so einfach. Wir tauchen ja mit Trockentauchanz\u00fcgen, bei denen man Druckluft von der Tauchflasche direkt in den Anzug pumpen kann (einerseits zur W\u00e4rmeisolation, anderer-seits zum Tarieren). Da die Luft unter Wasser immer den Weg nach oben sucht, habe ich jetzt alle Luft in den Bei-nen, die ich eigentlich nach unten nehmen will. Aber das geht nicht. Ich h\u00e4nge mit dicken Elefantenf\u00fcssen unter dem Eis und kann mich nicht drehen, da das Ablassventil f\u00fcr die Luft an der rechten Schulter ist. Mit Hilfe meines Tauchpartners gelingt es mir, mich flach unter die Eis-schicht zu legen und das Ablassventil zu bet\u00e4tigen. Nach diesem Experiment ist unser Luftvorrat zur H\u00e4lfte verbraucht, also das Zeichen, den Tauchgang zu been-den und zum Einsiegsloch zur\u00fcckzukehren. Aber wo ist dieses verflixte Einstiegsloch? Wir haben beide \u00fcber-haupt keine Orientierung mehr. Aber zum Gl\u00fcck haben wir ja unsere Sicherungsleinen, die an der Oberfl\u00e4che je von einem weiteren Taucher gef\u00fchrt und gesichert wer-den. So finden wir rasch wieder unser Einstiegsloch, wo wir erwartet werden. Wir ziehen unsere Ger\u00e4te im Wasser aus und reichen sie unseren Sicherungsleuten. So schaf-fen wir den Ausstieg und beginnen sofort begeistert zu erz\u00e4hlen.\nNach zwei Stunden sind wir wieder umgezogen und ha-\nben alles weg- und aufger\u00e4umt. Ziemlich m\u00fcde machen wir uns zu unserer Unterkunft in St. Moritz auf.\nAm n\u00e4chsten Tag gehen wir noch in den Marmorera-\nStausee zu einem zweiten Eistauchgang. Dort k\u00f6nnen wir vom Ufer aus unter das Eis tauchen. Die Sicht ist aber sehr schlecht. Es ist tr\u00fcbe und der Tauchgang ist ein ab-soluter Blindflug. Entt\u00e4uscht brechen wir ab und neh-men den langen Heimweg unter die R\u00e4der.\nMein letzter Eistauchgang war im Lago del Naret, ganz \nhinten im Maggiatal. Unendlich sch\u00f6n, aber ebenso un-endlich aufw\u00e4ndig.\nWas macht eigentlich die Faszination des Eistauchens \naus? F\u00fcr mich ist es die perfekte Abgeschiedenheit, die Quadratur der Stille und Einsamkeit. Unter dem Eis wird man sich der eigenen Wenigkeit und Verletzlichkeit  \nbewusst.\nArmin Bieri\n DEPARTMENT OF BIOMEDICINE FREIZEIT | FREETIME 57\nDirekt unter dem EisFaszination unter Eis\n58 WISSENSCHAFT | SCIENCE INSTITUTE OF PHYSIOLOGY\nDBM Facts 2|2009 Departement Biomedizin58 ADVENT UND WEIHNACHTEN DEPARTEMENT BIOMEDIZIN\nAdvent f\u00e4llt in die dunkle Jahreszeit, in die Zeit, die dem \nk\u00fcrzesten Tag entgegen geht. Symbolisch z\u00fcnden wir Woche f\u00fcr Woche eine Kerze mehr an, bis dann kurz nach dem 21. Dezember am Weihnachtsbaum viele Ker-zen ein warmes Licht verbreiten. Dieses zunehmende Licht kennen wir aus vielen Kulturen. So feiern die Juden \u201aChanukka\u2018, ihr Lichtfest zu dieser Zeit. Es ist erstaun-lich, was Weihnachten f\u00fcr einen hohen Stellenwert in unserer Gesellschaft geniesst. Dies nicht nur wegen ihrer Schattenseiten, dem Konsum,  sondern weil wir uns anr\u00fchren lassen, unsere Herzen und Seelen ber\u00fchrt \nwerden. Advent und Weihnachten k\u00f6nnte als seelische \nLichttherapie gesehen werden. \nWenn wir das menschliche Leben betrachten, sehen wir \nsolch rhythmisches Leben von hell und dunkel eben-falls. Kaum jemand wird sagen k\u00f6nnen, dass er oder sie nie im Leben auch dunkle, schwierige, bedr\u00fcckte, de-pressive Momente hat kennen lernen m\u00fcssen. Es sind nicht die angenehmen Zeiten, Phasen, die wir lieber \u00fcberspringen, auslassen m\u00f6chten. Es f\u00e4llt uns leichter, die H\u00f6hen und H\u00f6hepunkte zu leben. Diese k\u00f6nnen (und sollen!) wir mit jeder Faser unseres K\u00f6rpers und  \njedem Hauch unserer Seele geniessen. Doch wenn wir in Therapie und Beratung und noch viel mehr in das Leben von Menschen und in unser Leben schauen, so sehen wir, dass gerade die dunklen und schwierigen Zeiten in unserem Leben uns letztlich vorangebracht haben. Mit Voranbringen meine ich das innere Wachsen, nicht das \u00e4ussere, die Seele, nicht die Lohnt\u00fcte. \nDer Advent ist eine Zeit der Hoffnung. Die gr\u00f6sste und \nletzte Chiffre f\u00fcr Hoffnung k\u00f6nnen wir Jesus Christus \nnennen, Messias oder mit den anderen Religionen Gott, das grosse Licht. Gedanken zu Advent  \nund Weihnachten\nINSTITUTE OF PHYSIOLOGY WISSENSCHAFT | SCIENCE 59\nDBM Facts 2|2009 Department of BiomedicineIm Uni-Spital geh\u00f6ren die Pole Hoffnung und Verzweif-\nlung zum Alltag. Nicht nur auf der Notfall- und der In-tensivstation sind Menschen mit Extremsituationen konfrontiert. Unz\u00e4hlige Menschen kommen aus der  \nF\u00fclle ihrer Leben in dunkle Verzweiflung, Seelennot, Wut und Angst. \nDer Vater findet seine vierj\u00e4hrige Tochter, einen Wild-\nfang, auf dem Boden des Tenns liegend. Offensichtlich ist sie vom Dachboden gefallen. Sie ist nicht ansprech-bar. Die herbeigerufenen Ambulanzfahrer lassen den \nRettungshelikopter kommen. Der Bruder fl\u00fcchtet in der  \nNot in den Wald. Die Mutter kommt mit der Tochter  \nins USB. Auf einen Schlag ist nichts mehr, wie es war.  \nDie Tochter wird mit Hightech diagnostiziert; als Seel-  \nsorger begleite ich die Mutter mit Hightouch. In diesem \nFalle gibt es, zum Gl\u00fcck oder Gott sei Dank, Entwar-nung. \nIn der Onkologie ist der Absturz nicht so abrupt, der \nAusgang aber oft unklar und offen. Eine Frau, die l\u00e4n-gere Zeit wegen ihrer Magenschmerzen in Behandlung ist, erf\u00e4hrt, dass sie Magenkrebs hat. Die Entfernung des Magens sichert vorerst das \u00dcberleben. Wirkliche  \nSicherheit gibt es aber in diesem Bereich keine; die \u00c4ng-ste bleiben; ohne Magen zu leben, muss gelernt wer-den; das Leben erf\u00e4hrt eine \u00c4nderung. DEPARTMENT OF BIOMEDICINE ADVENT UND WEIHNACHTEN 59\n\u00abDas Sinken geschieht um des Steigens willen\u00bb, sagt eine \nj\u00fcdische Weisheit. Und Paul Tillich: \u00abDie Grenze ist der \neigentliche Ort der Erkenntnis\u00bb. Ich wage zu behaupten, \ndass an keinem Ort der Welt (ausser in den kirchlichen Gottesdiensten) so viel gebetet wird, wie im Uni-Spital. Wo die Not am Gr\u00f6ssten ist, ist die Hoffnung am N\u00f6tig-  \nsten. Wo die Tage k\u00fcrzer werden, muss der Dunkel-heit Licht beigegeben werden. Die Aufgabe der Arztes/  \nder \u00c4rztin ist es, in einem Menschen die Krankheit  \nzu suchen. Hat er sie gefunden, kann er oft nicht aus der Hoffnung heraus sprechen, sondern muss Klartext  \nreden.  \u00abDie   wahre    Humanit\u00e4t  liegt   in   der   Bek\u00e4mpfung  \nder Krankheit und nicht in der Behandlung von Kranken\u00bb, konnte Virchow noch sagen. Die heutige \u00c4rztegenera-tion w\u00fcrde das nicht mehr unterschrieben. Die Aufgabe des Seelsorgers, meine Aufgabe, ist es, den Menschen in der Krankheit zu sehen, \u00fcber seine Verzweiflung, Wut und \u00c4ngste zu reden, dabei die Hoffnung aber nie  \naussen vor zu lassen. Wie das konkret aussieht, muss die  \neinzelne Situation, der einzelne Mensch zeigen. Wir ver-  \nlassen hier auch den Pfad der manchmal nur zu tristen  \nGewissheit, und leben und handeln aus einem Glauben heraus, der schwierig zu kommunizieren ist. \u00abWir k\u00f6nnen \nin keinen Abgrund fallen, ausser in die H\u00e4nde Gottes\u00bb, sagt \nNietzsche (ausgerechnet!). In unserer j\u00fcdisch-christ-lichen Kultur soll niemand in seinem Leiden, in seiner Verzweiflung, mit seinen Diagnosen und \u00c4ngsten allein \ngelassen sein. \u00abDer Arzneien gr\u00f6sste aber ist die  \nLiebe!\u00bb, sagte Paracelsus. Das ist  Weihnachten. \nJ\u00fcrg Merz\nJ\u00fcrg Merz ist evangelisch-reformierter\nSpitalpfarrer am Universit\u00e4tsspital Basel\n60 WISSENSCHAFT | SCIENCE INSTITUTE OF PHYSIOLOGY\nDBM Facts 2|2009 Departement Biomedizin60 DBM INTERN  DEPARTEMENT BIOMEDIZIN\nDBM Facts: Vielleicht erz\u00e4hlt Ihr einmal, wie lange Ihr \nschon an der Uni seid, etwas \u00fcber Euren pers\u00f6nlichen \nWerdegang, warum es Euch das Personalwesen angetan hat. \nCD: Ich bin seit 1998 an der Uni.DBM Facts: Was hast Du vorher gemacht?CD: Nach meiner KV- Lehre war ich zehn Jahre bei einer \nVersicherungsgesellschaft in Basel im Personaldienst Der Personaldienst der\nUniversit\u00e4t Basel stellt sich vor\nt\u00e4tig. Anschliessend hat mir der damalige Personalleiter \nder Uni meinen jetzigen Job angeboten. Seitdem bin ich hier, wo es mir nach wie vor gef\u00e4llt.Im Jahr 2000 habe ich mich zur Personalfachfrau mit Fachausweis weitergebildet.\nDBM Facts: Ueli, vielleicht erz\u00e4hlst Du jetzt einmal von \nDir.\nUP: Ich bin jetzt zw\u00f6lf Jahre hier. Urspr\u00fcnglich komme \nich nicht aus dem Personalwesen. Ich war bei einer Ver-Interview mit Ulrich Pfister, stv. Personalleiter der Universit\u00e4t Basel, und Cinzia D\u2018Intino,  \nPersonalassistentin f\u00fcr die Medizinische Fakult\u00e4t an der Universit\u00e4t Basel\nINSTITUTE OF PHYSIOLOGY WISSENSCHAFT | SCIENCE 61\nDBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF BIOMEDICINE DBM INTERN  61\nsicherungsgesellschaft zun\u00e4chst Leiter der Betriebsor-\nganisation, danach der Assistent der Gesch\u00e4ftsleitung. Mit der Autonomie der Universit\u00e4t Basel im 1996 hat man erstmals einen Personalleiter gesucht, vorher war der Personaldienst des Kantons Basel-Stadt f\u00fcr die Personalbelange zust\u00e4ndig. Als Daniel Fischer-Ahr als Personalleiter der Uni angestellt wurde, hat er mich an-gefragt, ob ich an einer Stelle im Personalwesen interes-siert sei. Der Aufbau einer neuen Personalorganisation war f\u00fcr mich eine Herausforderung, die ich gerne ange-nommen habe. \nDBM Facts: Du hast dann im Personalwesen ganz neu \nangefangen ...\nUP: Ja. Vor meiner Anstellung in der Versicherungsbran-\nche war ich zw\u00f6lf Jahre in der Unternehmensberatung t\u00e4tig. Ich hatte Mandate in den unterschiedlichsten Branchen und Arbeitsgebieten. Als ich hier meine Arbeit aufgenommen habe, traf ich ein leeres B\u00fcro, das Mobili-ar habe ich selbst mitgebracht. Der Aufbau einer neuen Personalorganisation war eine echte Herausforderung. Im 2000 wurde das kantonale Abrechnungssystem durch SAP abgel\u00f6st. Ab 2003 hat die Uni zudem die Nati-onalfonds und Drittmittelverwaltung von der STG \u00fcber-nommen, was zur Folge hatte, dass zus\u00e4tzlich weitere 700 Personen durch unseren zentralen Personaldienst angestellt und verwaltet werden mussten.\nDBM Facts: Ihr seid wirklich durch Zufall zur Uni und ins \nPersonalwesen gekommen ... \nUP: Ich h\u00e4tte nie gedacht, dass ich nach meinem Studi-\num wieder einmal zur\u00fcck an die Uni komme. ...\nDBM Facts: H\u00e4ttest Du Dir mit 25 wahrscheinlich auch \nnicht gew\u00fcnscht ... Du bist von Haus aus Betriebswirt?\nUP: Ja. Ich habe Betriebswirtschaft studiert.DBM Facts: Cinzia, kannst Du einmal beschreiben, was \nDeine Funktion ist?\nCD: Ich bin Personalassistentin. Ich betreue die Mitarbei-\ntenden der Medizinischen Fakult\u00e4t und bin Ansprech-partnerin f\u00fcr die Angestellten und die Organisationsein-heiten in allen personellen Belangen. \nDBM Facts: Und arbeitest 50% ...CD: Ja, ich betreue rund 500 Personen.DBM Facts: Ueli, was sind Deine Hauptaufgaben?UP: Neben den Budget- und Controlling-Aufgaben so-\nwie der F\u00fchrung des Personaldienstes stehe ich den \nMitarbeitenden, den Organisationseinheiten und exter-\nnen Stellen beratend zur Seite. Die Fragestellungen sind vielschichtig, die Antworten darauf erfordern oft taktisches Geschick und Sensibili-t\u00e4t. Zur Zeit besch\u00e4ftigen wir uns mit einer kritischen \u00dcber-pr\u00fcfung der Personalprozesse und der Optimierung unseres Verwaltungssystems. Der Anteil an administra-tiven Aufgaben w\u00e4chst st\u00e4ndig und zwingt uns die Pro-zesse neu zu \u00fcberdenken, damit wir mit den bestehen-den Ressourcen das vielseitige Tagesgesch\u00e4ft effizient und effektiv bew\u00e4ltigen k\u00f6nnen. \nDBM Facts: Was sind f\u00fcr Dich die gr\u00f6ssten Herausfor-\nderungen?\nUP: Eine Herausforderung ist, die Organisation, die jetzt \nschon 13 Jahre alt ist, auf Vordermann zu bringen. Das wird mich die n\u00e4chsten zwei Jahre besch\u00e4ftigen. Die an-dere Herausforderung ist das Tagesgesch\u00e4ft. Das kennt man nicht im Voraus.\nDBM Facts: Wie versteht Ihr Euren Job?\nCD: Im Dienst der Mitarbeitenden, aber gleichzeitig der \nLinie. Ich versuche, beiden gerecht zu werden und das ist nicht immer einfach. \nUP: Das unterst\u00fctze ich auch auf jeden Fall. Denn einer-\nseits ist man Arbeitgebervertreter, andererseits hat der Personaldienst auch eine soziale Verantwortung wahr-zunehmen. 62 PENSIONIERUNGEN/R ETIREMENTS INSTITUTE OF PHYSIOLOGY\nDBM Facts 2|2009 Departement Biomedizin62 DBM INTERN  DEPARTEMENT BIOMEDIZIN\nDBM Facts: Was w\u00fcnscht Ihr Euch konkret von den F\u00fch-\nrungsbeauftragten und Mitarbeitenden?\nCD: Rechtzeitige Informationen sind die Voraussetzung, \num die Gesch\u00e4ftsvorf\u00e4lle termingerecht erledigen zu k\u00f6nnen. \nDBM Facts: Was w\u00fcrdest Du Dir w\u00fcnschen, Ueli?UP: Das Einhalten der Prozesse und eine gewisse Ter-\nmindisziplin. Die Administration wird auch aufgrund neuer gesetzlicher Bestimmungen immer aufwendiger und komplexer. Es ist nicht einfach, den Mitarbeitenden und den Organisationseinheiten zu vermitteln, dass \ndiese Anforderungen von staatlichen Stellen an unsere \nAdministration gestellt werden. Die Uni selbst ist nicht \u00fcberreglementiert. \nDBM Facts: Was k\u00f6nntet Ihr Euch beruflich sonst noch \nvorstellen, wenn Ihr jetzt nicht hier im Personalwesen w\u00e4ret  ...CD: Die Personalarbeit gef\u00e4llt mir gut und ist sehr ab-\nwechslungsreich und dies in einem bestens funktionie-rendem Team. Ich f\u00fchle mich wohl im jetzigen Umfeld.\nUP: Mir geht es genauso. DBM Facts: Herzlichen Dank f\u00fcr dieses Gespr\u00e4ch.DEPARTMENT BIOMEDICINE USB SPORT | SPORTS 63\nDBM Facts 2|2009 Department of BiomedicineDEPARTMENT OF BIOMEDICINE  DAS DBM STELLT SICH VOR 63\nUrspr\u00fcnglich komme ich vom The -\nater, wo ich lange als B\u00fchnenhand -\nwerker t\u00e4tig gewesen bin. Obwohl \nich die B\u00fchne liebe und ich mich heute immer mal wieder als S\u00e4nger der Basler Liedertafel auf einer wie -\nder finde, war die Hektik sehr gross und ich w\u00fcnschte mir eine Arbeit mit regul\u00e4ren Arbeitszeiten. Nach zwei Jahren kam dann die Nach -\nricht, dass das damalige Kantonsspi -\ntal Basel einen Handwerker suchte. Ich weiss es noch wie heute. Als ich mich vorstellen ging, lag meine Frau gerade in den Wehen mit unserem zweiten Sohn. Und ich hatte Gl\u00fcck, sie nahmen mich. Meine Aufgaben waren allgemeine Unterhaltsarbei -\nten, Revisionen im Klinikum 2, im Zentrum f\u00fcr Lehre und Forschung, in den Operations- und H\u00f6rs\u00e4len, in der \u00d6konomie und Pathologie und auch im Holsteinerhof. \n\u00dcber die Schreinerarbeiten habe \nich viele Menschen kennen gelernt. Nie vergessen werde ich den Lieb -\nlingsbesprechungstisch von Daniel Scheidegger, an den sich keiner herantraute, und den Umbau in \nder Nephrologie mit Christina Wolf-\nHeidegger, der uns eine Woche und viele Nerven gekostet hat. Auch im ZLF habe ich unterschiedliche Charaktere angetroffen : Bei Radek \nSkoda gab es kein Entrin -\nnen, er hat mich immer gleich geschnappt, wenn er mich sah und mich \u00fcber den neuesten Stand des Umbaus informiert, Alex Eberle hat mir gleich das \u00abDu\u00bb angeboten und bei Fritz B\u00fchler bleibt mir seine Warmherzigkeit in Erinnerung. Ed Palmer hat mir sogar einmal geholfen, eine T\u00fcr einzuh\u00e4ngen! Mit Herrn Conti habe ich \u00fcber -\ndies einmal ein Bier getrun -\nken und Frau Ziegler ein \nBild \u00fcbergeben. Das waren \nnoch Zeiten, das war noch Werkstatt. Gino Pancera, Schreinerei \u2026\noder das Erdm\u00e4nnchen des USB\n64 SPORT | SPORTS DEPARTEMENT BIOMEDIZIN USB\nDBM Facts 2|2009 Departement Biomedizin64 DBM INTERNATIONAL  DEPARTEMENT BIOMEDIZIN USB 64 DAS DBM STELLT SICH VOR DEPARTEMENT BIOMEDIZIN \nSp\u00e4ter wurden viele Arbeiten extern \nvergeben. In den 21 Jahren habe ich vier Vorgesetzte und viele Ver\u00e4n -\nderungen erlebt, aber das ZLF war \nf\u00fcr mich immer ein Zufluchtsort. So haben sich in der Werkstatt viele gewundert, wenn ich mittwochs  \n\u00abmit den Forschern\u00bb joggen gegan -\ngen bin. Mit Armin Bieri, der mir immer ein guter Kollege und Sportler war, und Verena J\u00e4ggin, die uns auf Trab gebracht hat. Manchmal bin ich auch f\u00fcr das \u00abSchyssdr\u00e4ggz\u00fcgli\u00bb des ZLF bei der Sola-Stafette gestartet. \nPrivat bin ich seit 23 Jahren verhei-\nratet und habe zwei S\u00f6hne, Yves ist auf dem Weg, Schauspieler zu werden, und Marc pendelt als Archi -\ntekt und S\u00e4nger zwischen Basel und Z\u00fcrich. In meiner Freizeit singe und musiziere ich f\u00fcr mein Leben gern, sind Bilder meine Anziehungs -\npunkte, fahre ich Velo, schwimme ich und gehe ich gerne Bergwan -\ndern, mal mit und mal ohne Hund. \nUnd Ende April gehe ich in Pension.\nDanke, Gino! \nFr\u00f6hlich, aufgestellt, motiviert, \nhilfsbereit  und freundlich \u2013 so haben wir Dich all die Jahre am ZLF erlebt. Mit Deiner Kompetenz, Deiner Kreativit\u00e4t und Deinem Humor hast Du uns manchen Umzug, viele handwerkliche Pro -\nbleme und unser Leben am USB erleichtert! Danke, Gino!DBM Facts 2|2009 Departement Biomedizin... gibt uns Rolf Zeller einen Einblick \nin sein Forschungsgebiet Develop -\nmental Genetics ... erfahren wir von Christian De Geyter \nmehr \u00fcber die Forschungsaktivit\u00e4ten \nim Labor Gynaecological Endocrino -\nlogy\n... d\u00fcrfen wir dabei sein, wenn Vivian \nKiefer auf den Philippinen Hilfe vor Ort \nleistet \n ... erz\u00e4hlt uns Chitraganda Acharya, warum ihr die Zeit in Basel so gefallen \nhat\n \n... stimmen wir uns auf die 550 Jahr-Feier der Universit\u00e4t Basel ein Personalabteilung\n17DBM \nCHRISTMAS \nPARTY", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}